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The use of imaging techniques such as molecular resonance imaging (MRI) is 
common and widely used for the diagnosis of various diseases. Although extremely 
useful, they can be time consuming, expensive and can require the use of radioactive 
molecules. For these reasons the use of optical imaging, a technique in which light is 
used to visualize the molecular processes or macroscopic tissues such as tumours, is 
now becoming more widely used.  
 
Currently, fluorescence optical imaging uses light in the visible region of the 
electromagnetic spectrum. In this region light is uncontrollably absorbed by tissue 
and biomolecules within the human body and is therefore not efficient at providing a 
fluorescence signal. To overcome this, near-infra red (NIR) fluorophores have been 
used as their emission in the NIR region of the electromagnetic spectrum results in 
less absorption by the body providing stronger signals. NIR fluorophores have 
obtained great interest over the past 20 years due to their high tissue penetration. 
Synthesis of new imaging agents is constantly required to increase signal intensity, 
increase specificity to the target under investigation and lower toxicity. This thesis 
describes steps towards this through the synthesis of a variety of NIR cyanine dyes 
and discusses their cellular uptake and toxicity. 
  
One practical application of these NIR fluorophores was the derivitisation of 
microspheres. Microspheres are small spherical particles which have several 
interesting properties such as good cell penetration. These spherical polymers are 
usually around 150 nm in diameter and can be modified with NIR fluorophores. Two 
types of fluorescent microspheres are reported within this thesis, with discussions 
into their cellular uptake and localisation. 
 
Synthesis of a fluorescent bacteria detector is also discussed, describing a simple tool 





The use of fluorescent imaging probes for the real time detection of cellular 
malfunctions, such as enzyme over expression has shown promise. Fluorescent dyes 
with absorption and emission values below 600 nm are limited in their in vivo 
applications due to high background auto-fluorescence and low resolution images. 
Employing near infrared (NIR) fluorophores such as cyanine dyes can overcome this 
disadvantage.  
 
Cyanine dyes can be synthesised using solution or solid-phase techniques with the 
use of solution phase chemistry allowing for larger scale and higher yielding 
reactions. Utilising a selection of functional groups and varying polymethine chain 
lengths a cyanine dye library with tuneable absorption and emission wavelengths was 
synthesised. This thesis gives the first detailed examples of how modifications on 
heptamethine cyanine dyes alter their cellular uptake and cellular toxicity. 
Furthermore, a NIR fluorescent microsphere is reported as well as NIR 
functionalised microspheres with the ability to be tracked within cells. 
 
Additional lines of work involved the synthesis of a fluorescent sensor for the 
visualisation of bacteria. Aminopeptidases are present within the peptidoglycan cell 
wall of Gram negative bacteria and therefore can be targeted for real time detection 
of bacteria to aid in the detection of infectious diseases. A coumarin based probe is 
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Near Infrared Fluorophores – A 
Future for Medical Imaging 
 
1.1 Medical Imaging  
Medical imaging is a broad term and covers imaging techniques that gain anatomic 
and functional information of a patient. Over the 20
th
 century, techniques such as 
magnetic resonance imaging
[1]
 (MRI), X-ray computed tomography
[2]
 (X-ray-CT) 




) have been developed to generate 
contrast between the target of interest and the surrounding tissue. Even still, the 
development of new imaging modalities that are safer, cheaper, easy to use and offer 
increased image resolution are sought after. 
Widely considered the future of medical imaging
[5]
, molecular imaging techniques 
have been the focus of 21
st
 century research. The development of clinical and optical 
imaging techniques over the past 100 years is described in Figure 1 and shows the 
immense technological advancements made since the first light microscope was 
developed. 
Many phrases have been used to define molecular imaging, leading to a general 
consensus that molecular imaging is the “visualisation of in vivo biological processes 











Figure 1: Imaging techniques used in: 1) clinical practice (above timeline) – imaging of 
bones (X-rays), soft tissue (ultrasound, MRI and CT). Tomographical 3D images (PET, CT 
and MRI). 2) Optical development (below timeline) - Imaging through microscopic, 
tomographic and macroscopic techniques. The timeline is approximate and not to scale. BLI, 
bioluminescence imaging; CT, computed tomography; FMT, fluorescence-mediated 
tomography; FRI, fluorescence reflectance imaging; HR-FRI, high-resolution FRI; LN-MRI, 
lymphotropic nanoparticle-enhanced MRI; MRI, magnetic resonance imaging; PET, positron-
emission tomography; PAT, photoaucoustic tomography. Image adapted with permission 
from reference
[7]
. All individual image reference permissions obtained, see appendix 1. PET 
image
[8]











all references copyright (2005-2013). 
 
The applications of molecular imaging are various, for example, Politi et al used 
MRI to monitoring tumour size variation after long term administration of a known 
anticancer drug, Erlotinib
[14]
. It was found that although the drug was initially 
successful at reducing the tumour size, intermittent drug administration failed to 
completely remove the tumour, while after 22 weeks, administration of the drug had 
no effect on the tumour. This was thought to be due to the up-regulation of growth 







Figure 2: Tumour resistance to Erlotinib after intermittent treatment
[14]
. Mice were 
treated with Erlontinib (25 mg/kg/day) 5 days per week for 4 weeks after which treatment 
was interrupted for 4 weeks. Treatment cycle repeated three times. Images show 
development of drug resistance after 22 weeks due to tumour growth despite drug 
administration. 
 
Molecular imaging has played a crucial role in oncology
[15]
 but also in the detection 
cardiovascular disease
[16]
 by targeting over-expression of specific enzymes or 
receptors. For example, Matrisian et al targeted the expression of matrix 
metalloproteinase (MMP) in a mouse model injected with cancer cells that either 
expressed or did not express MMP-7. MMP’s are over expressed in cancer cells and 
are therefore a good target for tumour imaging
[17]
. Using a quenched cyanine 
molecule (Cy 5.5) linked to an MMP-7 cleavable peptide, fluorescence was detected 




Figure 3: Detection of near infrared fluorescence of MMP specific imaging probe 
following subcutaneous injection of cancer cells expressing or not expressing MMP-7. 
a) Brightfield image of nude mouse 4 weeks post injection of cancer cells. b) Cyanine 5 
detection 4 hours post injection of imaging probe. Red represents high fluorescent intensity. 
Image adapted and reproduced with permission from reference
[18]
, copyright Society of of 
Nuclear Medicine and Molecular Imaging (2008). 
 
A large increase in fluorescence signal was detected for the MMP-7 expressing probe 








 in medical and molecular imaging over the last 30 
years have led to high resolution imaging modalities which are now used in tandem 
to give complimentary sets of information
[12, 20]
. For example, combination of the 
excellent soft tissue contrast properties of MRI and the high sensitivity of PET or 
SPECT to detect drug distribution can be applied
[11, 21]
. These advancements have 
also allowed medical imaging to be used in the field of drug discovery and 
development
[11, 22]
 and drug resistance investigations
[14]
. 
Often, the decision of which imaging technique to apply can be difficult
[23]
 as each 
technique has particular advantages and disadvantages. For example, MRI is easily 
used in clinical applications, however, the long imaging time, high cost and lack of 
patient compliance make it a difficult option for many. PET and SPECT offer images 
with unlimited depth penetration but require the use of radioactive materials which 
are costly and can raise safety concerns. Other techniques, such as CT and ultrasound 
allow high spacial resolution and are used clinically, but do not allow targeted 
specific imaging
[22b]
. Optical imaging is a highly sensitive technique which uses light 
to image target molecules in an affordable, safe, and quick to use manner. The main 
drawback for optical imaging is its low depth penetration making it difficult to use in 
clinical situations. Additionally, although FMT claims to generate quantitative data, 
these machines are often extremely specialised and not available to many research 
groups. To overcome the depth prenetration issue, investigations into near infrared 
(NIR) fluorophores as part of a molecular imaging probe are numerous and  
on-going
[24]
 as a solution to increase the depth penetration of the technique. Table 1 
summarises the main small animal imaging technologies and their respective 
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Table 1: Details of different pre-clinical imaging modalities and their properties. MRI, magnetic resonance imaging; CT, computed 
tomography; PET, positron-emission tomography; SPECT, single photon emission CT; FRI, fluorescence reflective imaging; FMT, 





, copyright (2008), Macmillan Publishers Ltd, Nature Medicine. 
I
For high resolution, small animal imaging systems; 
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1.2 Optical Imaging Techniques 
1.2.1 Fluorescence Reflective Imaging 
A technique at the forefront of molecular imaging is fluorescence reflective imaging 
(FRI). FRI is a macroscopic imaging technique in which fluorescence can be 
captured non-invasively by shining light (excitation) on to the desired surface and 
collecting the emitted light, either on the same side as the excitation source  
(epi-illumination) or on the opposite side of the excitation source (trans-
illumination), with the light (emission) collected by a highly sensitive camera using 
appropriate filters. Although useful, epi-illumination techniques do not allow 
quantitative measurements
[26]
. A modified version of this technique
[27]
 was used by 
Weissleder
[28]
 in the study of MMPs. This probe contained a self-quenched, modified 
cyanine dye attached to the cleavable peptide sequence GPLGVRGK which directed 
the probe in to the tumour region. On cleavage by MMP, the cyanine molecules were 
released resulting in an increase in fluorescence intensity (Figure 4).  
 
Figure 4: In vivo NIR fluorescence reflective imaging (modified) of tumour bearing 
mice. Column a) tumour bearing mice, Column b) tumour bearing mice, treated with MMP 
inhibitor. Top row shows raw image data acquired with ex = 675 nm and em =694 nm. 
Lower row shows colour-coded tumoural maps of MMP activity (yellow represents high 
fluorescent intensity). Reprinted and adapted with permission from reference
[28]
, copyright 






Mouse models, with and without a known MMP inhibitor (prinomastat) were 




1.2.2 Fluorescence Molecular Tomography 
Fluorescence molecular tomography gives 3-dimensional, high resolution images of 
in vivo fluorescence. By imaging through 360º’s and combining the emission profiles 
through complex algorithms
[29]
, FMT allows for quantification of the fluorescence 
signal making this modality superior to FRI. An excellent example of this tool was 
shown by Weissleder et al
[30]
 on incubation of cyclophosphamide (a common anti-
cancer drug) on cyclophosphamide resistant and non-resistant tumours. This study 
quantitatively determined the uptake of a tumour targeted probe modified with a 
fluorescent molecule (Annexin-Cy 5.5).  
 
 
Figure 5: FMT analysis of Annexin-Cy 5.5 probe uptake by cyclophosphamide treated 
and non-treated tumours. a) Planar fluorescence image, cyclophosphamide resistant 
tumour (green arrow), non-resistant tumour (red arrow) b) FMT slice superimposed on planar 
image of cyclophosphamide resistant tumour (green arrow) and non-resistant tumour (red 
arrow). ex = 670 nm, em = 692 nm. Imaging probe accumulation noted in resistant tumour. 
Reprinted and adapted with permission from reference
[30]
, copyright (2004), PNAS. 
 










1.2.3 Confocal Microscopy 
For sub-cellular studies, confocal microscopy
[26, 31]
 has seen applications across 





 or cellular processes in real time to aid in 
disease diagnosis
[34]
. Based on a point source of light focussed upon a specimen it 
allows good resolution and 3D studies of individual cells over time
[35]
. For example, 
Bradley and co-workers
[36]
 used confocal microscopy to show the real time 
intracellular deprotection of fluorescein using Pd
0
. Furthermore, multiple 
wavelengths could be used to create a merged image of the full cell highlighting the 
nucleus, palladium catalyst and deprotected fluorescein.  
 
 
Figure 6: Merged confocal image of a single HeLa cell showing the nucleus (blue – 
Hoechst stained), Pd
0
 microspheres (red – Texas red labelled) and deprotected 
rhodamine (green)
[36]
. Scale bar, 10 µm. Reprinted and adapted from reference
[36]
, 
copyright 2011, Nature Publishing Group. 
 
This was the first reported example of an intra-cellular Suzuki-Miyaura cross 







1.3 Reporter Technologies and Probe Design 
As highlighted by the example above, optical imaging requires a fluorescent imaging 
probe in order to generate the contrast required to visualise the target of interest. The 
concept and design of such molecular imaging probes require three features; 1) a 
targeting moiety specific to the imaging target. These can be DNA
[37]
, antibodies or 
peptides
[17]
, 2) a reporter molecule in order to generate a signal once the target has 
been reached, for example a PET radiolabel or fluorophore; 3) a carrier moiety to 
allow penetration into the cell if required, for example microspheres are often 
employed to aid in the cellular delivery of a cargo
[33a]
. 
Although all sections are equally important, this thesis will focus on the reporter 
molecules and their synthesis 
 
1.3.1 Reporter Molecules 
Reporter molecules can take many forms and must cause a change of a particular 
signal to be detected by the operator. For optical imaging, fluorophores are used and 
have advantages over other modalities as they are safe to use, can produce a long 
lived signal and can be tuned to give the desired reporting wavelength. Additionally, 
fluorophores can be manipulated to modify their emission or turn off the 
fluorescence completely. This has led to the synthesis of “smart” probes with the 
ability to “turn on” fluorescence in the presence of the target moiety.  
One technique is to utilise the ability of a fluorophore or chromophore to quench its 
own emission or that of a neighbouring fluorescent molecule. This is often described 
as Förster resonance energy transfer (FRET) and describes the energy transfer 
between two chromophores
[38]
. Each fluorophore has a bathochromic shift between 







Figure 7: General absorption (blue) and emission (red) spectra showing Stokes shift. 
 
A fluorophore with an extremely small Stokes shift, or in other words, a high overlap 
area between absorption and emission spectra, can quench its own fluorescence. 
FRET relies on the ability of one fluorophore (or quencher) to absorb the emitted 
fluorescence (acceptor) of the other fluorophore (donor). In order to be utilised in 
this manner the absorption profile of the acceptor, must overlap the emission profile 
of the donor. If the ability to quench is lost, fluorescence is regained. This technique 
forms the basis of many assays. 
 
 
Figure 8: FRET quenching and subsequent emission on cleavage of the linker 
molecule.  
 
Figure 8 shows a “turn on” system in more detail where the emission of Dye A is 
transferred to the acceptor Dye B. In the case of Dye B being a fluorophore, the 
emission wavelength of Dye B will be detected and in the case of Dye B being a 
quencher, no fluorescence will be observed. On cleavage of the linker, (for example 
a peptide substrate
[39]





the fluorescence of Dye A. In this case, the probe design must take into account the 
distance between the fluorophores with a maximum distance of 10 nm
[40]
. Beyond 
this distance, fluorescence quenching drops exponentially but it is this limitation 
which allows FRET to be used as a molecular ruler with the ability to measure 
distances within biomolecules with high accuracy
[41]
.  
Another technique which utilises an electron donor/acceptor system is photoinduced 
electron transfer (PeT)
[42]
. In this instance, electron transfer from the fluorophore 
receptor to the fluorophore occurs on excitation of the fluorophore. This in turn 
prohibits the relaxation and fluorescence of the fluorophore. On receptor binding to 






Figure 9: Relative energies of the frontier orbitals of fluorophore (blue) and 
fluorophore receptor (green). a) Analyte free, “off” conformation. b) receptor-analyte 
bound, “on” conformation. h represents emission of fluorophore. Reprinted and adapted 
with permission from reference
[42a]






Figure 9 shows the electron transfer between the receptor and fluorophore HOMO’s 
in the “off” situation and no transfer in the “on” situation. This technique has been 
used in the detection of ions
[43]
 and organic molecules
[44]
 as well as cancer 
imaging
[45]
. For example, Tusa et al synthesised a fluorescent ion sensor with the 





Figure 10: Tusa’s Potassium ion sensor. While in the K
+
 unbound state (left), no 
fluorescence emission is observed due to PeT. When K
+
 binds (right), the PeT quenching is 
interrupted allowing fluorescence emission. ex
 
= 470 nm, em = 540 nm. h1 represents 
excitation wavelength, h2 represents emission wavelength. Reprinted with permission from 
reference
[46]
, copyright (2003) American Chemical Society.  
 
This sensor was able to detect the presence of potassium ions at 2 mM allowing this 
probe to be used to measure the presence of extracellular potassium in serum or 
whole blood. 
 
1.4 Fluorescence and Fluorophores  
The choice of the fluorophore is an important decision and can determine the signal 
intensity of the reporting agent. Development of the optimum fluorophore allows 
better visualisation of the target. 
 
1.4.1 Fluorescence Principle 
Fluorescence
[47]
 is described as the “spontaneous emission of radiation from an 
excited molecular entity with retention of spin multiplicity”
[48]
. Fluorescence is based 
on electron excitation from a ground electronic state to an excited electronic state. In 





level of the lowest excited state. This relaxation occurs through several pathways and 
was first described by Alexsander Jablonski in 1933
[49]
. These pathways are namely, 
radiative emission (fluorescence) or non-radiative emission (heat)
[50]
 and is 
represented in the Jablonski diagram (Figure 11). It is the loss of energy through heat 
(vibrational relaxation) that results in the emission wavelength being higher than the 
excitation wavelength and the generation of Stokes shift (see section 1.3). When 
studying fluorophores various factors are to be considered such as quantum yield 
(Φ), extinction coefficient () and fluorescence lifetime ().  
 
 
Figure 11: Jablonski diagram for an organic molecule. Lines: blue - light absorption (10
-
15













), black – intersystem 
crossing (variable). Times indicate approximate speed of transition. Reprinted and adapted 
with permission from reference
[51]
, copyright (2010), The Royal Society of Chemistry. 
 
Quantum yield is arguably the most important factor relating to fluorophores and is 
described as a ratio between the number of photons absorbed, to the number of 
photons emitted. Although most fluorophores should have a quantum yield of at least 
0.05 to be termed fluorescent, ideal fluorophores would have a value at 1.0 with 
100% of photons being absorbed, re-emitting through fluorescence. Unfortunately, 
this is rare due to energy loss through heat or other relaxation pathways. Several 
factors must be taken into account when measuring a fluorescence quantum yield. 
These are mainly fluorophore concentration, pH and solvent system. Fluorophore 
concentration is a key factor with highly concentrated solutions resulting in  
self-quenching
[52]









Equation 1: Calculation of fluorescence quantum yield. kr and knr correspond to the 
radiative and non-radiative decay processes respectively and knr describes the sum of the 
rate constants for the pathways that compete with photon emission, (e.g. collisional 
quenching, or inter system crossing). 
 
Most simply, the quantum yield is calculated by comparing the sample under 
investigation with a reference sample of known quantum yield following procedures 




 and more recently by Brouwer
[55]
. In most 
cases, there are many options for the selection of a reference sample, however, for 
NIR fluorophores the scope is limited. An overview of the most common reference 











 DMSO 0.11 650-800 
Cresyl Violet
[55]
 Ethanol 0.56 600-650 
Chlorophyll A
[56]
 Ether 0.32 600-750 
Fluorescein
[57]





0.1 M H2SO4 0.54 400-600 
Norharmane
[58]













Experimentally, the fluorescence and absorbance of the reference is measured against 
the sample using the same conditions, i.e. same excitation wavelength, slit widths 
and gain. 
 
1.4.2 Fluorescent Dyes 
There are hundreds of fluorescent dyes with absorption and emission wavelengths 
ranging between 300-900 nm. The need for fluorescent dyes is high, and fortunately, 
the fluorophore tool box has never been as diverse as it is today. The ability to select 
a fluorophore with ideal photo-physical properties and reactive functional groups for 
a specific purpose is possible, although fluorescent dyes can be extremely expensive.  
 
1.4.2.1 Commercial Dyes 













 based molecules. Each 
molecule type has certain typical characteristics while due to the diverse 
modifications available, the variety and application of these molecules is high. 
 
 





The applications of these dyes include research into solar cells
[66]





 and reactive oxygen species detection
[69]
 to name but a 
few. 
Fluorophores are inherently highly conjugated molecules and therefore can often 
encounter solubility or aggregation issues when being utilised for biological 
applications. To overcome these problems, synthetic modifications often have to be 




Figure 13: Common fluorophores. X-axis represents approximate absorption wavelengths, 
Y-axis represents approximate fluorescence intensity. AMC, aminomethyl coumarin; 
BODIPY, Boron-dipyrromethane; Cy, Cyanine. Reprinted and adapted with permission from 
reference
[70]
, copyright (2008), American Chemical Society. 
 
Ideally, fluorophores to be used for molecular imaging purposes should have the 





to optimise depth penetration, 2) high quantum yield, 3) narrow absorption and 
emission bands, 4) high photo-stability, 5) non-toxic and 6) ability to be synthesised 
on a large scale. Currently, no fluorophores cover all of these requirements. 
 
1.4.2.2 NIR Dyes 
Fluorescence molecular imaging with the use of NIR imaging agents will provide 
new opportunities for diagnostic imaging
[70]
. Fluorophore excitation wavelengths are 
extremely important for a variety of reasons, for example, excitation in the ultraviolet 
(UV) region can cause tissue damage by crosslinking of DNA and therefore is 
unacceptable for clinical use
[71]
. Excitation in the blue/green region (< 495 nm) of the 
electromagnetic spectrum can be used for surface imaging applications, however, 
poor tissue penetration and tissue auto-fluorescence results in clinical limitations. 
Naturally occurring chromophores in biological tissue such as oxy- and 
deoxyhemoglobin, melanin, and fat absorb light below or above the NIR window. 
This is highlighted by the spectrum of naturally occurring endogenous fluorophores 
as shown in Figure 14. 
 
 
Figure 14: Extinction coefficients of water, oxyhemoglobin and deoxyhemoglobin over 
visible to near-infrared wavelengths. Reprinted with permission from reference
[5]
, 





NIR fluorophores absorb and emit light in the near infrared window (700-900 nm) 
and therefore do not suffer from high background auto-fluorescence. Recent 
advances in this field
[72]
 have seen the number of publications grow with fluorescent 




 and cancer metastasis
[75]
 common 
in the literature. For example, Bacskai et al targeted pathological deposits of 
amyloid-beta (A) peptide in the brain, a key sign in the development of Alzheimer’s 
disease. Synthesis of a NIR emitting smart probe with the ability to cross the blood 
brain barrier and to fluoresce intensely when bound to A plaques allowed 





Figure 15: NIR emitting smart probe to detect the presence of A plaques in mice 
brain. Tissues were incubated with NIR emitting probe and imaged with a fluorescence 
multispectral imaging system (Maestro). Red = A plaques. Blue = grey matter. Green = 
white matter. ex = 480 nm, em = 525-720 nm. Image adapted from reference
[74a]
, copyright 
European Journal of Nuclear Medicine (2007). 
 
Similarly, Gremlich et al synthesised a NIR oxazine derivative with an analogous 
ability to cross the blood brain barrier and bind with high affinity to A plaques. 
Semi-quantitative NIR imaging (modified fluorescence reflectance imaging) 
confirmed the specific interaction of the probe in the brain of mice over expressing 
amyloid plaques using an excitation wavelength of 670 nm
[74b]
. These in vivo studies 
using NIR fluorescent probes continue to advance the diagnosis of Alzheimer’s 





Figure 16: Specific binding of NIR fluorophore to A plaques in the brain of mice over 
expressing amyloid deposits. a) Structure of NIR fluorophore, ex = 650 nm, em = 670 nm, 
quantum yield = 0.41. b) Specific binding of NIR fluorophore (0.1 mg/kg in saline solution) to 
A plaques as a function of time. Calculated from fluorescent signal (APP23 transgenic 
mice), minus fluorescence signal (non-transgenic mice), divided by fluorescence signal 
(transgenic mice). Imaged reproduced from reference
[74b]
, copyright Nature Publishing Group 
(2005). 
 
1.4.2.3 Cyanine Dyes 
Cyanine dyes, named after the Latin word cyanos, meaning blue, were discovered by 
accident in 1856 by Williams when he reacted N-amyl quinolinium iodide with  
N-amyl lepidinium iodide in ammonia
[76]
. Shortly afterwards in 1857, Von Babo 
independently discovered “one of the most beautiful substances in organic 
chemistry” by reacting quiniline with alkyl sulphates
[77]
. By 1863 a brilliant blue 
cyanine dye was available commercially and new analogues were being sought
[76]
.  
The structures of cyanine dyes vary in complexity. Generally, two heterocyclic “head 
groups” are connected by an odd (x) number of methine groups with x+1 electrons. 
This conjugated system results in a coloured, fluorescent molecule (Figure 17). 
Cyanine dyes can absorb and emit light between the visible to near-infra red region 
and these wavelengths can be tuned by modification of the polymethine chain. This 
tuneability, along with narrow absorption and emission bands resulted in cyanine 

















Figure 17: General structure of cyanine dyes with delocalised cation along 
polymethine chain. 
 
Cyanine dyes are named depending on the number of carbon atoms in the 
polymethine chain with n = 0,1,2 or 3, the mono-, tri- (cyanine 3), penta (cyanine 5), 
or heptamethine (cyanine 7) cyanine’s respectively. Cyanine dyes cover a large part 
of the electromagnetic spectrum (500-900 nm) with each vinylene increment in the 
polymethine chain corresponding with a bathochromic shift of approximately 100 
nm. Due to the large variation in possible structures, cyanine dyes can have diverse 
quantum yields, extinction coefficients and Stokes shifts. Although cyanine quantum 
yields are generally lower than some other fluorophores such as fluorescein, the long 
NIR absorption and emission wavelengths of cy 5 and cy 7 result in brighter images 
when using light or confocal microscopes due to the decreased tissue absorption. 
Further, the addition of functional groups such as carboxylic acids can be achieved to 
allow conjugation to biomolecules for cellular or in vivo studies. 
As described by Tung
[83]
, NIR fluorophores generally suffer from problems such as 
low quantum yields, photo-instability and spectral broadening as the wavelength 
increases. Further, the hydrophobicity of cyanine dyes can cause aggregation with 
self-quenching becoming a problem
[84]
.  
Further studies into cyanine dyes may help overcome these issues with the synthesis 








1.5 Aims of Thesis 
The need for new imaging probes is growing with an ever increasing number of 
targets. For successful optical imaging probe design, the correct fluorophore must be 
selected. This thesis aims to synthesise a variety of cyanine dyes with differing 
functionalities to determine their effects on the photo-physical properties of the dyes. 
Detailed studies into the cellular uptake and toxicity of the new cyanine dyes will be 
discussed with a recent example of a cyanine dye as part of an imaging probe. 
Furthermore, the synthesis of an inherent NIR fluorescent microsphere and its 
cellular uptake will be investigated.  
Finally, the synthesis of a coumarin based aminopeptidase probe will be reported 
with the specific detection of several Gram negative bacteria over Gram positive 







Synthesis and In Vitro Studies of 
Cyanine Dyes  
2.1 An Introduction to Cyanine Dyes 
There is a pressing need for new fluorophores, with NIR cyanine dyes at the 
forefront of this demand. Many different synthetic routes to cyanine dyes have been 
reported as discussed in recent reviews by Mishra et al
[84b, 85]
. Most commonly, 
cyanine dyes are described as being symmetrical or non-symmetrical with respect to 
their indole head groups, with all cyanine dyes existing in the trans form with the 
two indole nitrogens in either a tertiary or quaternary form.  
Cyanine dyes are fully conjugated planar molecules showing resonance stabilisation 
along the polymethine chain. Non-symmetrical cyanine dyes exhibit less planarity 
than the symmetrical analogues, causing a decrease in fluorescence intensity. As with 
all fluorophores, increasing the rigidity of the molecule is beneficial, leading to 
brighter colours and higher fluorescence intensities.  
Although there are many examples, synthesis of tri- penta- and heptamethine cyanine 







Figure 18: General structures of cyanine dyes. Colours represent approximate colour in 
solution. Approximate absorption and emission properties (nm): cyanine 3 abs = 550, em = 
580, cyanine 5 abs = 650, em = 680, cyanine 7 abs = 750, em = 780. X = counter ion. 
 
2.2 Synthesis of Symmetrical and Non-Symmetrical Cyanine Dyes 
2.2.1 Tri-methine Cyanine Dyes 
Symmetrical cyanine dyes were first synthesised using the “orthoester” method in 
which various quaternary indolium salts are reacted with orthoesters in the presence 
of a base
[86]
 (Scheme 1).  
 
 




Almeida et al used a similar route to synthesise a ratiometric pH sensor
[87]
. This one 
pot reaction involved a single step where the heterocyclic base was refluxed in 













This probe was able to detect pH changes between 6-8 (Scheme 2) with protonation 




Stepwise synthesis of an un-symmetrical cyanine 3 dye was carried out by Jung, who 
synthesised dyes for use in difference gel electrophoresis
[88]
. This procedure (detailed 
in Scheme 3) begins with the alkylation of trimethyl indole with propyl bromide, 
followed by condensation with diphenylformamidine in excess acetic anhydride. 
Alkylation of the indole with 1-bromohexanoic acid afforded the second indolium 












To avoid the synthesis of the unwanted symmetrical cyanine dye, Bradley et al 
synthesised a non-symmetrical cyanine 3 using solid-phase methods and microwave 
mediated synthesis
[89]
 as described in detail in Chapter 3. 
 
Cyanine 3 molecules are highly fluorescent but do not fall within the classic NIR 
window with absorption and emission wavelengths below 600 nm.  
 
2.2.2 Pentamethine Cyanine Dyes 
The synthesis of pentamethine cyanine dyes is widely reported in the literature. A 
detailed synthesis is described by Romieu and co-workers in which, symmetrical and  













These molecules represented the first cyanine dyes with two orthogonal functional 
groups. 
 
Wilson exploited the DNA binding nature of cyanine 5 dyes to synthesise anti-cancer 
therapeutics that bound to G-quadruplexes
[91]












Cyanine dyes are known to bind to the minor groove of DNA duplexes
[92]
 and the 
addition of further quaternary ammonium cations increased aqueous solubility and 




Another synthesis relating to DNA binding involved a condensation reaction 
between cyclopentane-1,3-diones with the quaternary salts of  
2-methylbenzothiazolium at high temperatures. Yarmoluk et al utilised this method 









The resulting fluorophores showed that modification of the cyclopentene moiety had 










2.2.3 Heptamethine Dyes 
Heptamethine dyes have absorption and emission values above 750 nm and are 
therefore ideal candidates for use in molecular imaging. The most common synthesis 
of heptamethine cyanine dyes involves the introduction of a 6-membered hexene ring 
as part of the conjugated cyanine system. The 6-membered ring increases the rigidity 
of the molecule and decreases aggregation in solution, which results in an increase in 
fluorescence quantum yield. The reaction proceeds via a condensation of the 









The resulting heptamethine fluorophore has a labile chlorine group that can be 
substituted by a variety of nucleophiles leading to hundreds of possible 
derivatives
[94b, 94c]
. Interestingly, substitution of the chlorine atom can have a 
dramatic effect on the absorption and emission properties of the fluorophore
[95]
 and 
will be discussed in detail later in this chapter. 
 
Bradley and co-workers utilised solid-phase techniques to generate non-symmetrical 













This efficient procedure requires no purification of the final dye and only requires 




Commercially available heptamethine dyes include indocyanine green (ICG). 
Initially developed for photography by Kodak, ICG, which was approved by the food 
and drug administration (FDA) in 1958 has been utilised mainly in angiography and 
ophthalmology,
[96]









Scheme 9: Synthesis of indocyanine green. 
 





2.3 Further Applications of Cyanine Dyes 
2.3.1 Reactive Oxygen Species 
Reactive oxygen species
[98]
 (ROS) are important for many biological functions such 
as signal transduction
[99]
, blood pressure regulation
[100]
 and platelet production
[101]
, 







. ROS are often difficult to 
measure quantitatively in biological systems
[105]
 but due to the high sensitivity of 
fluorescent imaging, this technique may help overcome this
[69b]
. ROS can be in the 





), hydroperoxyl radical (HO2
·
) or species such as hydrogen peroxide 




One example is the synthesis of non-fluorescent hydrocyanine dyes by Knight et 
al
[69c]
. As discussed, it is the extended conjugation system of fluorophores which 
accounts for the colourful and fluorescent properties. By temporarily disrupting this 
conjugation, it is possible to “turn-off” the fluorescence. This can be done using 
NaBH4. On addition of the reducing agent, a colour change from green to yellow is 






Scheme 10: Reduction and oxidation of cyanine 7. 
 
In the presence of radicals, such as superoxide, a turn on fluorescence signal is 
observed allowing determination of the level of ROS species present. This is due to 







 also reported detection of ROS in real time by linking two NIR 
cyanine dyes with different oxidation potentials initially resulting in static quenching 
of the fluorophores. 
 
 





A turn on fluorescence signal was observed on oxidation of the more susceptible 
cyanine dye to the non-fluorescent oxindole by a variety of ROS such as the 





incubated with the probe and after activation with phorbol mysritstate acetate (PMA, 
O2
.-






Figure 19: Comparison of the white light and fluorogenic images of a peritonitis 
mouse model before and after PMA activation. a) No probe before stimulation, b) no 
probe after stimulation, c) probe before stimulation, d) probe after stimulation. Red = 
fluorogenic image. ex = 645 nm, em
 
= 668 nm. Reprinted and adapted with permission from 
reference
[106]
, copyright (2010) American Chemical Society. 
 
A mouse model of peritonitis also exhibited impressive oxidative stress detection 
showing the possibility of transfer to humans (Figure 19). 
 
2.3.2 Other Small Molecules 
There have been several published articles on the development of anion sensors
[107]
 




 ions receiving considerable 





 and most recently hydrogen sulfide
[112]
 have 











Zhang and co-workers developed a real time NIR sensor for H2S by incorporating m-
nitrophenol onto the heptamethine dye scaffold (Scheme 12), which as a result of 
PeT
[113]
, quenched its fluorescence. Reduction of the nitro group by H2S resulted in 
removal of the PeT process allowing fluorescence emission. Selectivity over reactive 




2.3.3 Metal Ions 











in biological systems have been investigated. Modification of the 
heptamethine scaffold by substitution of the labile chlorine atom, has led to the 
development of a ratiometric probes for the detection of metal ions, with Jiang 
developing a Ag
+ 












Scheme 13: Modified heptamethine cyanine dye for the detection of Ag
+





By modulation of the aggregation states
[118]
 of the cyanine dye with increasing 
concentrations of Ag
+
 ions, a fluorescence shift of 185 nm was observed. This sensor 
















Addition of the dipicolylethylenediamine moiety as a metal chelator resulted in a 
change in electron donating ability of the amine. Zinc binding resulted in a detectable 
change in absorption and emission maxima as well as a colour change from blue to 

















On binding copper ions, a complete reduction in fluorescence occurs. Addition of 
CN
-




2.4 Properties of Cyanine Dyes 
2.4.1 Solubility and pH dependence 
Cyanine dyes are hydrophobic organic molecules. This can often make synthesis and 
purification easy, however, limits their use in biological systems. To overcome this 
problem, the cyanine dye can be modified by the addition of polar functionalities, 
most commonly, the addition of sulfonates. 
 
Cyanine dyes are susceptible to their environment and the absorption and emission 
wavelengths can vary depending on solvent polarity and pH. Extensive studies, to 
investigate the complex link between solvent and cyanine dye have been carried out 
leading to the conclusion that variation of polarity causes changes in the 
conformation between a charge distributed along the full molecule or fixed ionised 
and non-ionised segments. A study into the effect of pH led to the synthesis of a 














In this study, the heptamethine construct was modified with a 1-methyl piperizine 
moiety resulting in a ratiometric probe to measure pH between 4 and 12. Similar 






Fluorophores are susceptible to photobleaching
[122]
 which mainly occurs due to the 
presence of singlet oxygen. This effect is irreversible and is dependent on the 
intensity and duration of light exposure. Although detrimental, photobleaching can 
be used to study cell membrane diffusion and protein binding by using fluorescence 
recovery after photobleaching (FRAP) where non-oxidised fluorophores diffuse into 
the non-fluorescent area
[123]
. Modifications to the cyanine fluorophore can reduce the 
tendency to photobleach, such as fluorination. Armitage showed that poly 
fluorination of a modified cyanine dye resulted in reduced aggregation in solution, as 





Figure 20: Structure of fluorinated cyanine dye with decreased sensitivity to 









2.5 Chapter Aims 
The aim of this chapter was to synthesise a library of hepta- and penta-methine 
cyanine dyes, to analyse their respective photo-physical properties and determine 
their cellular uptake ability. Although there are increasing reports on these dye 
molecules, (with many coming out during the duration of the author’s PhD) specific 
discussion into their cellular toxicity and cellular uptake is rarely mentioned. 
Additionally, the reactivity of heptamethine cyanine dyes in the meso position or 
susceptibility to nucleophilic attack is still not fully understood and investigation into 
this will help in the production of new molecular imaging probes for in vivo studies. 
Scheme 17 shows the proposed synthesis for the library.  
 
 









2.6 Results and Discussion 
2.6.1 Synthesis of Indolium Salts 
The synthesis of cyanine dyes requires two key intermediates. A conjugated carbon 
backbone and two indolium salts which act as “heads” or “capping groups”. In order 
to synthesise a range of cyanine dyes, several indolium salts were synthesised.  
 
The synthesis (Scheme 18) was high yielding and carried out using conventional 
heating, or microwave assisted heating which reduced reaction times significantly 
while maintaining good yields (Scheme 18). 
 
 
Scheme 18: Synthesis of indolium salts. Compound 2 was obtained from Dr Nicos 
Avlonitis, Edinburgh University. Compound 5 was commercially available. 
 
The quinolinium derivative was synthesised via alkylation of quinoline. 
 
 








2.6.2 Synthesis of a Cyanine Dye Library 
In 1995 Patonay described the synthesis of heptamethine cyanine dyes utilising a 
bisaldehyde originally described by Reynolds in 1977
[125]
 and an indolium salt. The 
bisaldehyde most commonly used is 2-chloro-1-formyl-3-hydroxymethylene 
cyclohexene (13). However, it is also possible to use isophthalaldehyde to generate 
different molecules with respect to optical properties. Although the synthesis 
generally results in symmetrical cyanine dyes, a labile chlorine atom on the backbone 
can be readily functionalised. It is possible to use other bisaldehydes to synthesise 
novel pentamethine cyanine dyes. Starting materials such as 2-(3-hydroxycarbonyl-
6-pyridyl) malondialdehyde or the chloro or nitro derivatives combined with 
indolium salts would produce symmetrical cyanine 5 analogues with modifiable 
motifs to allow for bioconjugation or further functionalization.  
 
2.6.3 Synthesis of Heptamethine Cyanine Dyes 
Synthesis of the bis aldehyde (Scheme 20) was carried out by in situ formation of the 
formylating agent using DMF and phosphorous oxychloride. 
 
 
Scheme 20: Synthesis of the bis aldehyde in a Vilsmeier type reaction. 
 
Synthesis of the NIR fluorophore (Scheme 21) was carried out using classical 
heating at 70-120 C in a mixture of acetic acid and acetic anhydride with NaOAc as 
the base. These reactions were monitored by TLC or HPLC with purification carried 







Scheme 21: Synthesis of a heptamethine cyanine dye. 
 
The mechanism requires the deprotonation of the quaternary indole followed by 
condensation with the bisaldehyde moiety (Scheme 22). 
 
 





Substitution of the chlorine group by nucleophiles (Scheme 23) can be carried out to 
create a variety of fluorophores with different properties. Substitution of the chloro 
group with thiolates, phenolates or amines was attempted with a wide range of 
solvents explored although methanol or DMF gave the best results.  
 
 
Scheme 23: Nucleophilic substitution to generate library. 
 
The substitution reaction mechanism is not trivial and can occur via two pathways. 
The first and most obvious pathway is the addition of the nucleophile, followed by 
the elimination of the chlorine atom as shown in Scheme 24.  
 
 
Scheme 24: Suggested addition-elimination mechanism. 
 
A second suggested mechanism is the radical nucleophilic aromatic substitution 
reaction (SRN1)
[94c, 126]
. This mechanism is supported by evidence obtained under 
certain reaction conditions. For example, when the reaction is attempted in the 
presence of molecular oxygen (a known free radical scavenger) the yields are 
reduced. Additionally, EPR spectroscopy was employed by Patonay which suggested 
the presence of radical intermediates
[94c]





the single electron transfer (SET) from the nucleophile Nu  to the conjugated π 
system of the fluorophore, generating the radical dye species. Dissociation of this 
species and reaction with the nucleophile Nu  gives the radical Dye-Nu species, 
which acts as a one electron donor to re-initiate the reaction (Figure 21).  
 
 




Although there are differences between all the heptamethine dyes synthesised in 
terms of photo-physical properties, the heptamethine dyes absorb light in the NIR 
region as expected. Interestingly, amino-substituted heptamethine dyes showed a 




The heptamethine dyes synthesised, reaction yields and photo-physical properties are 













Figure 22: Structure of Cyanine Dye. 
 








± 10 % 
F 
± 10 % 
14 Me H 
 
82 789 818 43500 0.160 
15 C6H12O2 H  68 793 822 41000 0.145 
16 C3H7O3S H  30 797 825 68000 0.150 
17 Me Nap 
 
16 833 >850 85500 - 
18 Me SO3H  57 800 833 29000 0.110 
19 Me H 
 
82 777 825 23000 0.100 
20 Me H 
 
50 777 803 70000 0.430 
21 Me SO3H 
 
57 787 814 40000 0.280 
22 Me H 
 
15 796 830 120000 0.190 
23 Me SO3H 
 





24 Me SO3H 
 
34 640 764 25500 0.030 
25 Me H 
 
69 650 760 31000 0.026 
26 Me H 
 
60 640 758 22000 0.034 
27 Me SO3H 
 
79 632 764 21000 0.051 
28 Me H 
 
57 626 763 25000 0.036 
29 Me H 
 
31 639 766 36000 0.078 
30 Me SO3H 
 





31 Me SO3H 
 
55 619 771 19000 0.040 
32 Me SO3H 
 
83 608 772 35500 0.061 
33 Me H 
 
90 612 767 86500 0.093 
34 Me H 
 
54 652 777 81000 0.100 
35 Me SO3H 
 
52 637 771 42000 0.110 
36 Me H 
 
57 631 767 32000 0.078 
37 Me SO3H 
 
42 628 771 34000 0.082 
38 Me SO3H 
 





39 Me H 
 
55 787 815 23500 0.160 
Table 3: Structure, yield and photo-physical properties of heptamethine cyanine dyes. 
Absorption, emission, extinction coefficient and quantum yields were all measured in DMSO 




. R* = dye scaffold, Me = CH3, Nap= phenyl moiety generating 
naphthalene ring. 
 
2.6.3.1 Chloro Heptamethine Dyes (14-18) 
The chloro-heptamethine derivatives 14-18 as described in Table 3 all had 
absorbance and emission values in the NIR region as expected. The benz[e]indolium 
analogue (17) had an emission maximum above 850 nm, and was out-with the limits 
of the fluorometer available due to the extended conjugation of the π system. 
Extinction coefficients of these derivatives varied with higher values for the 
sulfonated indole and benz[e]indolium modified structures (17 and 18). It is 
interesting to note that sulfonation at the R’ position (18) over the R position (16) 
seems to lower the extinction coefficient substantially, whereas the quantum yield 
was only moderately lowered. Quantum yields of these 5 compounds (14-18) were 
higher than ICG (see Table 2), between 0.11-0.16 which was due to increased 
rigidity due to the cyclohexene ring in the centre of the molecule. Compounds 14-16 
compare the effect of the alky chain on the indole moiety, showing a small increase 
in the extinction coefficient for the sulfonated derivative (16), although quantum 
yields were extremely similar leading to the conclusion that the alkyl chain does not 
affect the overall photo-physical properties of the fluorophores. Addition of polar 
sulfonate moieties does tend to red shift the absorbance and emission spectra (14 and 
15 compared to 16) and is most likely due to the increased solubility of the molecule 
in DMSO, leading to decreased self-quenching. 
 
All chloro derivatives except cyanine 15 exhibit symmetry in their NMR spectra with 






2.6.3.2 Ether, Thio and Carbon Derivatives (19-23) 
As water is known to supress the SRN1 single electron transfer pathway
[128]
 
anhydrous solvents were used as a reaction medium to facilitate the substitution. 
Compounds 19 and 22 were successfully synthesised at room temperature using 
sodium hydride as the base. In order to use a milder base, chloro starting materials 14 
and 18 were pre-incubated with K2CO3, however, this route required elevated 
temperatures (70 ºC, 40 min or 100 ºC, 30 min) to synthesise 20 and 21. Synthesis of 
23 employed the use of a Suzuki-Miyaura coupling reaction using Pd(OAc)2 and 
PPh3. The reaction required heating at 100 ºC for 15 hours to give the desired product 
in 80% yield.  
 
Addition of functional groups with phenolates resulted in changes in the  
photo-physical properties. The absorbance wavelengths ranged from 777 to 796 nm 
while emission wavelengths between 803 and 830 nm characteristically remained in 
the NIR region. The emission wavelengths also increased with the addition of polar 
moieties (20 vs 21), however, they are generally blue shifted with respect to their 
chloro starting materials (20 vs 14 and 21 vs 18). Introduction of a carboxylic acid 
(19) or protected amine (20-21) into the scaffold have differing effects. The 
carboxylic acid introduction results in a decrease in extinction coefficient and 
quantum yield, possible due to the increased aggregation or dimer formation. The 
addition of N-Boc-tyramine (20) or N-[(4-hydroxyphenyl)methyl]-, 1,1-dimethylethyl 
ester (21) increases the quantum yield and extinction coefficients compared to the 
chloro starting materials (14 and 18 respectively). This is most likely due to the 
decreased aggregation and therefore lower self-quenching. Substitution with a 
thiolate (22) gives a further bathochromic shift in absorbance to 796 nm. This 





), however, due to the possible instability in vivo, the sulphur 
derivatives were discontinued. Carbon-carbon bond formation allowed synthesis of 




1) and a high quantum 
yield (0.36) in DMSO
[129]





non-sulfonated chloro heptamethine dye starting material (14) was unsuccessful, 
despite maintaining a high pH. 
 
An example NMR spectrum of an ether derivative is shown in Appendix 3. 
 
2.6.3.3 Amine Derivatives (24-39) 
The synthesis of amine substituted heptamethine cyanine dyes is currently an 
extremely hot topic in the search for new ratiometric imaging probes. In order to 
further advance this field, a variety of amine substituted fluorophores were 
synthesised.  
 
The reactivity of the amines was extremely dependant on the overall amine structure 
and on its ability to act as a single electron donor, while generally, triethylamine was 
required to allow the reaction to proceed. Optimisation of the purification conditions 
gave yields up to 90% yield. The methylamine derivatives (33 and 34) were 
synthesised using 2 M methylamine in MeOH. Care had to be taken not to add too 
many equivalents of the methylamine as the starting material decomposed. 
 
As expected on heating the reagents at 70 ºC, a colour change from green to blue was 
observed allowing the conversion to the product to be followed by UV/Vis 
spectroscopy. The large hypsochromic shift is attributed to the electron donating 
ability of the nitrogen and the excited state intramolecular charge transfer as 




 synthesised a variety of analogues to 
investigate the nature of the amine substituent on the absorption and emission 
profiles, concluding that decreasing the electron density on the amine, increased the 
absorption and emission wavelengths. 
 
The absorbance values of amine derivatives 24-37 range between 612-652 nm with 
emission values between 758-777 nm. The smallest and largest Stokes shifts were  
110 nm and 164 nm (in DMSO). These large shifts are extremely useful and may be 





these fluorophores. Firstly, sulfonation of the indole moiety results in a blue shift in 
the absorbance spectrum between 5-10 nm and a red shift in fluorescence maxima of 
4-6 nm (for example 24 vs 25, 26 vs 27 or 32 vs 33). The resulting increase in Stokes 
shift is apparent. Further, the extinction coefficients of the sulfonated molecules are 
generally lower than the non-sulfonated counter parts while the quantum yields 
remain comparable to those found in the literature
[108a, 131]
. Derivitisation to novel 
PEGylated fluorophores revealed an increase in the quantum yield over the alkyl 
counter parts (34 vs 36 and 35 vs 37). The PEGylated derivatives had quantum yields 
of 0.10 (34) and 0.11 (35) and are similar to ICG. This increase can again be 





 found that the photo-stability of the amino substituted derivatives could be 
increased by modification of the amine moiety with an electron withdrawing group. 
This was due to the stabilization of the iminium intermediate that prevents the 
incorporation of the reactive oxygen species causing degradation
[127]
. For this reason, 
functionalization of the amine (30 and 33) was attempted to remove this instability. 
Interestingly, this reaction results in a shift in absorbance and emission wavelengths 
in to region of 750-800 nm.  
 
 
Scheme 25: Acylation of amino-modified heptamethine cyanine dyes. 
 
This reaction was complex and was only successful in the presence of acetyl 
chloride. On addition of acetyl chloride to the amine derivatives 30 or 33 at 0 ºC, an 
instantaneous colour change occurs as the absorbance wavelength shifts into the red 
region. Derivitisation of 33 with acetyl chloride caused a large shift of absorption 
from 612 nm to 787 nm and emission from 767 nm to 815 nm. Although the Stokes 





increase in quantum yield to 0.16. Acetylation of compound 30 to 38 resulted in a red 
shift of the absorbance (from 634 nm to 685 nm) but a large blue shift in emission 
spectra (from 770 nm to 714 nm). This reduction is Stokes shift to 29 nm, is 
accompanied by a large increase in quantum yield to 0.59 (from 0.035 for 30). The 
changes in wavelength can be attributed to the removal of the photoactivating lone 
pair of the nitrogen
[131]
, however, the increase in quantum yield is still not fully 
understood.  
 
The general symmetry of the heptamethine dyes is conserved in the amine 
derivatives, while on acetylation of the amine (38 and 39) the symmetry is lost, likely 
due to the electron donation ability of the amine being substantially reduced. An 
example NMR spectrum is shown in Appendix 4. 
 
2.6.3.4 Non-Fluorescent Derivatives  
To develop additional novel fluorophores, isophthalaldehyde was selected as the 
cyanine backbone, in this case the reaction with the indolium salts gave a yellow or 
orange solid which was non-fluorescent.  
 
 
Scheme 26: Synthesis of non-fluorescent analogues. 
 
As can be seen in Scheme 26, the 6π electron system will be conserved. The 





polymethine chain and is therefore rendered non-fluorescent. For this reason, these 
derivatives were discontinued. 
 
2.6.3.5 UV/Vis Spectroscopy 
The absorption wavelengths of selected substituted and non-substituted heptamethine 
cyanine dyes are in shown Figure 23. 
 
 
Figure 23: Absorbance spectrum of a selection of dyes. Black = chloro-substituted (14); 
Red = ether-substituted (20); Dark blue = sulfonated variant of ether substituted (21); Light 
blue = amino substituted (26); Pink = sulfonated variant of amino substituted (27). 
 
This UV/Vis profiles show the difference between the amino, chloro, thio-ether or 
ether heptamethine derivatives with amino substitution resulting in a large blue shift. 
 
2.6.4 Cell Penetration and Toxicity 
Although there are many reports of cyanine dyes being used as molecular imaging 
probes in vitro and in vivo, the mechanism of uptake and localisation of the 
fluorophores are less well represented. The most comprehensive study was published 
in 2010 by Tong et al
[132]
. This report discusses the uptake of two common 
























 reported that these non-toxic fluorophores are specifically taken up by 
cancer cells over normal human cells. Additionally they discuss that the uptake 
mechanism is an active process carried out by a member of the OATP (organic anion 
transporting polypeptide) family. This was confirmed by blocking the dye uptake in 
the presence of an OATP competitive inhibitor, bromosulphthalein
[132]
. The 
localisation of heptamethine cyanine dyes within cells has resulted in some debate, 
with some suggesting accumulation in the mitochondria
[134]
 while others suggest 
accumulation in the cytoplasm with binding to many types of intracellular 
proteins
[112, 132, 135]
. Within the molecular imaging community there are often 
discussions with regards to the “stickiness” of cyanine dyes, with binding throughout 
the cell. It was decided to investigate localisation of cyanine dyes within cancer cells 
while varying the functionality and overall aqueous solubility of the molecules. As 
mentioned, sulfonation is a common way to increase the aqueous solubility of 
cyanine dyes, with PEGylation of cyanine dyes yet to be investigated. The addition 
of the polar, uncharged PEG chain may affect cellular uptake due to limited 
interactions with the negatively charged cellular membrane. In order to assess the 
cell penetration ability of cyanine dyes, 4 modified heptamethine cyanine dyes were 







Figure 25: Structures of the 4 novel dyes for cellular uptake analysis. 
 
Before carrying out any cellular work, the toxicity of these dyes was determined. In 
order to evaluate the toxicity potential, MTT
[136]
 assays of compounds 34-37 and 60 
were carried out using adenocarcinomic human alveolar basal epithelial (A549) cells 
and human prostate cancer (PC-3) cells.  
 
 







Figure 27: A549 cells incubated with 0, 2.5, 5, 7.5, 10, 15 and 20 µM dye for 24 hours 
prior to MTT analysis. a) 34, b) 35, c) 36, d) 37, e) Cyanine 60. Dye + MTT used to confirm 
minor overlap between MTT absorption and cyanine dye absorption. (n = 4). 
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Figure 28: PC-3 cells incubated with 0, 2.5, 5, 7.5, 10, 15 and 20 µM dye for 24 hours 
prior to MTT analysis. a) 34, b) 35, c) 36, d) 37, e) Cyanine 60. Dye + MTT used to confirm 
minor overlap between MTT absorption and cyanine dye absorption. (n = 3). 
 
Analysis of the MTT assay data shows that all 5 heptamethine dyes were non-toxic 
up to 20 µM.  
 
In order to determine cellular uptake of the cyanine dyes, flow cytometry
[33a]
 was 
employed. This process begins by incubating cells with a fluorophore or molecule of 
interest for a given period. These cells were subsequently washed and analysed with 
flow cytometry (see Figure 29 for an example histogram). 
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Figure 29: Example flow cytometry histogram of fluorescein labelled cells (green) and 
un-labelled cells (grey). Y-axis = cell count, X-axis = fluorescence intensity. ex = 488 nm, 
em = 515-545 nm. Data courtesy of Dr Sunay Chankeshwara. 
 
From the histogram in Figure 29, the labelled cells have an approximate 100 fold 
increase in fluorescence. Although the literature is somewhat scarce regarding flow 
cytometry of cyanine dyes, some studies have been carried out using cyanine dyes to 




The cellular uptake of 4 selected amino-heptamethine cyanine dyes (34-37) and 







Figure 30: Flow cytometry histograms of A549 cells incubated with selected dyes at 
10 µM for 2 hours. a) 34, b) 35, c) 36, d) 37, e) Cyanine 60. X-axis represents fluorescence 
intensity, ex = 633 nm, em = 770-800 nm. Y-axis represents number of particles. Red = non-







Figure 31: Flow cytometry histograms of PC-3 cells incubated with selected dyes at 10 
µM for 2 hours. a) 34, b) 35, c) 36, d) 37, e) Cyanine 60. X-axis represents fluorescence 
intensity, ex = 633 nm, em = 770-800 nm. Y-axis represents number of particles. Red = non-
labelled cells, blue = labelled cells. 
 
Both cell lines exhibited similar results with good cell penetration of all cyanine 
dyes. There was a distinct difference in uptake with regards to the sulfonated dyes 
compared to the non-sulfonated derivatives. The non-sulfonated molecules showed a 
100-1000 fold increase in fluorescence where the sulfonated molecules only 
exhibited a 10 fold increase. Although these results were promising, they could not 
be taken as conclusive as the use of an extracellular quencher prior to analysis was 
not possible. Extracellular quenchers are usually employed to ensure that any 
fluorescence intensity measured using flow cytometry is due to intra-cellular 
excitation and not membrane bound dye. As there were no suitable quenchers 





uncertain. In order to determine the position cyanine dye accumulation, confocal 
microscopy studies were carried out. With confocal microscopy cells are imaged as a 
succession of slices (Z-slices) with only one “slice” in focus and being imaged at any 
one time. After the sample has been fully analysed, these individual images are 
combined to give a final 3-D image or video clip. 
 
After incubation of the 5 selected cyanine dyes in A549 cells at 10 µM for  
30 minutes, the cells were counter stained with Syto 82 (nuclei stain). The cells were 
then washed once with PBS and imaged directly. In order to obtain different images, 
different excitation wavelengths were used. To visualise the nuclei stain and cyanine 
dyes, a He-Ne laser was used and the sample excited at 543 nm (nuclei stain), and 





Figure 32: Confocal images of A549 cells labelled with cyanine 60 (10 µM) for 1 h. A) 
arrow shows localisation of cyanine 60 (ex = 633, em = 661-704 nm), B) nuclei staining with 
Syto 82 (ex = 543 nm, em = 554-587 nm), arrow shows localisation of Syto 82, C) brightfield 






As we can see from the images in Figure 32, the localisation of cyanine 60 is similar 
to that obtained by the aforementioned imaging probes
[112, 134b, 134c, 135]
. The 
localisation is clearly in the cytoplasm, however, as the fluorescence seems to be 
punctate, one can assume that the dye has collected in the mitochondria. It is useful 
to note that the fluorophore is not trapped in the membrane, and does not pass into 
the nucleus as can be seen from the merged image (Figure 32, Image D). Analysis of 
the other cyanine dyes (Figure 33-Figure 36) show similar results, however, the 
fluorescence is more evenly spread out and can we can therefore suggest that they 




Figure 33: Confocal images of A549 cells labelled with 34 (10 µM) for 1 h. A) arrow 
shows localisation of 34 (ex = 633, em = 661-704 nm), B) Nuclei staining with Syto 82 (ex = 
543 nm, em = 554-587 nm), arrow shows localisation of Syto 82 C) Brightfield image to 








Figure 34: Confocal images of A549 cells labelled with 35 (10 µM) for 1 h. A) arrow 
shows localisation of 35 (ex = 633, em = 661-704 nm), B) nuclei staining with Syto 82 (ex = 
543 nm, em = 554-587 nm), arrow shows localisation of Syto 82, C) brightfield image to 




Figure 35: Confocal images of A549 cells labelled with 36 (10 µM) for 1 h. A) arrow 
shows localisation of 36 (ex = 633, em = 661-704 nm), B) nuclei staining with Syto 82 (ex = 
543 nm, em = 554-587 nm), arrow shows localisation of Syto 82, C) brightfield image to 







Figure 36: Confocal images of A549 cells labelled with 37 (10 µM) for 1 h. A) arrow 
shows localisation of 37 (ex = 633 nm, em = 661-704 nm), B) nuclei staining with Syto 82 
(ex = 543 nm,em = 554-587 nm), arrow shows localisation of Syto 82, C) brightfield image to 
visualise cell, D) Merged image. 
 
As expected, the sulfonated derivatives showed lower fluorescence intensity 
confirming the flow cytometry results. It was expected that PEGylation would have 
some effect on cellular uptake. However, this does not seem to be the case 
(compounds 34 and 35). This can perhaps be explained due to the PEG chain being 
too small with only 3 ether linkages. 
 
To further confirm these results a Z-stacking experiment was carried out using 
confocal microscopy to confirm cell penetration while staining the cytoplasm with 







Figure 37: Z-stack confocal merged images of 34 (10 µM) in A549 cells. Pink – 34, ex = 
633 nm, em = 651-704 nm. Red –Syto 82, ex = 543 nm, em = 576-619 nm. Green – 
Calcein, ex = 488 nm, em = 501-522 nm. 20 image slices taken penetrating through the 
cell. Images from a-f show increasing cell depth. Cell centre located approximately at image 
9 a) Z-stack image 4/20, no cell visible b) Z-stack image 6\20 cell coming into focus with 
nuclei appearing. c) Z-stack image 8\20, full cell visible with cyanine dye and nuclei 
fluorescence. d) Z-stack image13\20, cell moving out of focus. e) Z-stack image13\20, 
cyanine particles no longer visible as cell moves out of focus. f) Z-stack image 18\20, initial 
cell out of focus with new cell appearing (white arrow). 
 
From these results we can confirm that the cyanine dyes are taken up by mammalian 
cells and are not bound to the membrane. Structural modifications do not seem to 
have an effect although it can be said that cyanine 60 looks to be localised in the 
mitochondria more so than the others. The negative charge associated with the 
sulfonated derivatives is the most likely cause for the lower cellular uptake. As the 
cell membrane is negatively charged, the cyanine dye will be repelled to a larger 
extent than the non sulfonated analogue.  
 
2.6.5 Towards the Synthesis of Molecular Imaging Probes 
Studies relating to the meso substitution of cyanine dyes by nucleophiles has been 
discussed
[126a]
 and has found to reduce the stability of the final fluorophore
[138]
. 
Research by Chang 
[127, 131]





position by analysing the decomposition products formed (Scheme 27) and found 
that reacting the amino-functionalised heptamethine dye with acetyl chloride, 
photostability was remarkably improved (Scheme 28) 
 
 
Scheme 27: Decomposition of heptamethine cyanine dye by light irradiation. 
 
Scheme 28: Increasing the photostability of heptamethine cyanine dyes. 
 
Interestingly, these studies do not discuss the differing fluorescence properties of the 
acylated and non-acylated amino modified heptamethine dyes. As discussed earlier 
in this chapter, amino substitution of heptamethine cyanine dyes causes a large blue 
shift in the absorption wavelength
[139]
. With this information in hand, the 
development of a new molecular probe was attempted following the concept detailed 







Scheme 29: Target synthesis of enzymatic cleavage ratiometric imaging probe. 
In order to determine whether these amino-functionalised heptamethine scaffolds 
would be a substrate for enzymatic cleavage of an amide bond as shown, an 
aminomethyl-heptamethine molecule was synthesised by stirring chloro derivative 
14 with 2 M methylamine in methanol for 4 hours at 70 C generating compound 33. 
Attempts to find milder conditions to acylate the secondary amine was tried using 
acetic anhydride and triethylamine, however, no product was formed. Amide bond 
formation using Fmoc protected amino acids was also attempted with a variety of 
coupling reagents including acid chloride formation, however, these were also 
unsuccessful. Successful acylation was found using the reported acetyl chloride in 
DIPEA to give compound 39 (Scheme 30). Taking insight from Nagano in their 
synthesis of a heptamethine esterase probe
[140]
 and due to the presence of an acyl 
group it may be possible to develop an acylase probe. 
 
. 
Scheme 30: Cyanine dye 39 Acylated aminomethyl heptamethine dye. 
 
The optimum concentration (i.e. highest fluorescence intensity) of 39 was 









Figure 38: Investigation into the concentration effects on fluorescence of 
heptamethine dye 39. Dark pink – 97 µM, Blue – 48 µM, Orange – 24 µM, Black – 12 µM, 
Purple – 6 µM, Cyan – 3 µM. ex = 700 nm, em = 790 nm. 
 
Figure 38 shows that higher concentrations result in self-quenching and lower overall 
fluorescence intensity. Sufficient dilution of the fluorophore was at a concentration 
of 24 µM and therefore this concentration was selected for our cleavage assay. To 
test the cleavage of the amide bond, 4 enzymes were selected: trypsin, chymotrypsin, 
acylase and pepsin. 39 was dissolved in 50 mM ammonium bicarbonate solution (pH 
7.8) to give a final concentration of 24 µM. After incubation with a 1 mg/mL enzyme 
solution for 3-48 hours the solution was then measured for any change in 
fluorescence maxima, absorption maxima or HPLC ELSD shift. 
 
Unfortunately, analysis revealed no fluorescence increase or HPLC shift, concluding 
that cleavage of the amide bond did not occur in the presence of any enzyme. This is 
most likely due to the large and rigid structure of the cyanine dye that is unable to fit 
into the active site of the enzymes selected. In order to address the steric hindrance of 
the probe, a “self-immolative” linker was selected in order to increase the distance 





which on initial reaction a protecting group is removed, therefore causing a 
subsequent elimination reaction to release the desired molecule. These linkers are 
commonly used when dealing with controlled release of drugs within delivery 
systems
[141]
. One such strategy was employed by Cohen
[142]
 to develop a hydrogen 
peroxide activated MMP inhibitor. Modification of this strategy and application to 
heptamethine dyes was attempted (Scheme 31). 
 
 
Scheme 31: Possible self-immolation of ratiometric acylase probe. 
 
Functionalization of the heptamethine fluorophore with 4-hydroxymethyl phenyl 
boronic acid pinocol ester would allow development of a NIR hydrogen peroxide 
probe as described in (Scheme 32).  
 
 








2.6.5.1 Heptamethine Dye H2O2 Stability 
Before further experiments were carried out, it was important to determine the 
stability of the heptamethine dye in the presence of H2O2.  
 
Figure 39: Absorption spectra of compound 33 (1 mL solution, 92 µM) with H2O2 - Dark 
blue – no H2O2. Light blue – 10 eq H2O2 (0.92 mM). Light green – 100 eq H2O2 (9.2 mM). 
Dark green – 250 eq H2O2 (23 mM). Purple – 500 eq H2O2 (46 mM). Red – 1000 eq H2O2 (92 
mM). 
 
Figure 39 shows that compound 33 was stable with up to 100 equivalents of H2O2 
(9.2 mM) after 1 hour. This confirms that heptamethine dyes could potentially be 
used as an H2O2 sensor
[142]
. It is interesting to note that a new absorption peak occurs 
at 500 nm which is accompanied by a colour change from blue to pink (Figure 40). 
This pink solution supports the non-fluorescent degradation product described earlier 
in Scheme 27. Full decomposition of the fluorophore occurs with 500 equivalents (46 








Figure 40: Compound 33 Left: without H2O2. Right: with H2O2. 
 
Synthesis of the acylase probe linker moiety began from 4-hydroxybenzaldehyde. 
Protection of the phenol by treatment with acetic anhydride in pyridine at room 
temperature gave 49 with reduction of the aldehyde with sodium borohydride in 
ethanol gave the desired alcohol 50 (Scheme 33).  
 
 
Scheme 33: Synthesis of acylase probe self-immolative linker. 
 
Activation of alcohol 50 was initially attempted using triphosgene, however, no 
product was isolated. As an alternative, nitrophenyl chloroformate was reacted with 
the alcohol of 50 (Scheme 34) and commercially available hydroxymethyl phenyl 
boronic acid pinocol ester (82) (Scheme 35). Immediate column chromatography was 
carried out to yield the desired products (51 and 53). Confirmation that the carbamate 
underwent reaction with amines was modelled with benzylamine to give compounds 







Scheme 34: Synthesis of activated carbonate and test reaction. 
 
 
Scheme 35: Synthesis of activated carbonate and test reaction. 
 
Activation using nitrophenyl chloroformate was carried out on a large scale (1 g) 
with the stable adduct kept at 4 C for up to 3 months.  
 
To complete the synthesis of the probes, carbamate bond formation was attempted. 
Initially, heptamethine dye 33 and compound 53 were dissolved in dry MeCN with 
potassium carbonate and heated under microwave irradiation for 30 minutes. As 
expected, the solution turned from blue to green, with a characteristic absorption 
band appearing at 780 nm. Additionally, the correct mass was found by LCMS, 
however, on purification, the compound could not be isolated. Several purification 







Figure 41: LCMS spectra of crude mixture of reactants showing presence of starting 
material (33) and the product. 
 
In order to increase the yield of this reaction, several different organic bases, solvents 
and reaction conditions were attempted with no success.  
 
2.6.5.2 Monoamine Oxidase Probe 
Monoamine oxidases (MAO) exist in two distinct forms, MAO A and MAO B. 
MAOs catalyse the oxidation of a variety of neurotransmitters such as dopamine 
within the body
[143]
 and are generally found in the mitochondria of most mammalian 
cells
[144]
. Up-regulation of MAO can result in several degenerative diseases such as 
Parkinson’s or Alzheimer’s and therefore, real-time detection of these enzymes has 
become of extreme importance in medicinal chemistry. Chang
[145]
 reported a 
fluorescent probe for detection of MAO A and B. This sensor relied on a coumarin 
based fluorophore and will therefore suffer from high background  
auto-fluorescence in cells. The turn on fluorescence signal relies on the oxidation and 













 synthesised a similar coumarin based MAO probe, specific 
for MAO B. A novel, NIR MAO A or MAO B imaging probe would help in the 
battle against the degenerative neurological disorders mentioned above. To 
accomplish this, insight was taken from Yoon in the development of a NIR cyanine 
sensor for cysteine
[110]
. In this study, modulation of the -conjugation system of 
meso substituted heptamethine cyanine dyes was utilised (Scheme 37).  
 
 











Scheme 38: Hypothetical NIR MAO heptamethine probe. 
 
The first strategy employed to synthesise this MAO probe started from the synthesis 
of the 3-aminopropanol moiety. The amine was first protected with  
2-acetyldimedone(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde-OH), a 
protecting group that can be removed under conditions suitable for the fluorophore. 
Protection of the amine was carried out in methanol with DIPEA, requiring a simple 
purification to obtain product 55.  
 
Scheme 39: Attempted synthesis of NIR MAO probe. Dde-OH courtesy of Aurelie Brunet, 
Edinburgh University. 
 
As the literature has yet to show the SRN1 mechanism by a hydroxy group on 
heptamethine dyes, NaH was chosen as a strong non-nucleophilic base, however, on 
reaction with heptamethine derivative 14 no product was found, only recovering the 
dye starting material (Scheme 39). 
 
As shown by Yoon et al
[110]
 it is possible to generate a free alcohol from 
heptamethine derivative 14 using sodium acetate in DMF shown in Scheme 37. 
Using this design, the amino-propanol moiety was modified and replaced with 1-
bromo-3-proylamine with Dde-OH protection was carried out to produce 56 before 







Scheme 40: Synthesis of DDE protected 3-bromo-1-propanamine. 
 
Synthesis of the hydroxyl-heptamethine dye was successful to give 57. 
 
Scheme 41: Attempted synthesis of MAO probe from hydroxy-heptamethine dye. 
 
Two attempts were made to synthesise the final MAO probe with neither proving 
successful. The difficulty in this reaction can be related to the basic conditions in 
which the hydroxy-heptamethine dye is likely to be in the ketone form and therefore 
cannot react. 
 
2.6.6 Pentamethine Cyanine Dyes (42-48) 
Pentamethine (cyanine 5 type) fluorophores absorb and emit around 630-680 nm. 
Although these wavelengths are similar to the amine substituted heptamethine dyes, 
these dyes do not suffer for the same instability problems as amino cyanines. The 
He-Ne laser
[147]
 is a commonly used laser in confocal microscopy and has an 










Novel fluorophores are required and therefore synthesis of a new type of 




Scheme 42: Synthesis of novel pentamethine cyanine dyes. 
 
The reaction was carried out on small (25 mg) or large (5 g) scale which purifications 
only becoming troublesome when using sulfonated indolium salts. This problem was 
overcome by developing a new silica based purification system using MeCN:IPA 
rather than DCM:MeOH as the solvent mixture during column chromatography.  
 
 
Figure 42: 10 g Pentamethine Dye. 
 








Figure 43: General structure of pentamethine dye. 
 










± 10 % 
F 
± 10 % 
42 Me Ph COOH N 37 677 702 51500 0.250 
43 Me SO3H COOH N 35 650 676 78500 0.220 
44 C3H6O3S Ph COOH N 57 683 708 62000 0.220 
45 C3H6O3S Ph Cl C 42 686 709 39500 0.210 
46 C3H6O3S Ph NO2 C 67 684 710 81000 0.120 
47 Me SO3H NO2 C 81 650 676 61000 0.070 
48 Me SO3H Cl C 82 654 678 68500 0.290 
Table 4: Structure, yield and photo-physical properties of pentamethine cyanine dyes. 







This new class of pentamethine cyanine dyes have an absorption maximum between 
676 and 686 nm and an emission maximum between 676 and 710 nm. These deep 
blue coloured molecules have a small Stokes shift (24-26 nm) characteristic of 
cyanine dyes and are suitable for excitation with a He-Ne laser (633 nm). The 
reaction yields vary between 35-82 % with increasing yields due to the optimisation 
of the purification solvent system. In general, purification of the sulfonated 
analogues was laborious, with the addition of acetic acid to the eluent system needed 

















). Interestingly, the quantum yields are remarkably high for 
cyanine dyes in the region of 0.20-0.29, however, addition of a nitro group to the 
phenyl ring (46 and 47), caused this value to drop dramatically to 0.070 and 0.120. 
Modification of the indole ring provides some insight into the effect of the sulfonate 
group in the R position. In addition to increased aqueous solubility, a slight red shift 
was observed when compared to the methylated fluorophore (42 vs 44). The 
increased rigidity and planarity of the structure in the case of the benz[e]indolium 
fluorophores supports the increased quantum yield when compared to the indole 
derivative (42 vs 43). The 
1
H NMR of all compounds showed symmetry down the 
centre of the molecule common to cyanine dyes.  
 
Compounds 42-48 were suitable for further functionalisation via Suzuki-Miyaura 
coupling for the chloro derivatives
[33a]
, nucleophilic substitutions or reduction of the 
nitro group to an amine
[150]
. Such modifications could be the generation of FRET 
probes by the addition of a cleavable sequence attached to an appropriate fluorophore 
such as cyanine 3.  
 
An example NMR spectra is shown in appendix 5.  
 
2.6.6.1 Photo-Stability of Pentamethine Cyanine Dyes 
For most practical procedures the fluorophore is exposed to light and it was 
important to verify the stability of these new fluorophores. Compound 43 was 
dissolved in NMP (0.01% w/v) and was irradiated with UV light for 30 minutes with 
and without the addition of a photoinitiator 1-hydroxycyclohexyl phenyl ketone 
(Iragacure 184) (0.2% w/v) and the fluorescence intensity measured. The 
photointiator under UV light generates free radicals (Scheme 43) which destroys the 







Figure 44: UV Irradiation of pentamethine dye 42 with and without the presence of 
photointiator. Left image: Before UV irradiation. Right image: After UV irradiation. Control is 
dye 42 alone at time 0. 
 
Visually, it is apparent that after 30 minutes in the presence of the photoinitiator the 
cyanine dye has decomposed, which was confirmed using fluorescence spectroscopy. 
 
 
Figure 45: Pentamethine dye (42) stability to UV irradiation. Fluorescence intensity of 
cyanine 42 dye after irradiation with UV light, with and without the photoinitiator. 
 
This data shows that without a photointiator, irradiation with intense UV light for 30 
minutes does not cause photobleaching of the cyanine dye. 
 
 








The synthesis of cyanine dyes has become trivial with the ability to use solid or 
solution phase chemistry. More pressing issues are the modification of heptamethine 
cyanine dyes to develop molecular sensors and optical imaging agents. The synthesis 
of 26 heptamethine dyes with a broad range of absorption and emission wavelengths 
and a large Stoke’s shift range has been carried out. Variation of the functional 
groups was found not to play a part in cellular toxicity or cellular uptake which may 
prove useful for qualification of new fluorescent molecules for use in vivo. These 
dyes can be further functionalised to generate turn-on fluorescent probes or imaging 
agents. 
A new class of pentamethine cyanine dyes is also described with ideal absorption 
wavelengths for the He-Ne laser. These molecules can be further functionalised 
increasing their possibility for use in molecular imaging. Currently, collaborators at 
DestiNA Genomics and STMicroelectronics are attempting to utilise these new 







Near Infrared Fluorescent 
Microspheres 
3.1 Introduction to Nanoparticles 
The need for new delivery systems and controlled release technologies for medical 
diagnostics is high with annual sales expected to exceed $133 billion by 2015
[151]
. 
Novel small molecules tend to have low solubility in aqueous media and often 
require delivery systems that are non-toxic
[152]
. Drug release from polymers dates 
back to 1960 when Folkman described the controlled release of drugs from silicone 
rubber
[153]
. Since then, polymeric particles including nano-materials have been used 
as drug delivery vehicles. Polymeric nanoparticles are becoming an increasingly 
viable option
[154]
 due to their ease of synthesis
[155]
 and their ability to easily 





and nanoparticles do not require removal of the delivery device after cargo release. 
 
Nanoparticles are becoming widely used in biological sciences due to their high 
cellular uptake
[33a, 158]
, and low cellular toxicity
[159]
. One of the most important 
features of nanoparticles is their high surface area to volume ratio, resulting in a high 
number of functional groups present on the surface of the particle
[160]
. Functionalised 
particles below 200 nm are very reactive with these high surface area molecules 
often being used in catalysis
[161]
. One example of the use of nanoparticles is shown in 
the field of “theranostics”
[162]
 in which both diagnosis and therapy can be 
administered simultaneously
[163]
. For example, Rossi
[164]
 functionalised silica coated 
magnetic particles with methylene blue (a photodynamic therapy drug) and then 






The addition of fluorophores to nanoparticles has resulted in a number of 
applications, for example, Bradley functionalised microspheres with fluorescein 
imparting the ability to sense intracellular pH between 6 and 8
[165]





 and drug delivery
[36]
. So far, the 
fluorophores used absorb and emit light below the near infrared window and 
therefore novel NIR microspheres are sought after.  
 
Although the addition of fluorophores to the outside of polymeric particles through 
covalent linkers have interesting applications, the synthesis of more exotic probes 
can be difficult. Furthermore, functionalisation can be problematic due to the large 
number of molecules on the particles surface. The ability to penetrate the particle 
core and produce inherent fluorescent nanoparticles may overcome this. Such 
synthesis of organic NIR inherent microspheres, with the ability to be further 
functionalised have to my knowledge, never been investigated and could provide a 
useful tool for the imaging of cellular process in vivo.  
 
3.2 Inherent Near Infrared Nanoparticles (NIR-NPs) 





 and emulsion free polymerisation
[170]
 procedures. Emulsion free 
polymerisation uses charged monomer units such as 4-vinylbenzylamine 
hydrochloride
[171]
 or acrylic acid. These monomers prevent particle aggregation and 
also introduce reactive functional groups at the particle surface which can be used for 
derivitisation. 
 
Currently, to obtain inherent fluorescent particles the most common route is to use a 
solvent evaporation method
[172]
 or a swelling and shrinking procedure to trap a 
fluorophores inside the particle of choice
[173]
. These techniques may give the desired 
fluorescent core, however, the encapsulated molecule may leak out of the 
particle
[174]
. For example, Yang et al
[175]
 utilised the solvent evaporation method to 





drug distribution in tropical fish. Utilising the fluorescence attribute of BSA and by 
varying the microsphere structure, the rate of BSA diffusion was monitored using 
confocal microscopy (ex 488 nm)
[175]
. It is also possible to synthesise fluorescent 
particles by incorporating the fluorophore into the particle during synthesis as a 
monomer. some examples include Hostasol Yellow 3G
[176]
 through emulsion 
polymerisation with an anionic surfactant (max 450 nm, Figure 46), Europium based 
-diketonate complexes
[177]
 (max 300-450 nm) or styrene containing fluorescein
[158a]
 




Figure 46: Emulsion polymerisation of Hostasol Yellow derivative (HYC2MA) in the 
presence of surfactant to give polymer particles with Styrene (30% wt), AIBN (1% wt) 




Gold or Fe3O4 based NIR absorbing particles have also been constructed with the 





 exist including Ag-Au
[180]
 or lanthanide 
based nanoparticles
[181]
. Nanoparticles such as these can provide a synergistic effect 
due to their ability to be used as contrast agents for MRI while having the  
photo-physical ability to convert NIR irradiation into heat, enabling proximity 
damage to tumour cells. Although useful, these particles contain unwanted metal 









Figure 47: Dual imaging Fe3O4 based nanoparticles coated with Cu9S8 (left). Magnetic 
properties allow MRI imaging (top right) and NIR absorption allowing for thermal 
imaging (bottom right). Reprinted with permission from
[179b]
, copyright (2013) American 
Chemical Society. 
 
Similarly, quantum dots, most commonly constructed from cadmium and selenium 
have excellent photo-physical properties with tuneable absorption and emission 
wavelengths
[183]
. Quantum dots are commonly described as toxic to cells
[184]
, 
however, more recent studies have suggested that this toxicity to cells may not be 




3.3 Chapter Aims 
Fluorescent microspheres most commonly include fluorophores with absorption and 
emission wavelengths below the NIR window. The use of nanoparticles which 
absorb and emit light in the NIR region will allow for increased in vivo applications. 
The synthesis of a NIR fluorescent particle with the ability for further modification 
was targeted with investigations into the particles’ cellular uptake and toxicity 
explored.  
 
Furthermore, the use of NIR fluorophores to track the localisation of microspheres 
within cells while covalently attached to polymeric nanoparticles is discussed, with 






3.4 Results and Discussion 
3.4.1 Synthesis of Polymerisable Cyanine Dyes 
In order to synthesise near infrared organic fluorescent particles, a heptamethine dye 
was designed with a styrene moiety to allow polymerisation (Scheme 44). Starting 
from chloro-heptamethine cyanine dye (14 or 18) (see Chapter 2, Table 3),  
4-aminomethyl styrene was attached by stirring at 100 ºC for 1 hour under 
microwave irradiation in the presence of a base. Purification gave the desired 
compounds in reasonable yields. 
 
 
Scheme 44: Synthesis of styrene modified heptamethine dye. 
 
 
Figure 48: HPLC-ELSD traces of a) 24 (HPLC method 3) and b) 25 (HPLC method 2). x-
axis represents retention time in minutes, y-axis represents signal intensity. (see chapter 6.1 







3.4.2 Synthesis of Inherent Near Infrared Nanoparticles 
The synthesis of the near infrared nanoparticles (NIR-NP) was carried out using an 
emulsifier free polymerisation. Styrene, divinylbenzene (DVB, 2%),  
para-vinylbenzylamine hydrochloride (VBAH, 3%), heptamethine dye (25, 3%) and 
the water soluble initiator 2,2'-azobis(2-methylpropionamidine)dihydrochloride  
(V-50) were stirred in water at 80 ºC for 15 hours. The particles were collected by 
centrifugation and washed with DMF, MeOH and water until the supernatant was no 
longer coloured (Scheme 45). 
 
 
Scheme 45: Synthesis of NIR particles 58 and cartoon of fluorescent nanoparticle with 
free amines at surface. 
 
Particles 58 were examined by flow cytometry and dynamic light scattering to 







Figure 49: Analysis of NIR-NP 58 a) Flow cytometry histogram, ex = 633 nm, em = 785 
nm, grey section – particles without cyanine dye monomer, blue section –particles with 
cyanine dye monomer. y-axis represents number of particles, x-axis represents fluorescence 
intensity b) Dynamic light scattering analysis, y-axis represents percentage of particles, x-
axis represents particle size. Average particle size was 165 nm with a polydispersity index of 
0.09. 
 
NIR-NPs 58 were synthesised with an average hydrodynamic diameter of 165 nm 
and a polydispersity index of 0.09. Particle fluorescence was confirmed using flow 
cytometry showing an increase in fluorescence intensity over particles with no 
fluorophore by over 100 fold. 
 
3.4.3 Cellular Toxicity and Uptake of Near Infrared Nanoparticles 
In order to determine the toxicity of the NIR-NPs 58, the MTT assay was utilised to 
determine cell viability. Incubation of particles 58 with HeLa cells for 24 hours 
confirmed internalisation did not cause cell death up to a concentration of 75 µg/mL 







Figure 50: HeLa cells treated with 0 to 75 µg/mL of 58 for 24 hours prior to MTT 
analysis. DMSO represents no cells. (n = 3). 
 
Confocal microscopy was carried out to show the location of the nanoparticles within 
the cell. A549 cells were selected and incubated with 58 (100 µL of 75 µg/mL in 
PBS pH 7.4) for one hour followed by washing once with PBS and live cell imaging. 
To determine the location of the particles the A549 cells were incubated with Syto 82 








Figure 51: Confocal images of A549 cells incubated with 58 at 75 µg/mL for 1h. a) 
Microsphere uptake and cellular labelling with 58 (pink, ex = 633, em = 651-704 nm), arrow 
shows localisation of NIR-NP’s throughout the cell, b) Nuclei staining with Syto 82 (red, ex = 
543 nm, em = 576-619 nm), arrow shows localisation of Syto 82 within nucleus c) cytosol 
labelling with Calcein (green, ex = 488 nm, em = 501-522 nm) arrow shows outer 
membrane, d) Merged image. Arrows show aggregated microspheres localised within the 
cytoplasm. 
 
The confocal images suggested cellular uptake of the microspheres into the cells, 
throughout the cytoplasm, although the microspheres appeared to have aggregated. A 












Figure 52: Z-stack confocal merged images of A549 cells incubated with 58 at 75 
µg/mL for 1h. Pink – Particles 58, ex = 633 nm, em = 651-704 nm. Red -Syto 82, ex = 543 
nm, em = 576-619 nm. 38 image slices taken penetrating through the cell. Cell centre 
located at image 11 a) Z-stack image 2/38, no NIR-NP detection b) Z-stack image 5\38 
arrow highlights nucleus, little NIR-NP detection c) Z-stack image 8\38, arrow shows 
emergence of NIR-NP’s within the cell, d) Z-stack image 11\38, arrow shows localisation of 
NIR-NP’s within the cell, e) Z-stack image 17\38, arrow shows localisation of NIR-NP’s 
outside the cell, f) Z-stack image 24\38. 
 
Figure 53: Zoom of Z-stack slice image 12/38 of A549 cells incubated with 58 at 75 
µg/mL for 1 h. Pink – Particles 58, ex = 633 nm, em = 651-704 nm. Red -Syto 82,  
ex = 543 nm, em = 576-619 nm. Red arrow shows nucleus, white arrows show fluorescent 





The NIR particles were visualised inside the cell and were not observed to penetrate 
the nucleus. Analysis of the Z-stack images confirmed cellular uptake and revealed 
attachment to the cellular membrane and aggregation of particles outside the cell. 
Aggregation of these particles may result in lower fluorescent intensity and therefore, 
the optimum concentration should be determined to limit this aggregation. 
 
3.5 Functionalised Particles 
3.5.1 Aim 
Functionalisation of polymer particles is an effective tool to develop optical imaging 
probes. The ability to attach both a reporter molecule to track the particle, and a 
cargo moiety to be delivered can be difficult, however, polymer particles with 




Figure 54: Targeted dual functionalised microspheres for attachment of cyanine dyes 
and cargos. 
 
Orthogonal reactive groups allow the controlled addition of two individual 
components to a particle surface. Synthesis of a NIR fluorophore with a free 
carboxylic acid moiety would allow particle attachment with further orthogonal 
functionalization of the particle through a Suzuki-Miyaura coupling reaction allows a 
secondary cargo moiety to be attached. Development of a polymer particle for 
cellular uptake and a turn on fluorescent signal on activation was attempted by dual 







Figure 55: Hypothetical cellular delivery probe undergoing intracellular cleavage to 
release cargo and fluorescein moieties. Cyanine dye allows tracking of particle within cell 
at all times. Intracellular cleavage results in removal of fluorescence quenching and a “turn 
on” signal of fluorescein. 
 
3.5.2 Solid-Phase Synthesis of Cyanine 
3.5.2.1 Synthesis of Starting Materials 




Figure 56: Targeted cyanine dyes. 
 
The initial synthetic steps were the same for both cyanine 3 and cyanine 5 and 









Scheme 46: Amine protection with Boc-anhydride. 
 
Specific amine protection was achieved by using di-tert-butyl dicarbonate  
(Boc-anhydride), following the procedure by Chankeshwara et al
[186]
 with the pure 
product precipitating. 
 
To perform solid-phase synthesis, 1% divinyl benzene (DVB) cross-linked 
chloromethyl polystyrene resin (Merrifield resin, 2.0 mmol g
-1
) was reacted with the 






Scheme 47: Attachment of 61 and deprotection of the Boc group. 
 
Boc deprotection of 62 in 20% TFA in DCM gave aniline 63 allowing dye synthesis 
to begin (Scheme 47).  
 
3.5.2.2 Cyanine 3 Synthesis 
The synthesis of cyanine 3 requires a three carbon polymethine chain and thus 





4-hydroxyphenylimidoformate polystyrene (PS) (64) and 2-[(E)-2-(4-
hydroxyanilino)ethenyl]-1,3,3-trimethyl-3H-indolium iodide PS (65) (Scheme 48). 
 
 
Scheme 48: Synthesis of ethyl 4-hydroxyphenylimidoformate PS. 
 
Extensive washing was essential to remove any residual 1,2,3,3-tetramethyl-3H-
indolium iodide (9) still present. 
 
The final step of the reaction involved simultaneous cleavage of the dye and addition 
of the carboxypentyl carboxylic acid functionalised indole (Scheme 49). 
 
 
Scheme 49: Synthesis of cyanine 3. 
 
Evaporation of the solvent and purification of the pink solid by column 
chromatography (a slow gradient of methanol in DCM) gave the pure product 59. 
The column did suffer from some difficulties owing to the fact that the pure dye 





carboxylic acid in the acid or carboxylate form. The symmetrical hemicyanine dye 
was also synthesised (Figure 57), however, due to its apolar nature, it was eluted 
before the un-symmetrical cyanine 3 (59). Although most of the product eluted at 
15% MeOH in DCM, increasing the solvent polarity to 20% MeOH ensured 
maximum dye recovery. Dye synthesis was confirmed using proton and carbon NMR 
spectroscopy, specifically observing the presence of the aliphatic carbons on the 
carboxypentyl acid chain. The cyanine 3 molecule had a maximum absorption of 547 
nm and a maximum emission of 570 nm in MeOH. 
 
 
Figure 57: Undesired symmetrical cyanine dye. 
 
3.5.2.3 Cyanine 5 Synthesis 
The addition of the polymethine chain to obtain a chain length of 5 carbons was 
carried out using tetramethoxy propane (Scheme 50).  
 
 
Scheme 50: Synthesis of 4-[(E,2E)-3-methoxy-2-propenylidene ]amino}phenol PS. 
 
Once again, extensive washing of the resin with DCM and MeOH was essential to 
reduce formation of the symmetrical dye. The final step of the reaction involved 
simultaneous cleavage of the dye and addition of the carboxypentyl carboxylic acid 






Scheme 51: Synthesis of cyanine 5. 
 
The dark blue solid (60) was purified by column chromatography in a similar manner 
to cyanine 3, with only small quantities of the symmetrical by-product formed 
(Figure 58). The cyanine 5 molecule had a maximum absorption of 640 nm and a 
maximum emission of 665 nm in MeOH. 
 
 
Figure 58: Undesired symmetrical cyanine 5 dye. 
 
Although the unwanted symmetrical by-product was obtained, it was easy to 





As cyanine 5 dye has higher absorption and emission wavelength than cyanine 3 it is 
less affected by the auto-fluorescence of biological tissue and was therefore was 








3.5.3 Synthesis of Functionalised Polymer Particles 
In order to obtain amino-boronic acid particles of the required size (~200 nm), the 
particles were synthesised as discussed previously (Chapter 3 Section 3.4.2) by an 
emulsifier-free emulsion polymerisation
[189]
 The addition of para-vinylbenzyl 
boronic acid (VBA) to the synthesis (Scheme 52) allowed for the synthesis of dual 
amino and boronic acid functionalised nanoparticles. 
 
 
Scheme 52: Synthesis of dual functionalised nanoparticles. 
 
The emulsifier free synthesis was attempted using styrene, DVB (3%), VBAH (3%) 
and VBA (3%) in water using the water soluble initiator V-50. These conditions gave 
particles 68 with an average hydrodynamic diameter of 230 nm and a PDI of 0.071. 
Increasing levels of VBA to 6 and 9 % resulted in increasing PDI’s. This may be 
because of the acid-base interactions between VBAH and VBA disturbed  
VBAH-mediated micelle formation during polymerisation
[169]
. To measure the 
functionalization level of the particles, a ninhydrin test
[190]
 was used to determine 
amine loading. To quantify the boronic acid loading, inductively coupled 
 plasma – optical emission spectroscopy (ICP-OES
[191]
) was employed. Particles 68 
exhibited an amine loading of 129 ± 15 µmol g
-1
 and boronic acid loading of 62 ± 1 
µmol g
-1
. After, the efficiency of the Pd-mediated cross-coupling reaction to an aryl 
halide was tested.  
 
3.5.4 Palladium Mediated Suzuki-Miyaura Cross-Coupling 
Palladium mediated cross-coupling on to the boronic acid functionalised particles 68 





conditions (Scheme 53 and Table 5)
[192]
. Introduction of a fluorescent molecule to the 
particle surface allowed monitoring of the coupling reaction using flow cytometry 
and ICP-OES to monitor the decreasing boron content.  
 
 
Scheme 53: Pd mediated particle conjugation. 
 
Run Catalyst/Conditions Yield (%) 
1 PPh3/Pd(OAc)2/PBS/37 ºC/24h 26 
2 Pd(dppf)Cl2/Pd(OAc)2/PBS/37 ºC/24h 22 
3 Pd(OAc)2/PPh3/K2CO3/ PBS/37 ºC/24h 24 
4 Pd(OAc)2/PPh3/Cs2CO3/ PBS/37 ºC/24h 17 
5 Pd(OAc)2/o-Tol3P/K2CO3/ PBS/37 ºC/24h 15 
6 Pd(PPh3)4/K2CO3/ Glutathione/PBS/37 ºC/24h 24 
7 Pd(PPh3)4/K2CO3/ PBS/microwave/60 °C/1h 23 
8 Pd(OAc)2/NaADHP/PBS/37 ºC/12h 38 ± 4 (n=3) 
 
Table 5: Palladium mediated coupling conditions (Pd, 5 % with respect to  
iodo-fluorescein). 
 
The coupling reaction was carried out using an excess of 5-iodofluorescin (40 µM, 
50 eq) and a palladium catalyst concentration of 5% with respect to iodo-fluorescein. 
Analysis of the boron content of the fluorescein labelled particles showed the 
optimum reaction conditions were 37 C using the water soluble catalyst complex 
~2-amino-4,6-dihydroxypyrimidine-Pd(OAC)2 in PBS (entry 8 in Table 5, 
compound 69). ICP-OES analysis of the particles revealed a 40% reduction in boron 
content with flow cytometry showing a 500-fold increase in fluorescence compared 





non-iodinated fluorescein and no catalyst showed no reaction took place as expected. 
The low reduction in boron content (40% reduction) was attributed to the boronic 
acid groups residing throughout the particles and as the surface moieties react, the 




3.5.5 Probe Synthesis 
A molecule containing a disulphide linkage, iodo-fluorescein and a fluorescence 
quencher
[194]
 (methyl red) that could be attached to the particle via the Pd mediated 
coupling as described above (Figure 55 and Scheme 54) was synthesised by Dr Frank 
Thielbeer. Reduction and cleavage of the disulphide linkage by reducing agents such 
as glutathione
[195]
 results in release of the fluorescein-cargo moiety from the 
quencher, allowing the emission of fluorescein to be detected. A non-cleavable 







Scheme 54: Synthesis of dual functionalised particles. Cyanine 60 (blue), methyl red 
quencher (red), fluorescein (green). Quenched fluorescein section of probe courtesy of Dr 
Frank Thielbeer. 
 
The particle was prepared by coupling cyanine 60 using ethyl 2-cyano-2-
(hydroxyimino)acetate (Oxyma) and N,N-diisopropylcarbodiimide (DIC) in DMF. 
The iodo-fluorescein molecule was attached using Pd mediated chemistry as 
described above. To confirm coupling of the large molecule, ICP-OES was carried 
out, revealing a 23% drop in boron content. The cargo molecule was a short anionic 
peptide (DDGD-NH2) to ensure the fluorescein would remain within the cell due to 








3.5.6 In Vitro Analysis of Dual Functionalised Particles 
To determine cellular uptake, the particles were incubated with HEK293T and HeLa 
cells and the uptake monitored by flow cytometry detecting the cyanine 60.  
Figure 59 confirms the ability of the disulphide linked probe particles and  
non-cleavable control particles to be taken up by cells.  
 
 
Figure 59: Cyanine 60 fluorescence intensity of a) HEK293T and b) HeLa cells 
following uptake of dual functionalised particles with cytosol cargo. Disulfide-linked 
cleavable probe (70, red), non-cleavable control particles (71, blue). Data courtesy of Dr 
Frank Thielbeer. 
 
To determine the localisation of the probe, and confirm tracking of the nanoparticles 
with cyanine 60, HEK293T cells were incubated with 70 and 71 for 48 hours and 
imaged using confocal microscopy. The nuclei and cytoplasm of HEK293T cells 










Figure 60: Confocal microscopy images of HEK293T cells following incubation with 
cytosol targeted disulphide linked cleavable probe 70 (50 mg mL
-1
) and non-cleavable 
control 71 (50 mg mL
-1
). a) nuclei stain Hoechst 33342 (blue, ex = 404 nm, em = 535-590 
nm), cytoplasm stain cell tracker red CMTPX (red, ex = 594 nm, em = 575-615 nm); b) 
nucleus stain (blue), and particles labelled with cyanine 60 (pink, ex = 633 nm, em = 650-710 
nm); c) nucleus stain (blue) and released fluorescein (green, ex = 488 nm, em = 480-520 
nm); d) merged image. Scale bar: 50 µm Data courtesy of Dr Frank Thielbeer. 
 
 
The images verified linker cleavage and cytosol localisation of the disulphide 
cleavable probe. The ability to track both the nanoparticle (cyanine 60  
excitation - ex 633 nm) and the cargo moiety (fluorescein - ex 488 nm) was 
successful (Figure 60). As the cargo moiety was an anionic peptide, both segments of 
the probe remained in the cytoplasm. Additionally, the non-cleavable control 
particles showed only the microsphere (cyanine dye) fluorescence and confirmed that 







A synthesis of NIR microspheres was developed and the beads characterised. In vitro 
experiments showed that the particles were non-toxic while confocal microscopy 
images, including z-stacking, confirmed cellular uptake and localisation within the 
cytoplasm, with no nuclear penetration observed. The particles were also found to 
aggregate, with binding to the cell membrane detected. The amine groups present on 
the surface of the microspheres allows for further derivitisation, with opportunities to 
track intra-cellular processes or help in the design of delivery vehicles. Addition of 
further functionalities may also be achieved by increasing the number of 
polymerisable starting materials, such as para-vinylbenzyl boronic acid to introduce 
a boronic acid group, suitable for Suzuki-Miyaura cross coupling. Currently, 
collaborators are working on the functionalisation of these beads with different 
chargd moieties to determine the effect on cellular uptake.  
 
These studies also reported the successful synthesis of dual functionalised 
nanoparticles. Cyanine 60 was synthesised and attached to the microspheres through 
carbodiimide chemistry while dual functionalisation was achieved through the 
addition of a fluorescent reporting cargo moiety using a water soluble, optimised, 
Suzuki-Miyaura cross-coupling reaction. The quenched probe molecule could be 
taken up by cells while cleavage of the disulphide linker resulted in the removal of 
quenching. Non-cleavable control particles did not exhibit fluorescein fluorescence 
after cellular uptake. Tracking of the particles using cyanine 5 and the cargo moiety 
was carried out using confocal microscopy. This study provided the first example of 
employing a bio-orthogonal approach to dual functionalization of particles resulting 
in monitoring and controlled release within the cytoplasm. A cyanine 3 molecule 
(59) was also developed and could be used in a similar manner if the wavelengths are 







Development of a Sensor for Gram 
Negative Bacteria 
4.1 Bacteria Introduction 
Bacteria are unicellular micro-organisms which lack a membrane bound nucleus. 
Most commonly described as prokaryotes (Figure 61), bacteria can vary in size from 
the micro bacteria family of thermodiscus at 0.2 µm in diameter to the 
gigantobacteria of thiomargarita namibiensis which can reach a diameter of 750 
µm
[196]
. Although these are immense size differences, in general the prokaryotic cell 





Figure 61: Cartoon representation of prokaryotic cell. 
 
Although bacteria can be characterised by their morphology, for example rod, 
spherical or spiral, characterisation of bacteria is most commonly discussed by the 
cell wall structure present. First described by Gram in 1884 while developing a 
colorimetric test based on crystal violet
[198]











Figure 62: Crystal violet structure. 
 
Gram positive bacteria, have a thick peptidoglycan cell wall which mainly consists of 
glycan strands which are cross-linked by alternating N-acetylglucosamine and  
N-acetymuramic acid sugar subunits linked together by covalent bonds
[197]
. This wall 
can retain crystal violet, staining the bacteria purple. Gram negative bacteria have the 
same cell wall, however, it is much thinner and therefore does not retain the stain as 
effectively, staining the bacteria pink
[200]
. Gram negative bacteria do however have 
an outer cell membrane containing phospholipids and lipopolysaccharides (LPS). 
This outer layer functions as an exclusion barrier, hindering the passage of large (> 









Figure 63: Structures of Gram positive and Gram negative bacterial cell wall. 
 
Although the Gram stain test is popular, it can give false positives or negatives, can 
be time consuming and due to being a colorimetric test, can have low sensitivity
[201]
. 
Another issue is the occurrence of false negatives due to some Gram positive bacteria 
decolouring
[202]
. Additionally, Edlich suggested that various factors may cause a 
false decolourisation, these include the amount and mode of fixation of the 
sample
[203]
. For this reason other tests have been developed. For example, 
Gregerson
[204]
 developed a KOH test to distinguish between Gram positive and Gram 
negative bacteria. This protocol requires the use of 3% KOH in order to dissolve the 
thin cell wall of Gram negative bacteria, resulting in a visible change in viscosity of 
the test solution. Gram positive bacteria are un-affected as 3% KOH cannot rupture 
the thicker cell wall. Although this seems reasonable, some studies have found 





a colorimetric test using the presence of aminopeptidases in the LPS membrane of 







Scheme 55: Colorimetric detection of alanine-aminopeptidase. 
 
This probe takes advantage of the cleavage of amide bonds by proteases, in this case, 
alanine aminopeptidase. L-alanine 4-nitroanalide is weakly coloured but hydrolysis 
of the amide results in the highly coloured 4-nitroalanine molecule
[207]
.  
Specific detection of bacterial infections in real time is lacking and it would be of 
great use to clinicians to accurately diagnose patient infections and personalise 
treatment. Diagnosis of respiratory problems such as lung infections most commonly 
require a bronchoalveolar lavage followed by colorimetric culture tests like those 
described above to determine the type of bacterial infection
[208]
. Advancing 
technologies in the field of imaging has led to development of a micro-endoscope 
which allows real time fluorescence imaging of the lungs
[209]
. Utilising this 
technology, development of a bed side imaging probe to specifically detect Gram 






Aminopeptidases are enzymes that catalyse the cleavage of amino acids from the 
amino terminus of proteins and peptides. Although there are many different 
aminopeptidase enzymes, the periplasmic alanine aminopeptidase has received the 
most attention
[207]





 ions at the active site. Aminopeptidases are found throughout the 
cell, including in organelles such as the mitochondria
[211]
 and can even be membrane 
bound
[212]









Figure 64: Bestatin. 
 
Aminopeptidases are found in the cell membrane of Gram negative bacteria and are 
therefore a good target for developing simple and fast methods of detecting specific 
bacteria. During this work, the Cerny method has been adapted by others to generate 
more sensitive fluorescent sensor
[214]
. However, this research does not discuss live 
bacterial assays.  
 
4.2 Chapter Aims 
The ability to detect the presence of Gram negative bacteria in a specific and fast 
manner would be of great benefit to the medical community. Fluorescent imaging is 
a highly sensitive technique which can be used in real-time to provide a turn on 
response to a given target. This chapter aims to synthesise a coumarin based 
aminopeptidase probe, specific for Gram negative bacteria.  
 
4.3 Results and Discussion 
4.3.1 Synthesis of Aminopeptidase Probe 
The first step in the synthesis of the coumarin based aminopeptidase probe was the 
high yielding carbamate formation between 3-aminophenol and ethyl chloroformate 
in ethyl acetate. This was followed by the Pechman reaction between carbamate 72 
and diethyl acetyl succinate in 70% H2SO4. On reaction completion, addition of ice 
water caused the crude product to precipitate to give compound 73. The next two 
steps were the hydrolysis of the ester with LiOH in water/ethanol under reflux, 
followed by hydrolysis of the carbamate with 10 M NaOH while also heating to 





precipitated in good yield. Temporary protection of the aniline was carried out using 
Fmoc-OSu. This reaction required the use of TMS-Cl (to temporarily protect thte 
carboxylic acid), followed by cooling and addition of  
Fmoc-OSu. Initially low yielding, this step was optimised by distillation of TMS-Cl 
prior to the reaction reducing the possible side reaction, giving quantitative yields 
(75) (Scheme 56). 
 
Scheme 56: Synthesis of Fmoc-Coum (76) with free carboxylic acid moiety. 
 
To allow for the addition of the amino acid using solid phase techniques a 
polystyrene aminomethyl resin was chosen as the solid support due to ease of 
handling and low cost. Fmoc-Rink linker was first attached to the resin to allow for 
simple cleavage of the product on completion of the synthesis. Pre-swelling of the 
resin in DCM was required and the coupling was carried out using Oxyma and DIC 
to give compound 76 with qualitative measurement of the coupling efficiency 
monitored using the Kaiser Test
[215]
. After Fmoc deprotection of the solid supported 
coumarin (20% piperidine in DMF), Oxyma and DIC were again used to couple 
Fmoc-Ala-OH, however, the Kaiser test revealed that the coupling was inefficient 




[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methaniminium hexafluorophosphate (HATU) 
with DIPEA was selected as the coupling reagent and proved successful to yield final 







Scheme 57:Synthesis of aminopeptidase probe 78 and control probe 79. 
 
The aminopeptidase probe 78 was cleaved from the resin using TFA:DCM:TIS 
(90:5:5) and purified by preparative HPLC. Synthesis of the D-Ala-Coumarin 
derivative 79 was carried out in the same manner using Fmoc-D-Ala-OH. 
 
4.3.2 Absorption and Emission Properties 
The absorption and emission properties of the coumarin, 78, over the amino acid free 
coumarin 74 were analysed. Absorption wavelengths were similar at 312 nm and  






Figure 65: Fluorescence spectra of 74 (black, ex = 312 nm) and 78 (red, ex = 322 nm) 
in water at equivalent concentrations. 
 
Figure 65 shows that upon addition of alanine to the coumarin, the fluorescence 
maxima is again only slightly shifted, however, as expected, the fluorescence was 
greatly reduced to approximately one fifth of the intensity.  
 
4.3.3 Solvent Effects  
As this project aimed to carry out biological studies of this probe, it was important to 
ascertain solvent effects on the fluorescence intensity of the coumarin probe. The 
phenomenon of solvatochromic effects is explained by the fact that a change in 
solvent can represent a change in polarity and dielectric constant. As explained by 
the Jablonkski diagram (Chapter 1, Figure 11), the fluorescence of a molecule is 
dependent on the ground and excited electronic states, which are altered by the 

































Figure 66: Solvent effects on fluorescence of 74 (blue, ex = 400 nm) and 78 (red, ex = 
350 nm) at 165 µM. 
 
Figure 66 shows the differing fluorescence intensities in 6 solvents of varying 
polarities. It is interesting to note that although DMSO and MeCN have similar 
polarities, their fluorescence maxima are extremely different. This may be due to the 
increased solubility of the coumarin molecule in DMSO. Compound 78 was only 
soluble in water after sonication and may account for the low but acceptable 
fluorescent intensity.  
 
4.3.4 Bacterial Studies 
Previous studies by Minyong
[214a]
 report a turn on fluorescent coumarin based probe 
for aminopeptidase, however, they do not distinguish between Gram negative and 
Gram positive bacteria and rely on the presence of the aminopeptidase enzyme 
directly.  
Before extensive bacterial studies were carried out, the turn on capabilities of 78 
were investigated. For the fluorescence studies an excitation wavelength of 400 nm 
was selected to give optimum emission of the cleaved coumarin molecule. As the 






































selected for preliminary studies. The bacteria were sub-cultured and re-suspended in 
a hypo-tonic buffer to cause osmotic shock releasing periplasmic proteins such as 
aminopeptidase
[218]
. Probe 78 was then incubated with the bacteria at 37 ºC for  
1 hour at varying concentrations. 
 
 
Figure 67: Concentration dependence of 78 with Escherichia coli. ex = 400 nm. 
 
From this study, it was found that 50 µM of probe 78 generated the maximum 
fluorescence increase over time. Furthermore, probe 78 shows an limit of detection 




To investigate the specific cleavage of 78, six bacterial strains were selected, three 
Gram positive: Staphylococcus aureus, Staphylococcus epidermis, and Enterococcus 
and three Gram negative: Escherichia coli, Pseudomonas aeruginosa and Klepsiella 
pneumonia. To monitor the different effects of Gram negative and Gram positive 
bacteria, 50 µM of probe was incubated with 10 billion bacteria (OD = 1) of each 































Figure 68: Cleavage of 78 (50 µM). pseudomonas aeruginosa (blue), Escherichia coli 
(green), Klepsiella pneumonia (orange), Staphylococcus aureus (red), Staphylococcus 
epidermis (black), Enterococcus (pink) for 30 minutes at 37 ºC. ex = 400 nm. Circles 
represent Gram negative bacteria, squares represent Gram positive bacteria. Data shown is 
one set of data obtained. Experiment was carried out in duplicate on 3 different days giving 
similar results on all occasions. 
 
As can be seen in Figure 68 incubation of 78 with Gram negative bacteria causes a 
large increase in the fluorescence intensity when compared with incubation with 
Gram positive bacteria confirming cleavage of the amide bond. A marked 
fluorescence signal is detected after 30 minutes with a maximum increase after 120 
minutes. 
To investigate inhibitor effects and confirm that it was the aminopeptidase enzyme 
responsible for the fluorescence increase, the Gram negative bacteria were also  
pre-incubated with the inhibitor bestatin for 30 minutes prior to incubation with the 






Figure 69: Probe 78 (50 µM) was incubated with Gram negative bacteria (blue), and 
Gram negative bacteria plus bestatin (40 nM) for 30 minutes at 37 ºC. ex = 400 nm. 
Experiment carried out in duplicate on 2 different days. 
 
On pre-incubation with bestatin there was a decrease of approximately 20-55% in 
fluorescence signal confirming that significant amide bond cleavage is due to the 
presence of aminopeptidase. As can be seen, the error values are quite large. This 
may be avoided in future by incubating with the recommended 60 nM concentration 
of bestatin. 
To confirm these results, L-alanine was replaced with the D-alanine to generate 
control probe 79. Control probe 79 was incubated with 3 Gram negative bacteria 
Pseudomonas aeruginosa, Escherichia coli and Klepsiella pneumonia at 50 µM at  
37 C for a longer period of 2 hours to further stress the experiment. The 
fluorescence intensity increase of 79 incubated with Gram negative bacteria 






Figure 70: Effect of Gram negative bacteria on 79 (50 µM): control probe 79 only 
(black), pseudomonas aeruginosa (pink), Escherichia coli (red), Klepsiella pneumonia 
(green). ex = 400 nm. One data set shown. Experiment carried out in duplicate with the 
same results on both occasions. 
 
This data confirms that, as expected, cleavage of the amide bond does not occur on 
the control probe 79 and that the aminopeptidase enzyme is specific for the natural L 
amino acid.  
 
4.3.5 Specificity of Aminopeptidase Probe 
As the main target for this probe was to detect bacterial infection in the lungs, 
selectivity over other proteases must be achieved. During a bacterial infection the 
body attempts to defend itself by releasing proteases such as neutrophil elastase
[219]
, 
an enzyme capable of degrading almost all extracellular matrix proteins. Even after 
the infection subsides an imbalance in the level of protease inhibitors within the body 
can cause neutrophil elastase to remain active, causing harm to the host
[220]
. 
Additionally, mammalian cells also contain enzymes that can break down or modify 
proteins. As our bacterial probe may be susceptible to these side processes, the 





To investigate, A549 epithelial cells, neutrophils and Gram negative bacteria were 
incubated with 78 and the fluorescence response recorded.  
 
 
Figure 71: Incubation of 78 (50 µM) with Gram negative bacteria (green, 10 billion 
cells), neutrophils (blue, 100 million cells), epithelial cells (red, 100 million cells) for 30 
minutes at 37 ºC. ex = 400 nm. Probe 78 alone (orange).  
 
Figure 71 shows the fluorescence response recorded on incubation of 78 (50 µM) for 
1 hour at 37 ºC with Escherichia coli, neutrophils and mammalian epithelial cells. 
Unfortunately, the greatest fluorescence increase occurs in the presence of 
neutrophils. This is not surprising as neutrophils contain many proteases which could 
account for this high fluorescence increase. 
To determine the number of neutrophils and epithelial cells required to generate a 
maximum response, the number of cells was varied and probe 78 (50 µM) incubated 































Figure 72: Fluorescence increase on incubation of (78) (50 µM) with varying numbers 
of neutrophils (blue) and epithelial cells (red). ex = 400 nm. Experiment carried out in 
duplicate. 
 
As expected, the cleavage by neutrophils exceeds that of epithelial cells and 
decreases on lowering the number of cells. In order to continue research into a bed 
side tool for bacterial infections, the specificity over other proteases must be 
improved and further work must be done to investigate the effect of neutrophils and 
other cells on the aminopeptidase probe in vivo. For example, Walling et al report 
that the specificity of aminopeptidases are dependant on the length of the peptide and 
the peptide sequence
[221]
. Additionally, the tripeptide Aspargine-Glycine-Arginine 








The synthesis of an aminopeptidase probe has been carried out and has shown to 
produce a turn on fluorescence signal for Gram negative bacteria over Gram positive 
bacteria. Live bacterial cell assays showed a marked increase in fluorescence on 
probe incubation at concentrations below 20 µM while inhibition by bestatin resulted 
in a lower fluorescence increase. Synthesis of the D-amino acid analogue resulted in 
no turn on signal confirming the specificity for the natural L-amino acid. This probe 
can be adapted and modified to increase the specificity over neutrophils and 
epithelial cells, possibly by the introduction of more amino acids or more 
specifically, the NGR peptide sequence should be added onto the coumarin molecule. 
Further, modification to the fluorophore itself to increase the absorption and 
emission wavelengths will help in reducing the background signal. Modification to 
generate a hemi-cyanine-coumarin hybrid molecule will alter the photo-physical 








Conclusions and Future Work 
 
The aim of this thesis was to contribute to the field of optical imaging by 
synthesising a variety of NIR cyanine dyes and optical imaging agents for use as or 
part of in vitro and in vivo imaging probes.  
 
Chapter 2 discusses the synthesis of novel heptamethine cyanine dyes with a broad 
range of absorption and emission wavelengths and a large Stoke’s shift range. The 
photophysical properties of the dyes are reported, comparing the effects of differing 
functionalities. In vitro analysis of cellular toxicity and cellular uptake of a selection 
of these dyes showed no toxicity and localisation of the dyes within the cytoplasm of 
the cell. Investigations into the synthesis of novel ratiometric imaging probes were 
attempted, however, further studies into the reactivity of heptamethine dyes should 
be carried out to finalise the synthesis. 
Chapter 2 also details the synthesis of a new class of pentamethine cyanine dyes with 
ideal absorption wavelengths for the He-Ne laser. These molecules are photostable 
and can be further functionalised increasing their possibility for use in molecular 
imaging. Currently, collaborators at DestiNA Genomics and STMicroelectronics are 
attempting to utilise these new cyanine dyes as part of a microchip based system for 
the detection of substrates with publications expected in the near future.  
 
In chapter 3 a synthesis of novel inherent NIR microspheres was developed and the 
beads characterised. In vitro experiments confirmed that the particles were non-toxic 
while, using confocal microscopy, the ability to penetrate the cell membrane was 





microspheres to carry out further derivitisation, with opportunities to track  
intra-cellular processes or help in the design of delivery vehicles. Collaborators are 
currently investigating the effects of introducing charged functionalities on cellular 
uptake. Addition of further functionalities may also be achieved by increasing the 
number of polymerisable starting materials, allowing bio-orthogonal reactions to be 
carried out. 
 
Chapter 3 also reports the successful synthesis of dual functionalised nanoparticles. 
Dual functionalisation of the beads was carried out using carbodiimide chemistry to 
attach the NIR fluorophore and a water soluble, optimised, Suzuki-Miyaura  
cross-coupling reaction to attach a quenched fluorescein-cargo moiety. The quenched 
probe molecule could be taken up by cells while intracellular cleavage of the 
disulphide linker resulted in the removal of quenching. Tracking of the particles 
within cells using cyanine 5 and the fluorescein-cargo moiety was carried out using 
confocal microscopy. This study provided the first example of employing a  
bio-orthogonal approach to dual functionalization of particles resulting in monitoring 
and controlled release within the cytoplasm. This work could be adapted to 
effectively deliver other cargos into the cell. 
 
Chapter 4 reports the synthesis of an aminopeptidase probe shown to produce a  
turn on fluorescence signal for Gram negative bacteria over Gram positive bacteria. 
Live bacterial cell assays showed a marked increase in fluorescence on probe 
incubation with Gram negative bacteria at concentrations below 20 µM while 
inhibition by bestatin resulted in a lower fluorescence increase. Synthesis of the D-
amino acid analogue resulted in no turn on signal confirming the specificity for the 
natural L-amino acid. This aminopeptidase probe should be adapted and modified to 
increase the specificity over neutrophils and epithelial cells. One such method may 
be the introduction of more amino acids, inparticular the NGR trimer onto the 








6.1 General Section 
All solvents and reagents were obtained from commercial suppliers and used without 
purification, unless otherwise stated. Evaporation of solvents was performed at 
reduced pressure, using a Büchi rotary evaporator. 
All solution phase reactions were stirred magnetically unless otherwise stated and 
followed to completion by thin layer chromatography (TLC) where appropriate using 
TLC aluminium sheets coated with silica gel 60 F254. TLC visualisation was 
performed using short wave UV light (254 nm) and/or TLC staining solutions where 
stated. Reactions involving moisture sensitive reagents were performed under dry 
nitrogen and reactions involving light sensitive compounds were kept under 
aluminium foil at all times. 
 
Flash column chromatography was carried out on silica gel 60 (mesh 0.040-0.063).  
 
Solid-phase synthesis was carried out in polypropylene syringes equipped with 





C spectroscopy were recorded on automated Bruker ARX-250, DPX-360, 
AV 400 or a AV 500 spectrometer in the deuterated solvents indicated at 298K. 
Chemical shifts are reported on the  scale in ppm. Resonances were characterised as 
singlet (s), broad singlet (bs), doublet (d), doublet of doublet (dd), triplet (t) or 
multiplet (m) with coupling constants given in hertz (Hz). 
 
FTIR spectra were obtained using neat compounds on a Fourier transform IR 
Bruker Tensor 27 spectrophotometer, with 16 scans, resolution  4 cm
-1





Specac single reflection diamond attenuated total reflexion (ATR) Golden Gate 
accessory. 
 
Melting points were determined using Gallenkamp melting point apparatus.  
 
Microwave assisted heating was carried out by irradiating the reaction mixture in a 
Biotage Initiator at 2.45 GHz. Experiments were carried out in a sealed, heavy-
walled Pyrex tubes. Microwave irradiation was conducted at a defined temperature, 
pressure and power during the reaction time.  
 
UV/Vis Spectroscopy analyses were conducted on an Agilent 8453 
spectrophotometer or a Bio Tek Synergy H1 plate reader. 
 
Fluorescence spectra were recorded on a SPEX Fluoromax, using a 1 cm path 
length fused silica cuvettes or a BioTek Synergy H1 plate reader using Costar
®, 
96 
well, flat bottom, clear well plates with readings made from the bottom and analysed 
using the Gen 5 (1.11) software. 
 
Quantum yield measurement was carried out on a BioTek Synergy H1 plate reader 
using Costar
® 
96 well, flat bottom, clear plates with readings made from the bottom 
and analysed using the Gen 5 (1.11) software. Fluorophore absorption and emission 
(ex 600 nm for cyanine 5 analogues, ex 750 nm for cyanine 7 analogues) were 
analysed at a concentration of 5 µM in DMSO and compared to a 5 µM solution of 
ICG in DMSO. The equation to calculate the quantum yield is shown in Equation 2. 
 
 
Equation 2: Quantum yield calculation QY = quantum yield of the sample, QYref = 
quantum yield of the reference sample, η = refractive index of the solvent in which the 
sample is in ηref = refractive index of the solvent in which the reference sample is in, I = 
integrated fluorescence of the sample, Iref = integrated fluorescence of the reference, A = 





Analytical reverse-phase high-performance liquid chromatography (RP–HPLC) 
was performed on an Agilent Technologies 1100 modular HPLC system coupled to a 
Polymer Lab 100 ES Evaporative Scattering Detector (ELSD), with detection at 220, 
254, 260, 282 and 495 nm. Column: Discovery® C18, 5 µM particle size,  
reverse-phase (5 cm x 50 mm) with a flow rate of 1 mL/min. Solvents used were 
HPLC grade. 
 
Solution A: MeOH + 0.1% formic acid 
Solution B: H2O + 0.1% formic acid 
Solution C: MeCN + 0.1% formic acid 
 
Method 1: 5% to 95 % A in B over 3 min; Isocratic for 1 min; 95% to 5% A over 1 
min; 1 min isocratic. 
Method 2: 5 to 95 % A in B over 6 min; Isocratic for 3 min; 95 %to 5% A over 1 
min; 2 min isocratic. 
Method 3: 5% to 95 % A in B over 10 min; Isocratic for 4 min; 95% to 5% A over 1 
min; 1 min isocratic.  
Method 4: 5% to 95 % C in B over 3 min; Isocratic for 1 min; 95% to 5% C over 1 
min; 1 min isocratic.  
Method 5: 5 to 95 % C in B over 6 min; Isocratic for 3 min; 95 %to 5% C over 1 
min; 2 min isocratic. 
Method 6: 5% to 95 % C in B over 10 min; Isocratic for 4 min; 95% to 5% C over 1 
min; 1 min isocratic.  
Method 7: 5% to 95 % C in B over 11 min; Isocratic for 3 min; 95% to 5% C over 1 
min; 1 min isocratic.  
 
Semi-preparative RP–HPLC was performed on an HP1100 system equipped with a 
Phenomenex Prodigy C18 reverse-phase column (250 x 10 mm, 5 μm) with a flow 
rate of 2.5 mL/min eluting with 0.1% HCOOH in H2O (A) and 0.1% HCOOH in 
CH3CN (B), with a gradient of 5 to 95% B over 18 min and an initial isocratic period 






Electrospray ionization mass spectrometry (ESI–MS) analyses were carried out on 
an Agilent Technologies LC/MSD Series 1100 quadrupole mass spectrometer (QMS) 
in the ESI mode. 
 
High Resolution Mass Spectra (HRMS) was obtained from the MS section of the 
University of Edinburgh performed on a Finnigan MAT 900 XLP high resolution 
double-focussing mass spectrometer. 
 
Inductively coupled plasma – optical emission spectroscopy (ICP-OES) analysis 
were obtained from Dr Lorna Murray (Edinburgh University, School of Chemistry) 
on a Perkin Elmer Optima 5300 DV ICP-OES (detection limits: 0.0002-1000ppm). 
 
Centrifugation was performed on an Eppendorf 5430R equipped with a fixed-angle 
rotor (Eppendorf, 45-24-11-HS). 
 
Light Scattering: The hydrodynamic diameter was determined with a Malvern 
Zetasizer Nano-ZS. A suspension of particles 1 µL was diluted in 10% PBS (pH = 
7.4, 8 g/L NaCl, 0.2 g/L KCl, 1.15 g/L Na2HPO4, 0.2 g/L KH2PO4) in water (1 mL), 
vortexed and transferred into a 4 mL polystyrene cuvette (FB55143, Fisher 
Scientific). The data were collected and analysed with the Dispersion Technology 
Software 4.20 (Malvern) giving histograms for the particles size as a number 
distribution. 
 
6.2 General Coupling Reactions and Capping. 
To the Fmoc-amino acid (3 eq) in DMF (0.10 M), Oxyma (3 eq) was added and 
allowed to stir for 5 min. DIC (3 eq) was added and stirred for a further 5 min. The 
coupling solution was then added to Fmoc-Rink amide-aminomethyl PS resin (0.10 
g) pre-swelled in DCM and allowed to stir for 1 h. The resin was isolated by 





mL). Capping was carried out using DMF, pyridine and Ac2O (15:3:2) (2 mL, 2 x 10 
min). 
 




Coupling of 7-amino-4-methylcoumarin-3-acetic acid PS (76) was carried out using 
2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl 
uroniumhexafluorophosphatemethanaminium (HATU, 5 eq) and DIPEA (10 eq) 
under microwave irradiation at 60 C for 20 min. 
 
Colourimetric test for the detection of the chloromethyl groups  
A 75 mM solution of 4-(4-nitrobenzyl)pyridine in toluene with 5% of TEA (1 mL) 
was added to 2 mg of resin 4. No colouration was observed (naked eye). The test was 
repeated on Merrifield resin. The resin turned pink. 
 
Fmoc Deprotection 
Fmoc deprotection was carried out by suspending the resin (0.10 g) in 20% 
piperidine in DMF (2 mL) for 10 min. The resin was filtered and a fresh solution of 
20% piperidine in DMF (2 mL) was added and shaken for 10 min. The resin was 
then filtered and washed with DMF (3 x 10 mL) and DCM (3 x 10 mL).  
 
TFA Cleavage  
The resin (0.10 g), pre-swollen in DCM, was treated with the cleavage cocktail of (3 
mL) for 3h. The solution was drained and the resin was washed with the cleavage 
cocktail. The crude material was concentrated under reduced pressure and  
re-dissolved in a minimum amount of cleavage cocktail (500 μL). Ice-cold ether (7.5 
mL) was added and the precipitate was collected by centrifugation. The precipitate 
was washed further with cold ether (3 x 5 mL). Cleavage cocktails were either 








Qualitative Ninhydrin Test[215] 
This test was carried out after washing of the resin on a few beads. 3 drops of 
reagents A and 1 drop of reagent B are added to the beads and allowed to sit at 100 
C for 3 min. A blue solution indicated the presence of free amines, a yellow solution 
corresponds to protected amines, or no amines present. 
Preparation of ninhydrin reagents A and B: 
 
Reagent A, solution 1: 
Reagent grade phenol (40.0 g, 0.43 mmol) was added to absolute ethanol (10 mL) 
and allowed to heat at 40 C until the solution became clear. Amberlite mixed-bed 
resin MB-3 (4.0 g) was added, stirred for 45 min at room temperature and filtered. 
 
Reagent A, solution 2: 
KCN (65 mg, 1 mmol) was dissolved in water (100 mL). This solution (2 mL) was 
diluted with freshly distilled pyridine to 100 mL. Amberlite mixed-bed resin MB-3 
(4 g) was added, stirred for 45 min and filtered. Solutions 1 and 2 were mixed to 
obtain reagent A. 
 
Reagent B: 
Ninhydrin (2.5 g, 14 mmol) was dissolved in absolute ethanol (50 mL) and stirred for 
15 min at room temperature. 
 
Cellular Studies 
Cell culture experiments were carried out in a HERAsafe KS 18 class II  
negative-flow cabinet and in a HERAcell 150 incubator both from Heraeus. 
 
General Cell Culture 
Human embryonic kidney cells (HEK293T), human cervical cancer cells (HeLa), 
human prostate cancer cells (PC-3) and human adenocarcinomic alveolar basal 
epithelial cells (A549) were cultured in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% (v/v) heat inactivated fetal bovine serum,  





streptomycin) at 37 °C and 5% CO2. Cells were cultured in T-75 flasks until 80% 
confluency followed by removal of growth medium, washing with PBS (10 mL) and 
harvesting by trypsination (trypsin/EDTA, Gibco) (1 mL) at 37 ºC. Detached cells 
were collected in fresh growth media and an aliquot was reseeded to a flask for 
regrowth. Cell experiments were carried out with cells passaged between 4- and  
20-times. 
 
Cell Labeling  
HEK293T, HeLa, PC-3 or A549 cells were plated in DMEM, supplemented with 
10% (v / v) heat inactivated fetal bovine serum, L-glutamine (4 mM) and antibiotics 
(100 units/mL penicillin and 100 units/L streptomycin) in a 8, 24 or 96-well plate at 
a density of 20,000 cells per well and grown for 24 h at 37 °C and 5% CO2. 
Thereafter, the probe of interest was added and incubated with the cells for 0.5-24 h. 
Cells were washed with PBS and either imaged live with confocal microscopy, 
fluorescent microscopy (microplate reader) or harvested with trypsin/EDTA and 
analysed. Commercial membrane or organelle stains used when stated and incubated 
with cells 30 min prior to analysis. 
 
Stain Target Commercial Name Laser Excitation (nm) Filter (nm) 
Nucleus Syto 82 543 554-587 
Cytosol Calcein 488 501-522 
Nucleus Hoechst 33342 404 535-590 
Cytoplasm Cell Tracker Red CMTPX 594 575-615 
Table 6: Commercial membrane and organelle stains. 
 
Flow Cytometry 
A suspension of the material under investigation (1 µL, 20 µg, solid content 20 
mg/mL) was diluted in 350 µL of water, vortexed and analysed using the appropriate 
filters according to the fluorophores under investigation using the BD FACSAria 
(Table 7). Results were analysed using FlowJo Version 7.6.3 software. Quantitative 






Laser Excitation (nm) Filter (nm) Fluorophore 
375 450/20 DAPI/Hoechst blue 
488 530/30 Fluorescein 
561 670/14 
Cyanine 5 and cyanine 
5 analogues 
633 780/60 Cyanine 7 analogues 




Cell Viability Assay (MTT Assay): HEK293T,HeLa, PC-3 or A549 were plated in 
DMEM, supplemented with 10% (v/v) heat inactivated fetal bovine serum,  
L-glutamine (4 mM) and antibiotics (100 units/mL penicillin and 100 units/mL 
streptomycin) in a 96-well plate and allowed to grow for 24 h at 37 °C and 5% CO2. 
Thereafter, the probe of interest was added at varying concentrations and allowed to 
incubate with the cells for 24 h. After incubation, cells were washed with PBS and 
then further incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution (7 mg MTT in 7 mL PBS and 3 mL phenol red free 
DMEM) for 4 h at 37 °C. 100 µL of solubilisation solution (10% triton-X 100 in 
acidic isopropanol (0.1 M HCl)) was added and the absorbance at 570 nm measured 
(Benchmark Biorad microplate reader) and results compared to untreated cells. Cell 
viability was calculated using Equation 3. 
 
% of cellular viability = (Abs 570exp/ Abs 570 cont) x 100 
Equation 3:“Abs 570 exp” is the absorbance at 570 nm of cells treated with compound of 





Cells were fixed on to 8 well chambers and incubated (37 C, 5% CO2) for 24 h prior 





twice with PBS and imaged directly using a Zeiss LSM 510 Meta microscope. Zeiss 
510 meta software was used for digital image acquisition.  
 
6.3 Synthesis of Starting Materials 
 




A mixture of 2,3,3-trimethyl-3H-indole 5 (40.0 mL, 0.25 mol) and methyl iodide 
(38.9 mL, 0.63 mol) in acetonitrile (150.0 mL) was heated under reflux for 3 days. 
The reaction mixture was cooled to room temperature and the solvent evaporated 
under vacuum. The residue obtained was washed with ether (50.0 mL) and ethanol 
(50.0 mL) to remove any starting material. The residue was dried in vacuo to give a 
pink solid (36.5g, 84%). 
 
HPLC (method 2) tr = 0.82min, Purity 100% (ELSD). 
MS (ES): calculated for C12H16N [M]
+
 m/z 174.1. Found 174.1 (100%).
 




H NMR (250 MHz, DMSO-d6) δ: 7.92-7.90 (m, 1H,4), 7.84-7.82 (m, 1H, 6),  
7.64-7.62 (m, 2H, 5,7), 3.97 (s, 3H, 10), 2.77 (s, 3H,9), 1.53 (s, 6H, 11). 
13
C NMR (62.9 MHz, DMSO-d6) δ: 196.0 (1), 142.0 (3), 141.5 (8), 129.3 (6), 129.8 
(5), 123.2 (4), 115.1 (7), 53.9 (2), 34.6 (9), 21.63 (10), 13.7 (11). 












A mixture of 2,3,3-trimethyl-3H-indole 5 (12.1 mL, 75.4 mmol) and  
6-bromohexanoic acid (30.0 g, 189.0 mmol) in acetonitrile (50.0 mL) was heated at 
100 C for 16 h. The solution was cooled to room temperature and the solvent 
evaporated under vacuum. The residue obtained was washed with ether and DCM 
until removal of starting material to give a pink solid (2.3 g, 19 %). 
 
HPLC (method 2) tr = 3.74 min, Purity 100% (ELSD).  
MS (ES): calculated for C17H25NO2 [M+H]
+
 m/z (%) 275.2. Found 275.2 (100%). 




H NMR (500 MHz, DMSO-d6)δ: 7.96-7.98 (m, 1H,4), 7.83-7.85 (m, 1H, 6),  
7.61-7.63 (m, 2H 5,7), 4.42-4.45 (m, 2H, 13), 2.83 (s, 3H, 15), 2.23 (t, 2H, J=7.3Hz, 
9), 1.82-1.84 (m, 2H, 10), 1.56-1.58 (m, 2H, 12), 1.53 (s, 6H, 16),1.41-1.44 (m, 2H, 
11). 
 13
C NMR (125 MHz, DMSO-d6):δ 197.0 (1), 174.8 (14), 142.4 (3), 141.5 (8), 129.9 
(6), 129.5 (5), 124.0 (4), 116.0 (7), 54.6 (2), 47.9 (9), 33.8 (13), 27.43 (10), 25.9 (12), 
24.5 (11), 22.5 (15), 14.4 (16). 


















2,3,3-trimethyl-3H-indole-5-sulfonic acid 4 (18.0 g, 75.3 mmol) and methyl iodide 
(23.5 mL, 377.0 mmol) were dissolved in EtOH (280.0 mL) and heated under reflux 
for 72 h. The solvent was evaporated and the crude product washed with cold Et2O 
(50.0 mL) and EtOH (50.0 mL) to yield a red solid (16.9 g, 88%).  
 
HPLC (method 1) tr = 0.8 min, Purity 70% (ELSD). 
MS (ES): calculated for C12H16INO3S [M+I]
 
m/z 381.0. Found 380.8 [M+I] (100%). 
Mp. 260 C decomposed. 




H NMR (500 MHz, MeOD) δ: 8.00 (s, 1H, 4), 7.85-7.75 (m, 2H, 6,7), 4.10 (s, 3H, 
10), 2.77 (s, 3H, 9), 1.63 (s, 6H, 11). 
13
C NMR (126 MHz, MeOD) δ: 173.80 (1), 146.97 (5), 143.08 (3), 141.74 (8), 
126.89 (6), 120.65 (4), 114.86 (7), 54.59 (2), 34.26 (9), 20.98 (10), 19.36 (11). 








Trimethyl-benzindole 3 (1.7 g, 8.0 mmol) and MeI (3.0 mL, 48.0 mmol) were 





1 h. The crude product was cooled and washed with ether to give a yellow solid (1.7 
g, 96%). 
HPLC (method 2) tr = 0.77 min, Purity 100% (ELSD). 
MS (ES): calculated for C16H18N [M] m/z 224.1. Found 224.2 [M] (100%). 
Mp. 220C. 




H NMR (500 MHz, MeOD) δ: 8.34 (dd, J = 8.5, 1.3 Hz, 1H, 9), 8.26 (d, J = 8.9, 1.1 
Hz, 1H, 6), 8.18 (d, J = 8.3 Hz, 1H, 11), 8.01 (d, J = 8.9 Hz, 1H, 12), 7.83 (ddd, J = 
8.4, 6.9, 1.3 Hz, 1H, 8), 7.74 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H, 7), 4.20 (s, 3H, 2), 2.93 
(s, 3H, 14), 1.86 (s, 6H, 15). 
13
C NMR (126 MHz, MeOD) δ: 196.03 (1), 139.40 (13), 136.85 (4), 133.88 (11), 
130.89 (8), 129.66 (7), 128.27 (9), 127.62 (5), 127.19 (10), 123.01 (6), 112.18 (12), 
55.75 (3), 34.43 (14), 20.75 (2), 12.94 (15). 








A solution of 1,3-propansultone 3 (0.7 g, 5.4 mmol) in 1,2-dichlorobenzene (10.0 
mL) was added to 1,1,2-trimethylbenz(e)indole (1.0 g, 4.9 mmol) and allowed to stir 
at 120 C for 18 h. The solvent was evaporated and the product crystallised from 
cold Et2O to yield an orange solid (1.4 g, 85%). 
 
HPLC (method 2) tr = 5.0 min, Purity 100% (ELSD). 
MS (ES): calculated for C18H20NO3S [M-H]
-
 m/z 331.1. Found 330.1 (75%). 









H NMR (500 MHz, DMSO-d6) δ: 8.37 (d, J = 8.4 Hz, 1H, 5), 8.30 (d, J = 8.9 Hz, 
1H, 8), 8.26 – 8.20 (m, 2H, 10,11), 7.79 (t, J = 7.0 Hz, 1H, 6), 7.73 (t, J = 7.1 Hz, 
1H, 7), 4.81 – 4.76 (m, 2H, 16), 2.95 (s, 3H, 13), 2.69 (t, J = 6.5 Hz, 2H, 17), 2.23 (t, 
J = 7.3 Hz, 2H, 15), 1.77 (s, 6H, 14). 
13
C NMR (126 MHz, DMSO-d6) δ: 196.88 (1), 139.11 (12), 137.47 (3), 133.51 (10), 
131.17 (7), 130.23 (6), 128.83 (8), 127.73 (4), 127.66 (9), 123.85 (5), 113.82 (11), 
55.95 (2), 47.87 (15), 47.32 (16), 24.42 (14), 22.13 (17), 14.10 (13). 
 




Quinalidine 11 (1.9 mL, 14.0 mmol) and iodomethane (4.4 mL, 7.0 mmol) were 
stirred in MeCN (20.0 mL) for 70 h under reflux. The solvent was then evaporated 
and the orange product crystallised from cold Et2O (Iodate salt - 3.6 g, 90 %). 
 
MS (ES): calculated for C11H12N [M] m/z 158.1. Found 158.2 (100%). 
Mp. 191 C. 





H NMR (400 MHz, DMSO-d6) δ:9.10 (d, J = 8.6 Hz, 1H, 3), 8.59 (dd, J = 9.0, 0.5 
Hz, 1H, 5), 8.40 (dd, J = 8.1, 1.4 Hz, 1H, 8), 8.23 (ddd, J = 8.8, 7.0, 1.5 Hz, 1H, 7), 
8.12 (d, J = 8.6 Hz, 1H, 2), 7.99 (ddd, J = 7.9, 7.2, 0.7 Hz, 1H, 6), 4.45 (s, 3H, 11), 
3.08 (s, 3H, 10). 
13
C NMR (100 MHz, MeOD) δ:161.04 (1), 145.80 (3), 139.87 (9), 135.29 (7), 
130.35 (6), 129.04 (5), 128.46 (4), 124.96 (2), 118.47 (8), 39.31 (11), 22.50 (10). 













3-Amino-1-propanol (0.1 g, 1.3 mmol), Dde-OH (0.2 g, 1.5 mmol) and DIPEA 
(226.0 µL, 1.3 mmol) were dissolved in MeOH (2.0 mL) and allowed to stir at room 
temperature for 3 h. The solvent was evaporated and the crude product purified by 
column chromatography (99:1 DCM:MeOH) to yield a white solid (0.2 g, 70%). 
 
HPLC (method 2) tr = 5.9 min, Purity 100% (ELSD). 
MS (ES): calculated for C13H20NO3 [M-H]
-
 m/z 240.2. Found 240.2 (55%). 
MS (HRMS, ES) m/z calc [M+Na]
+
 262.14137. Found 262.14130. 
Mp. 141 C. 




H NMR (400 MHz, CDCl3) δ: 3.82 (t, J = 5.9 Hz, 2H, 5), 3.59 (dd, J = 12.3, 6.8 Hz, 
2H, 3), 2.61 (s, 3H, 1), 2.39 (s, 4H, 8,8’), 1.99 – 1.92 (m, 2H, 4), 1.06 (s, 6H, 10). 
13
C NMR (100 MHz, CDCl3) δ: 197.99 (7,7’), 173.80 (2), 107.94 (6), 59.34 (5), 










Dde-OH (0.15 g, 0.99 mmol) in MeCN (0.5 mL) and DIPEA (60.0 µL, 0.33 mmol) 
were stirred at room temperature for 10 min. 3-bromopropylamine (72 mg, 0.33 
mmol) in MeCN (2.0 mL) was added dropwise over a period of 30 min and allowed 
to stir at room temperature for 4 h. The solvent was evaporated and the crude product 
was washed with 1 M HCl (20.0 mL) before purification by column chromatography 
(100% DCM) to yield a pale yellow solid (53 mg, 53%). 
 
HPLC (method 2) tr = 7.8 min, Purity 100% (ELSD). 
MS (ES): calculated for C13H21BrNO2 [M+H]
+
 m/z 302.1. Found 302.1 (100%). 
MS (HRMS, ES) m/z calc [M+Na]
+
 324.05696. Found 324.05770. 
Mp. 61 C. 




H NMR (500 MHz, CDCl3) δ: 3.63 (dd, J = 12.3, 6.6 Hz, 2H, 3), 3.52 (t, J = 6.2 Hz, 
2H, 5), 2.63 (s, 3H, 1), 2.39 (s, 4H, 8,8’), 2.24 (m, 2H, 4), 1.06 (s, 6H,10). 
13
C NMR (126 MHz, CDCl3)δ: 198.09 (s, 7,7’), 173.92 (s, 2), 108.16 (s, 6), 52.91 (s, 








Di-tertbutyl-dicarbonate (1.95 g, 8.9 mmol) was dissolved in water (8.0 mL). 4-
hydroxybenzylamine (1.0 g, 8.0 mmol) was added and stirred at 35 C for 2 h. The 
organic layer was extracted with DCM (50.0 mL) and dried over sodium sulphate. 






HPLC (method 2) tr = 5.5 min, Purity 79% (ELSD). 
MS (ES): calculated for C12H17NNaO3 [M+Na]
+ 
m/z 246.1. Found 246.1 (100%).
 
Mp. 92 C. 




H NMR (500 MHz, CDCl3) δ: 7.11 (d, J = 8.4 Hz, 2H, 2,2’), 6.76 (d, J = 8.3 Hz, 
2H, 3,3’), 5.29 (s, 1H, NH), 4.86 (s, 1H, OH), 4.22 (d, J = 3.4 Hz, 2H, 5), 1.46 (s, 
9H, 8). 
13
C NMR (126 MHz, CDCl3) δ: 155.48 (6), 150.29 (1), 128.94 (4), 121.46 (3,3’), 
115.51 (2,2’),44.22 (7), 28.45 (5), 27.71 (8). 








4-hydroxybenzaldehyde (5.0 g, 40.1 mmol) was dissolved in a mixture of acetic 
anhydride and pyridine (1:1, 20 mL) and stirred at room temperature for 2 h. The 
solvent was evaporated and the product was washed with 1 M NH4HCO3 (25.0 mL) 
and extracted with DCM (100.0 mL) to give a clear oil (6.6 g, 99%). 
 
HPLC (method 5) tr = 3.7 min, Purity 100% (ELSD). 




H NMR (500 MHz, CD3CN) δ: 9.98 (s, 1H, 1), 7.94 (d, J = 8.7 Hz, 2H, 3,3’), 7.31 
(d, J = 8.4 Hz, 2H, 4,4’), 2.28 (s, 3H, 7).
 
13
C NMR (126 MHz, CD3CN) δ: 191.47 (1), 169.09 (6), 155.54 (5), 134.26 (2), 
130.99 (3,3’), 122.72 (4,4’), 20.32 (7). 











Aldehyde 49 (2.5 g, 15.3 mmol) was dissolved in ethanol (45.0 mL) and cooled to 0 
C. While stirring, NaBH4 (0.23 g, 6.1 mmol) was added over a period of 1 h. After a 
further 1 h, 6 M aqueous HCl was added until the solution reached pH 2. The solvent 
was evaporated and the product extracted with DCM (60.0 mL). Volatiles were 
removed under reduced pressure and the desired product obtained as a viscous oil 
(1.2 g, 48%). 
 
HPLC (method 2) tr = 3.7 min, Purity 100% (ELSD). 
MS (ES): calculated for C9H10NaO3 [M+Na]
+
 m/z 189.1. Found 189.2 (100%). 
MS (HRMS, ES) m/z calc [M] 166.06245. Found 166.06316. 




H NMR (500 MHz, CD3CN) δ: 7.36 (d, J = 8.5 Hz, 2H, 3,3’), 7.05 (d, J = 8.5 Hz, 
2H, 4,4’), 4.57 (s, 2H, 1), 2.24 (s, 3H, 7). 
13
C NMR (126 MHz, CD3CN) δ: 169.77 (6), 149.92 (5), 139.79 (2), 127.76 (3,3’), 
















Alcohol 50 (0.1 g 0.60 mmol), pyridine (53.0 µL, 0.66 mmol), and 
nitrophenylchoroformate (0.13 g, 0.66 mmol) were dissolved in anhydrous THF (1.5 
mL) and stirred at room temperature for 2 h. The solvent was evaporated and the 
residue was immediately purified by column chromatography (93:7 Hexane:EtOAc) 
to yield a white powder (0.17 g, 87%). 
 
HPLC (method 2) tr = 5.6 min, Purity 100% (ELSD). 
MS (ES): calculated for C16H13NNaO7 [M+Na]
+ 
m/z 354.1. Found 354.0
 
(100%). 
MS (HRMS, ES) m/z calc [M] 331.06865. Found 331.06831. 
Mp. 101 C. 





H NMR (500 MHz, CD3CN) δ: 8.31 (d, J = 9.3 Hz, 2H, 11,11’), 7.53 (d, J = 8.7 Hz, 
2H, 4,4’), 7.48 (d, J = 9.3 Hz, 2H, 10,10’), 7.18 (d, J = 8.6 Hz, 2H, 5,5’), 5.32 (s, 2H, 
2), 2.29 (s, 3H, 8). 
13
C NMR (126 MHz, CD3CN) δ: 155.69 (7), 152.49 (1), 151.28 (6), 145.68 (9), 
132.57 (3), 129.88 (4,4’), 129.31 (12) 125.33 (11,11’), 122.29 (10,10’), 122.18 












Nitrocompound 53 (50 mg, 0.15 mmol), benzylamine (25.0 µL, 0.23 mmol) and 
TEA (42.0 µL, 0.30 mmol) were dissolved in dry MeCN (0.5 mL) and stirred at 
room temperature for 2 h. The solvent was evaporated and the residue dissolved in 
DCM (1.0 mL), which was washed with 1 M aqueous HCl (5.0 mL) and 1 M 
aqueous NaOH (5.0 mL) and dried over sodium sulphate. The organic solvent was 
evaporated to yield the product (16 mg, 35%). 
 
HPLC (method 1) tr = 5.3 min, Purity 100% (ELSD). 
MS (ES): calculated for C17H17NNaO4 [M+Na]
+
 m/z 322.1. Found 322.0
 
(100%). 
MS (HRMS, ES) m/z calc [M] 299.11521. Found 299.11571. 
Mp. 80 C. 




H NMR (500 MHz, CD3CN) δ: 7.39 (d, J = 8.2 Hz, 2H, 4,4’), 7.30 (m, 5H, 
11,11’,12,12’,13), 7.08 (d, J = 8.3 Hz, 2H, 5,5’), 6.13 (s, 1H, NH), 5.07 (s, 2H, 2), 
4.28 (d, J = 6.3 Hz, 2H, 9), 2.24 (s, 3H, 8). 
13
C NMR (126 MHz, CD3CN) δ: 169.62 (7), 156.52 (1), 150.61 (6), 139.64 (10), 
135.05 (3), 129.05 (13), 128.45 (4,4’), 127.17 (12,12’), 127.05 (11,11’), 121.91 












4-(hydroxymethyl) phenyl boronic acid pinocol ester (1.0 g, 4.3 mmol), 
nitrophenylchloroformate (0.94 g, 4.7 mmol) and pyridine (0.39 mL, 4.7 mmol) were 
dissolved in anhydrous THF (20.0 mL) and allowed to stir at room temperature for 2 
h. The solvent was evaporated and the crude product was purified by column 
chromatography [eluting solvent: Hexane:EtOAc (93:7)] to yield a white powder (1.5 
g, 88%). 
 
HPLC (method 5) tr = 6.6 min, Purity 100% (ELSD). 
MS (ES): calculated for C40H44B2N2NaO14 [2M+Na]
+ 
m/z 821.3. Found 821.3 (85%). 
MS (HRMS, ES) m/z calc [M] 399.14838. Found 399.14911. 
Mp. 108 C. 





H NMR (500 MHz, CD3CN) δ: 8.16 (d, J = 9.2 Hz, 2H, 4,4’), 7.64 (d, J = 8.0 Hz, 
2H, 11,11’), 7.38 – 7.28 (m, 4H, 5,5’,10,10’), 5.19 (s, 2H, 2), 1.21 (s, 12H, 8,8’). 
13
C NMR (126 MHz, CD3CN) δ: 156.57 (1), 153.40 (9), 146.57 (3), 138.89 (12), 












Nitrocompound 51 (50.0 mg, 0.13 mmol), benzylamine (20.6 µL, 0.19 mmol) and 
TEA (34.7 µL, 0.25 mmol) were dissolved in anhydrous MeCN and allowed to stir at 
room temperature for 3 h. The solvent was evaporated and the residue purified by 
column chromatography [eluting solvent: Hexane:EtOAc (90:10)] to yield a yellow 
oil (24 mg, 52%). 
 
HPLC (method 5) tr = 6.1 min, Purity 100% (ELSD). 
MS (ES): calculated for C21H26BNNaO4 [M+Na]
+
 m/z 390.2. Found 390.2 (25%), 
757.3 [2M + Na]
+
(100%). 
MS (HRMS, ES) m/z calc [M] 367.19494. Found 367.19494. 




H NMR (500 MHz, CD3CN) δ: 7.70 (d, J = 7.7 Hz, 2H, 4,4’), 7.39 – 7.23 (m, 7H, 
5,5’,11,11’,12,12’,13), 6.19 (s, 1H, NH), 5.09 (s, 2H, 2), 4.28 (d, J = 6.3 Hz, 2H, 9), 
1.32 (s, 12H, 8,8’). 
13
C NMR (126 MHz, CD3CN) δ: 156.55 (1), 140.65 (10), 139.64 (3), 134.59 (5,5’), 
128.45 (12,12’), 127.16 (13), 127.04 (4,4’), 126.88 (11,11’), 83.90 (7,7’), 65.80 (2), 












A mixture of DMF (40.0 mL) in DCM (40.0 mL) was cooled to -10 C. A solution of 
phosphorousoxychloride (37.0 mL, 0.4 mol) in DCM (35.0 mL) was added dropwise 
over 15 min. Cyclohexanone (10.0 g, 0.1 mol) was added and the solution was 
refluxed for 3 h. The solution was cooled, poured onto 200 g of ice and left to stand 
overnight. The product was re-crystallised from acetone to yield a brown solid (2.7 g, 
32%). 
 
HPLC (method 2) tr = 5.8 min, purity: 100% (ELSD). 
MS (ES): calculated for C16H18Cl2NaO4 [2M+Na]
+ 
m/z 367.1. Found 367.2, (65%). 
Mp: 129 C. 
1
H NMR (500 MHz, DMSO-d6) δ: 10.84 (s, 1H, 8), 10.05 (s, 1H, 7), 7.62 (s, 1H, 5), 
2.37 (m, 4H, 2,4), 1.59 (m, 2H, 3). 
13
C NMR (126 MHz, DMSO-d6) δ: 189.73 (8), 149.93 (7), 127.82 (6), 112.41 (1), 
61.96 (5), 31.08 (3), 24.19 (2,4). 


















6.4 Experimental for Chapter 2 
6.4.1 Synthesis of Heptamethine Cyanine Dyes: Chloro Derivatives 
 
2-(2-[2-Chloro-3-([1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene]ethylidene)-1-




Indolium salt 9 (6.0 g, 34.8 mmol) and diadehyde 13 (2.0 g, 11.6 mmol) were stirred 
with NaOAc (5.7 g, 69.6 mmol) in a solution of acetic acid and acetic anhydride (1:1, 
450.0 mL) for 4 h at 115 C under N2. The solvent was evaporated and the product 
extracted with DCM (150.0 mL) and dried over sodium sulphate. The crude product 
was purified by column chromatography [eluting solvent: DCM:MeOH (95:5)] to 
yield a green solid (4.2 g, 74%). 
 
HPLC (method 2) tr = 3.9 min, Purity: 100% (ELSD). 
MS (ES): calculated for C32H36ClN2 [M] m/z 483.3. Found 483.3 (100%). 
MS (HRMS, ES) m/z calc [M] 483.25615. Found. 482.25685 
λabs= 775 nm, λem= 795 nm (MeOH); λabs= 789 nm, λem= 718 nm (DMSO). 
Mp: 245 C. 
1
H NMR (500 MHz, DMSO-d6) δ: 8.25 (d, J = 14.2 Hz, 2H, 5,5’), 7.63 (d, J = 7.4 
Hz, 2H, 10,10’), 7.43-7.45 (m, 4H, 11,11’,13,13’), 7.38 – 7.23 (m, 2H, 12,12’), 6.30 
(d, J = 14.2 Hz, 2H,6,6’), 3.68 (s, 6H, 15,15’), 2.71 (t, J = 6.0 Hz, 4H, 2,2’), 1.92 – 
1.79 (dt, J= 11.8, 6.3 Hz, 2H, 3), 1.67 (s, 12H, 16,16’). 
13
C NMR (126 MHz, DMSO-d6) δ: 173.13 (7,7’), 148.21 (5,5’), 143.33 (10,10’), 





(13,13’), 111.84 (11,11’), 101.77 (6,6’), 49.35 (8,8’), 31.90 (15,15’), 27.89 (16,16’), 








Indolium salt 7 (800 mg, 2.90 mmol), and dialdehyde 13 (130 mg, 0.73 mmol) were 
stirred with NaOAc (23.0 mg, 0.29 mmol) in acetic anhydride (37.5 mL) and stirred 
at 70 C for 2 h under N2. The reaction was allowed to cool and the resulting mixture 
was extracted with DCM (25.0 mL) and dried over sodium sulphate. The crude solid 
was purified by column chromatography [eluting solvent: DCM:MeOH (92:8)] to 
yield a green solid (67 mg, 68%). 
 
HPLC (method 2) tr = 7.5 min, Purity 100% (ELSD). 
MS (ES): calculated for C42H52ClN2O4 [M] m/z 683.4. Found 683.3 (100%). 
Mp. 219C. 
λabs= 780 nm, λem= 805 nm (MeOH); λabs= 793 nm, λem= 822 nm (DMSO). 




H NMR (500 MHz, MeOD) δ: 8.48 (d, J = 14.1 Hz, 1H, 5), 8.46 (d, J = 14.1 Hz, 
1H, 5’), 7.55 (d, J = 7.5 Hz, 2H, 10,10’), 7.46 (t, J = 8.2 Hz, 2H, 11,11’), 7.36 (t, J = 
7.4 Hz, 2H, 12,12’), 7.32 (dt, J = 7.7, 2.8 Hz, 2H, 13,13’), 6.33 (d, J = 14.1 Hz, 1H, 





Hz, 4H, 2,2’), 2.38 – 2.31 (m, 4H, 19,19’), 2.00 – 1.97 (m, 2H, 3), 1.93 – 1.89(m, 
4H, 18,18’), 1.76 (s, 12H, 21,21’), 1.75 – 1.71 (m, 4H, 16,16’), 1.56 – 1.48 (m, 4H, 
17,17’). 
13
C NMR (126 MHz, MeOD) δ: 173.79 (20,20’), 173.01 (7,7’), 149.76 (5), 144.26 
(5’), 144.04 (10), 142.25 (10’), 142.20 (9), 141.26 (9’), 141.20 (14), 128.54 (14’), 
126.64 (4), 126.58 (1), 125.24 (1’), 125.15 (12,12’), 122.16 (11,11’), 110.96 
(13),110.88 (13’), 101.07 (6), 100.87 (6’), 49.25 (15,15’), 43.73 (9,9’), 43.66 









Indolium salt 8 (270.0 mg, 0.96 mmol), dialdehyde 13 (83.3 mg, 0.48 mmol) and 
NaOAc (80.0 mg, 0.96 mmol) were dissolved in a mixture of acetic acid and acetic 
anhydride (1:1, 27 mL) and stirred at 70 C for 3 h under N2. The solution was 
allowed to cool and the solvent evaporated. The crude product was purified by 
column chromatography [eluting solvent: DCM:MeOH (83:17)] to yield a green 
solid (100 mg, 30%). 
 
HPLC (method 3) tr = 7.18 min, Purity 95% (ELSD). 
MS (ES): calculated for C36H42ClN2O6S2 [M– H]
- 
m/z 697.2. Found 697.0 (100%). 







λabs= 780 nm, λem= 811 nm (MeOH); λabs= 797 nm, λem= 825 nm (DMSO). 




H NMR (500 MHz, MeOD) δ: 8.45 (d, J = 14.1 Hz, 2H, 5,5’), 7.53 (d, J = 7.4 Hz, 
2H, 10,10’), 7.45 – 7.43 (m, 4H, 11,11’, 13,13’), 7.34 – 7.26 (m, 2H, 12,12’), 6.47 
(d, J = 14.1 Hz, 2H, 6,6’), 4.44 – 4.37 (m, 4H, 15,15’), 3.01 (t, J = 6.8 Hz, 4H, 2,2’), 
2.79 (t, J = 6.0 Hz, 4H, 17,17’), 2.34 – 2.24 (m, 4H, 16,16’), 2.00 – 1.96 (m, 2H, 3), 
1.75 (s, 12H, 18,18’). 
13
C NMR (126 MHz, MeOD) δ: 172.77 (7,7’), 150.17 (5,5’), 144.44 (9,9’), 142.1 
(14,14’) 141.34 (4), 128.71 (1,1’), 127.24 (10,10’), 124.95 (12,12’), 122.12 (11,11’), 
110.94 (13,13’), 101.52 (6,6’), 49.23 (15,15’), 48.50 (8,8’) 42.61 (16,16’), 26.75 








Benz[e]indolium salt 6 (0.26 g, 1.16 mmol), dialdehyde 13 (0.10 g, 0.58 mmol) and 
NaOAc (0.10 g, 1.16 mmol) were dissolved in a mixture of acetic acid and acetic 
anhydride (1:1, 20.0 mL) and allowed to stir at 70 C for 3 h under N2. The solvent 
was evaporated and the crude product purified by column chromatography [eluting 
solvent: DCM:MeOH (94:6)] to yield a green solid (53 mg, 16%). 
 





MS (ES): calculated for C40H40ClN2 [M] m/z 583.3. Found 583.3 (100%). 
Mp.190 C. 
MS (HRMS, ES) m/z calc [M] 583.28745. Found. 583.28800. 
λabs= 812 nm, λem= 837 nm (MeOH); λabs= 833 nm, λem= >850 nm (DMSO). 




H NMR (500 MHz, MeOD) δ: 8.57 (d, J = 13.8 Hz, 2H, 5,5’), 8.29 (d, J = 8.5 Hz, 
2H, 16,16’), 8.07 -8.01 (m, 4H, 11,11’,17,17’), 7.69 – 7.62 (m, 4H, 12,12’,13,13’), 
7.51 (t, J = 8.2 Hz, 2H, 14,14’), 6.33 (d, J = 13.8 Hz, 2H, 6,6’), 3.81 (s, 6H, 19,19’), 
2.82-2.76? (m, 4H, 2,2’), 2.04 (s, 12H, 20,20’), 2.02 – 2.01 (m, 2H, 3). 
13
C NMR (126 MHz, MeOD) δ: 174.82 (7,7’), 149.02 (5,5’), 143.11 (9,9’), 140.34 
(14,14’), 133.66 (4), 132.18 (1,1’), 130.43 (16,16’), 129.76 (13,13’), 127.96 (12,12’), 
127.43 (14,14’), 124.81 (15,15’), 122.03 (10,10’), 112.10 (11,11’), 110.63 (17,17’), 








Sulfonated indole 10 (6.7 g, 22.0 mmol), dialdehyde 13 (0.95 g, 5.4 mmol) and 
NaOAc (0.89 g, 10.8 mmol) were dissolved in a mixture of acetic acid and acetic 
anhydride (1:1, 285.0 mL) and allowed to stir at 70 C for 2 h under N2. The solvent 
was evaporated and the crude product purified by column chromatography [eluting 
solvent: DCM:MeOH (80:20)] to yield a green solid (2.0 g, 57%). 
 
HPLC (method 2) tr = 5.7 min, Purity 99% (ELSD). 
MS (ES): calculated for C32H34ClN2O6S2 [M– H]
-





MS (HRMS, ES) m/z calc [M+H]
+
 643.16979. Found. 643.16970. 
Mp. 170 C. 
IR (): 1557 (C=N), 1436 (S=O), 1167 (C-N), 1055 (S=O), 1032 (S-O) cm
-1
. 
λabs= 783 nm, λem= 800 nm (MeOH); λabs= 800 nm, λem= 833 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 8.49 (d, J = 14.2 Hz, 2H, 5,5’), 7.95 (d, J = 1.5 Hz, 
2H, 10,10’), 7.92 (dd, J = 8.3, 1.6 Hz, 2H, 12,12’), 7.39 (d, J = 8.3 Hz, 2H, 13,13’), 
6.35 (d, J = 14.1 Hz, 2H, 6,6’), 3.72 (s, 6H, 15,15’), 2.77 (t, J = 6.1 Hz, 4H, 2,2’), 
2.02 – 1.96 (m, 2H, 3), 1.79 (s, 12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 179.05 (7,7’), 175.32 (5,5’), 151.64 (9,9’), 145.75 
(14,14’), 143.58 (4), 142.44 (11,11’), 129.01 (1,1’), 128.14 (12,12’), 121.34 (10,10’), 
111.61 (13,13’), 103.19 (6,6’), 50.54 (8,8’) 31.97 (15,15’), 28.12(16,16’), 27.32 
(2,2’), 23.32 (3). 
 









3-(p-Hydroxyphenyl) propionic acid (160.0 mg, 1.0 mmol) was dissolved in 





mixture was stirred for 15 min at room temperature. Chloro dye 14 (50.0 mg, 0.1 
mmol) was added and the reaction allowed to stir for 3 h at room temperature. The 
reaction was quenched with water (0.5 mL) and the crude product was purified by 
column chromatography [eluting solvent: DCM:MeOH (92:8)] to yield a green solid 
(78 mg, 82%). 
HPLC (method 3) tr = 9.5 min, Purity 75% (ELSD). 13% isolated as iodide salt. 
MS (ES): calculated for C41H45N2O3 [M] m/z 613.3. Found 613.3 (100%). 
Mp: 210 C. 
λabs= 750 nm, λem= 775 nm (MeOH); λabs= 777 nm, λem= 797 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ:8.01 (d, J = 14.3 Hz, 2H, 5,5’), 7.44 – 7.34 (m, 
4H,10,10’,13,13’), 7.27 (t, J = 8.5 Hz, 4H, 12,12’,19,19’), 7.23 (t, J = 7.1 Hz, 2H, 
11,11’), 7.05 (d, J = 8.7 Hz, 2H, 18,18’), 6.14 (d, J = 14.2 Hz, 2H, 6,6’), 3.60 (s, 6H, 
15,15’), 2.87 (t, J = 7.4 Hz, 2H, 22), 2.76 (t, J = 6.1 Hz, 4H, 2,2’), 2.53 (t, J = 7.5 Hz, 
2H, 21), 2.06 (dt, J = 12.9, 6.6 Hz, 2H, 3), 1.36 (s, 12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 176.89 (23), 173.92 (7,7’), 165.35(17), 159.97 
(5,5’), 144.09(10,10’), 143.30(4), 142.24 (9,9’), 136.60 (14,14’), 131.01 (20), 129.59 
(1,1’), 125.93 (19,19’), 123.17 (12,12’), 122.95 (11,11’), 115.52 (18,18’), 
111.49(13,13’), 100.77 (6,6’), 54.63 (8,8’), 37.38 (22), 31.29 (21), 31.15 (15,15’), 












N-Boc-tyramine (420.0 mg, 1.7 mmol) was dissolved in anhydrous MeCN (7.0 mL) 
under N2. K2CO3 (260.0 mg, 1.8 mmol) was added and the mixture was stirred for 60 
min at room temperature. Chloro dye 14 (170 mg, 0.35 mmol) was added and 
allowed to stir for 30 min at 100 C under microwave irradiation. The solvent was 
evaporated and the crude product was purified by column chromatography [eluting 
solvent: DCM:MeOH (94:6)] to yield a green solid (120 mg, 50%). 
 
HPLC (method 2) tr = 7.2 min, Purity 100% (ELSD). 
MS (ES): calculated for C45H54N3O3 [M] m/z 684.4. Found 684.4 [M] (100%). 
MS (HRMS, ES) m/z calc [M] 684.41597. Found. 684.41640. 
Mp. 149 C. 
IR (): 1697 (C=O), 1504 (C=N), 1248 (C-O), 1212 (C-N), 1151 (OC-O) cm
-1
. 
λabs= 762 nm, λem= 781 nm (MeOH); λabs= 777 nm, λem= 803 nm (DMSO). 
1
H NMR (400 MHz, CDCl3) δ: 7.90 (d, J = 14.2 Hz, 2H, 5,5’), 7.37 (td, J = 7.9, 1.2 
Hz, 2H, 11,11’), 7.26 (d, J = 6.7 Hz, 2H, 13,13’), 7.23 – 7.17 (m, 4H, 12,12’, 
19,19’), 7.13 (d, J = 8.0 Hz, 2H, 10,10’), 7.01 (d, J = 8.6 Hz, 2H, 18,18’), 6.12 (d, J 
= 14.2 Hz, 2H, 6,6’), 4.54 (s, 1H, NH), 3.69 (s, 6H, 15,15’), 3.29 (dd, J = 13.0, 6.4 
Hz, 2H, 22), 2.82 – 2.74 (m, 6H, 21, 2,2’), 2.09 – 2.04 (m, 2H, 3), 1.39 (s, 9H, 25), 
1.36 (s, 12H, 16,16’). 
13
C NMR (100 MHz, MeOD) δ: 174.03 (7,7’), 165.40 (23), 159.99 (17), 144.21 
(5,5’), 143.31 (4), 142.32 (9,9’), 134. 79 (20), 131.64 (14,14’), 129.68 (1,1’), 126.06 
(19,19’), 123.24 (12,12’), 123.19 (11,11’), 115.81 (10,10’), 111.70 (18,18’), 101.05 
(13,13’), 79.96 (6,6’), 54.84 (24), 50.10 (8,8’), 43.15 (22), 36.09 (21), 31.69 (15,15’), 















N-[(4-hydroxyphenyl)methyl]-, 1,1-dimethylethyl ester 81 (87.0 mg, 0.39 mmol) and 
K2CO3 (65.0 mg, 0.47 mmol) were stirred under N2 for 60 min at room temperature 
in anhydrous DMF. Sulfonated chloro dye 18 (50.0 mg, 0.78 mmol) was added and 
the mixture stirred at 70 C for 40 min under microwave irradiation. The crude 
product was purified by column chromatography [eluting solvent: DCM:MeOH 
(84:16)] to yield a green solid (22 mg, 34%). 
 
HPLC (method 2) tr = 6.2 min, Purity 97 % (ELSD). 
MS (ES): calculated for C44H51N3O9S2 [M] m/z 829.3. Found 829.0 (100%). 
MS (HRMS, ES) m/z calc [M+H]
+
 830.31395. Found. 830.31100. 
Mp. 186 C. 
IR (): 1694 (C=O), 1560 (C=N), 1483 (S=O), 1212 (C-O), 1162 (C-N), 1093 (OC-
O), 1054 (S=O), 1003 (S-O) cm
-1
. 
λabs= 768 nm, λem= 788 nm (MeOH); λabs= 787 nm, λem= 814 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 8.02 (d, J = 14.2 Hz, 2H, 5,5’), 7.86 (dd, J = 8.3, 1.7 
Hz, 2H, 12,12’), 7.80 (d, J = 1.5 Hz, 2H, 10,10’), 7.34 (d, J = 8.8 Hz, 2H, 19,19’), 
7.29 (d, J = 8.3 Hz, 2H, 18,18’), 7.12-7.08 (m, 2H, 13,13’), 6.19 (d, J = 14.2 Hz, 2H, 
6,6’), 4.16 (s, 2H, 21), 3.62 (s, 6H, 15,15’), 2.77 (t, J = 5.9 Hz, 4H, 2,2’), 2.09 – 2.01 






C NMR (126 MHz, MeOH) δ: 173.30 (7,7’), 164.51 (22), 159.06 (17), 144.20 
(5,5’), 142.33 (9,9’), 141.83 (4), 140.87 (14,14’), 129.09 (11,11’), 128.15 (20), 
126.62 (19,19’), 122.80 (18,18’), 119.80 (12,12’), 114.74 (1,1’), 114.38 (10,10’), 
109.86 (13,13’), 100.43 (6,6’), 78.81 (23), 42.86 (8,8’), 30.5(21), 27.42 (24), 27.07 








2-(Boc-amino) ethanethiol (92.0 mg, 0.52 mmol) was dissolved in anhydrous DMF 
(3.5 mL) under N2. NaH (40.0 mg, 1.7 mmol) was added and the mixture was stirred 
for 15 min at room temperature. Chloro compound 14 (25.0 mg, 0.52 mmol) was 
added and allowed to stir for 3 h at room temperature. The solvent was evaporated 
and the crude product was purified by column chromatography [eluting solvent: 
DCM:MeOH (94:6)] to yield a green solid (5 mg, 15%). 
 
HPLC (method 2) tr = 7.2 min, Purity 100% (ELSD). 
MS (ES): calculated for C39H50N3O2S [M] m/z 624.4. Found 624.1 (100%).
 
λabs= 780 nm, λem= 802nm (MeOH); λabs= 796 nm, λem= 830 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 8.91 (d, J = 14.2 Hz, 2H, 5,5’), 7.51 (d, J = 7.4 Hz, 
2H, 10,10’), 7.42 (t, J = 7.2 Hz, 2H, 12,12’), 7.32 – 7.25 (m, 4H, 11,11’,13,13’), 6.28 
(d, J = 14.2 Hz, 2H, 6,6’), 3.66 (s, 6H, 15,15’), 3.27 – 3.21 (m, 2H, 18), 2.91 (t, J = 
7.2 Hz, 2H, 17), 2.70 (t, J = 6.1 Hz, 4H, 2,2’), 1.99 – 1.91 (m, 2H, 3), 1.77 (s, 12H, 






C NMR (126 MHz, MeOD) δ: 173.15 (7,7’), 156.38 (19), 145.68 (9,9’), 143.04 
(14,14’), 140.95 (5,5’), 133.27 (1,1’), 128.40 (4), 125.11 (12,12’), 124.84 (11,11’), 
121.94 (10,10’), 110.37 (13,13’), 100.81 (6,6’), 78.90 (20), 53.40 (8,8’), 49.01 (18), 
48.22 (17), 30.19 (15,15’), 29.26 (16,16’), 27.33 (21), 26.90 (2,2’), 25.83 (3). 
 
2-(2-[2-hydroxy-3-([1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene]ethylidene)-




Chloro dye 14 (100.0 mg, 0.21 mmol) and NaOAc (52.0 mg, 0.63 mmol) were 
dissolved in DMF (5.0 mL) and stirred for 12 h at room temperature under N2. The 
reaction was quenched with water (0.5 mL) and the solvent evaporated. The crude 
product was purified by column chromatography [eluting solvent: DCM:MeOH 
(95:5)] to yield a green solid (61 mg, 45%). 
 
HPLC (method 7) tr = 12.3 min, Purity 94% (ELSD). 
MS (ES): calculated for C32H37N2O [M] m/z 465.3. Found 465.4 (100%). 
MS (HRMS, ES) m/z calc [M] 465.29004. Found 465.28900. 
1
H NMR (500 MHz, CDCl3) δ: 8.20 (d, J = 13.1 Hz, 2H, 5,5’), 7.24 – 7.18 (m, J = 
7.8 Hz, 4H, 12,12’,13,13’), 6.93 (t, J = 7.3 Hz, 2H, 11,11’), 6.72 (d, J = 7.6 Hz, 2H, 
10,10’), 5.44 (d, J = 13.2 Hz, 2H, 6,6’), 3.24 (s, 6H, 15,15’), 2.65 (t, J = 5.0 Hz, 4H, 
2,2’), 1.94 – 1.85 (m, 2H, 3), 1.70 (s, 12H, 16,16’). 
13
C NMR (126 MHz, CDCl3) δ: 186.50 (7,7’), 163.20 (4), 144.64 (5,5’), 139.64 
(9,9’), 132.71 (14,14’), 127.65 (1,1’), 126.89 (12,12’), 121.75 (11,11’), 120.49 
(10,10’), 106.43 (13,13’), 92.55 (6,6’), 46.45 (8,8’), 29.30 (2,2’), 28.72 (16,16’), 





The substitution of Cl to OH was confirmed by observing a colour change from 







Sulfonated chloro dye 18 (500.0 mg, 7.8 mmol), 4-carboxyphenylboronic acid (230.0 
mg, 1.4 mmol), Pd(OAc)2 (12.6 mg, 0.17 mmol) and triphenylphosphine (44.1 mg, 
0.17 mmol) were dissolved in H2O (10.0 mL) and stirred at under reflux for 15 h. 
The solvent was evaporated and the green residue was purified by column 
chromatography [eluting solvent: DCM:MeOH:AcOH (86:13:1)] to yield a green 
solid (100 mg, 18%). Starting material was recovered (80%). 
 
HPLC (method 2) tr = 6.8 min, Purity 100% (ELSD). 
MS (ES): calculated for C39H39N2O8S2 [M-H]
-
 m/z 728.2. Found 727.4(100%). 
MS (HRMS, ES) m/z calc [M-H]
-
 727.21533. Found 727.21810. 
Mp. 265 C. 
IR (): 3380 (O-H), 1704 (C=O), 1547 (C=N), 1339 (S=O), 1184 (C-O), 1163 (C-N), 
1092 (S=O), 1009, (S-O) cm
-1
. 
λabs= 780 nm, λem= 805 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 8.24 (d, J = 8.0 Hz, 2H, 5,5’), 7.80 (dd, J = 8.3, 1.6 





(d, J = 8.4 Hz, 2H, 13,13’), 6.21 (d, J = 14.1 Hz, 2H, 6,6’), 3.56 (s, 6H, 15,15’), 2.74 




NMR (126 MHz, MeOD)δ: 176.83 (7,7’), 172.88 (21), 162.67 (17), 148.30 (4), 
144.25 (5,5’), 141.55 (9,9’), 141.19 (14,14’), 140.55 (11,11’), 136.71 (19,19’), 
132.12 (17), 129.52 (12,12’,10,10’), 128.94 (18,18’), 126.62 (13,13’), 119.74 (20), 
109.67 (1,1’), 100.47 (6,6’), 48.36 (8,8’), 30.26 (15,15’), 24.26 (2,2’), 21.32 (16,16’), 
21.09 (3). 
The surprisingly low coupling constant for the trans system was also observed by 












Sulfonated chloro dye 18 (72.0 mg, 0.11 mmol), 4-aminomethyl styrene (30.0 mg, 
0.23 mmol) and TEA (31.0 µL, 0.23 mmol) were dissolved in MeOH (2.0 mL) and 
stirred at 100 C for 1 h under microwave irradiation in a sealed vial. The solvent 
was evaporated and the residue purified by column chromatography [eluting solvent: 
DCM:MeOH (85:15)] to yield a blue solid (71 mg, 85%). 





MS (ES): calculated for C41H44N3O6S2 [M-H]
-




MS (HRMS, ES) m/z calc. 740.28226. Found 740.28248. 
Mp. 226 C decomposed. 
IR (): 1524 (C=N), 1480 (S=O), 1168 (S=O), 1109 (C-N), 1020 (S-O) cm
-1
. 
λabs= 635 nm λem= 738 nm (MeOH), λabs= 640 nm, λem= 764 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.79 (dd, J = 8.3, 1.4 Hz, 2H, 12,12’), 7.72 (d, J = 
1.5 Hz, 2H, 10,10’), 7.68 (d, J = 12.8 Hz, 2H, 5,5’), 7.57 (d, J = 8.0 Hz, 2H, 19,19’), 
7.38 (d, J = 8.0 Hz, 2H,20,20’), 7.09 (d, J = 8.3 Hz,2H13,13’), 6.83 (dd, J = 17.6, 
11.0 Hz, 1H, 22), 5.87 (m, 2H, 23), 5.33 (d, J = 10.9 Hz, 2H, 6,6’), 4.94 (s, 2H, 17), 
3.44 (s, 6H, 15,15’), 2.62 (t, J = 6.1 Hz, 4H, 2,2’), 1.92-1.88 (dt, m, 2H, 3), 1.47 (s, 
12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 170.44 (7,7’), 147.03 (5,5’), 141.64 (4), 141.30 
(9,9’), 140.95 (14,14’), 139.67 (18), 139.39 (21), 138.05 (22), 129.52 (11,11’), 
128.78 (12,12’), 128.27 (20,20,19,19’), 123.64 (1,1’), 121.37 (10,10’), 115.50 
(13,13’), 109.66 (23), 97.34 (6,6’), 55.23 (8,8’), 29.13 (16,16’), 28.99 (17), 28.65 












Chloro compound 14 (0.20 g, 0.41 mmol), 4-aminomethylstyrene (0.14 g, 1.04 
mmol) and TEA (176.0 µL, 1.24 mmol) were dissolved in MeOH (4 mL) and stirred 
at 100 C for 90 min under microwave irradiation. The solvent was evaporated and 
the residue purified by column chromatography [eluting solvent: DCM] to yield a 
blue solid (0.17 g, 69%). 
 
HPLC (method 2) tr = 5.7 Purity 95% (ELSD). 
MS (ES): calculated for C41H46N3 [M] m/z 580.4. Found 580.4 (100%). 
MS (HRMS, ES) m/z calc 581.37645. Found 581.37694. 
Mp. 138 C. 
IR (): 1562 (C=N), 1453 (S=O), 1165 (S=O), 1100 (C-N), 1069 (S-O) cm
-1
. 
λabs= 650 nm, λem= 760 nm (DMSO). 
1
H NMR (500 MHz, CD3CN) δ: 7.64 (d, J = 13.2 Hz, 2H, 5,5’), 7.55 (d, J = 8.1 Hz, 
2H, 20,20’), 7.39 (d, J = 8.1 Hz, 2H, 10,10’), 7.36 – 7.33 (m, 4H, 12,12’,19,19’), 
7.10-7.13 (m, 2H, 11,11’), 7.06 (d, J = 7.8 Hz, 2H, 13,13’), 6.85 (dd, J = 17.7, 10.9 
Hz, 1H, 22), 5.89 (d, J = 17.7 Hz, 1H, 6 or 6’), 5.80 (d, J = 13.2 Hz, 2H, 23), 5.34 (d, 
J = 11.6 Hz, 1H, 6 or 6’), 4.85 (s, 2H, 17), 3.41 (s, 6H, 15,15’), 2.56 (t, J = 6.3 Hz, 
4H, 2,2’), 1.88 – 1.81 (m, 2H, 3), 1.47 (s, 12H, 16,16’). 
13
C NMR (126 MHz, CD3CN) δ: 169.31 (7,7’), 168.22 (5,5’), 143.78 (4), 140.17 
(9,9’), 139.59 (14,14’), 138.25 (18), 137.55 (21), 136.35 (22), 128.68 (12,12’), 
128.22 (19,19’), 126.95 (20,20’), 122.92 (11,11’), 121.84 (10,10’), 120.79 (13,13’), 
114.11 (23), 109.08 (1,1’), 95.20 (6,6’), 53.74 (8,8’), 47.56 (17), 30.18 (2,2’), 27.56 














trimethyl-3H-indolium iodide (26) 
 
 
1-(N-boc-aminomethyl)-4-(aminomethyl) benzene (0.15 g, 0.62 mmol), TEA (86.0 
µL, 0.62 mmol) and chloro dye 14 (0.15 g, 0.31 mmol) were dissolved in MeOH (2.5 
mL) and stirred at 70 C for 4 h. The solvent was evaporated and the crude product 
was purified by column chromatography [eluting solvent: DCM:MeOH (99:1)] to 
yield a blue solid (0.13 g, 60%). 
 
HPLC (method 1) tr = 4.6 min, Purity 100% (ELSD). 
MS (ES): calculated for C45H55N4O2 [M] m/z 683.4. Found 683.4 (100%). 
MS (HRMS, ES) m/z calc. 684.43978. Found 684.43945. 
Mp. 198 C. 




λabs= 642 nm, λem= 737 nm (MeOH); λabs= 640 nm, λem= 758 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.74 (d, J = 13.0 Hz, 2H, 5,5’), 7.46 -7.39 (m, 6H, 
20,20’,19,19’,12,12’), 7.34 (d, J = 7.6 Hz, 2H, 10,10’), 7.15 -7.10 (m, 4H, 
11,11’,13,13’), 5.86 (d, J = 13.1 Hz, 2H, 6,6’), 4.92 (bs, 2H, 17), 4.36 (bs, 2H, 22), 







C NMR (126 MHz, MeOD) δ: 169.07 (7,7’), 168.78 (23), 157.16 (5,5’), 143.53 (4), 
140.09 (9,9’), 139.67 (14,14’), 137.06 (21), 127.99 (18), 127.80 (20,20’), 127.60 
(19,19’), 125.82 (1,1’), 122.68 (12,12’), 121.76 (11,11’), 120.69 (10,10’), 108.61 
(13,13’), 94.88 (6,6’), 78.81 (24), 53.56 (8,8’), 46.66 (17), 43.37 (22), 29.36 (15,15’), 








Sulfonated chloro dye 18 (0.15 g, 0.23 mmol), 1-(N-boc-aminomethyl)-4-
(aminomethyl) benzene (0.16 g, 0.69 mmol) and TEA (95.0 µL, 0.69 mmol) were 
dissolved in MeOH and stirred at 70 C for 4 h under N2. The solvent was 
evaporated and the residue purified by column chromatography [eluting solvent: 
DCM:MeOH (80:20)] to yield a blue solid (0.15 g, 79%). 
 
HPLC (method 2) tr = 6.6 min, Purity 100% (ELSD). 
MS (ES): calculated for C45H54N4O8S2 [M] m/z 842.3. Found 842.3 (100%). 
Mp. 220 C decomposed. 










H NMR (500 MHz, MeOD) δ: 7.81 (dd, J = 8.3, 1.7 Hz, 2H, 12,12’), 7.77 (s, 2H, 
10,10’), 7.71 (d, J = 13.0 Hz, 2H, 5,5’), 7.43-7.35 (m, 4H, 19,19’,20,20’), 7.09 (d, J 
= 8.3 Hz, 2H, 13,13’), 5.86 (d, J = 12.8 Hz, 2H, 6,6’), 4.93 (s, 2H, 17), 4.31 (s, 2H, 
22), 3.44 (s, 6H, 15,15’), 2.62 (t, J = 6.3 Hz, 4H, 2,2’), 1.94 – 1.87 (m, 2H, 3), 1.51 
(s, 12H, 15,15’), 1.46 (s, 9H, 25). 
13
C NMR (126 MHz, MeOD) δ: 170.17 (7,7’), 168.60 (23), 145.09 (5,5’), 140.22 (4), 
139.51 (9,9’), 138.91 (14,14’), 138.76 (21), 136.56 (18), 127.68 (11,11’), 127.34 
(12,12’), 126.42 9 (1,1’), 121.59 (20,20’), 119.64 (19,19’), 113.32 (10,10’), 107.71 
(13,13’), 95.33 (6,6’), 78.88 (24), 53.22 (8,8’), 33.51 (17), 31.68 (22), 29.36 (15,15’), 








Chloro compound 14 (100.0 mg, 0.21 mmol), N-1-boc-1,6-diaminohexane (130.0 
mg, 0.62 mmol) and TEA (86.0 µL, 0.62 mmol) were dissolved in MeOH (2.5 mL) 
and stirred for 4 h at 70 C. The solvent was evaporated and the crude product was 
purified by column chromatography [eluting solvent: DCM:MeOH (99:1)] to yield a 






HPLC (method 2) tr = 7.2 min, Purity 100% (ELSD). 
MS (ES): calculated for C43H59N4O2 [M] m/z 663.5. Found 663.4 (100%).
 
MS (HRMS, ES) m/z calc 664.47108. Found 664.47111. 
Mp. 136 C. 
IR (): 1690 (C=O), 1523 (C=N), 1165 (C-O), 1100 (C-N) cm
-1
. 
λabs= 622 nm, λem= 750 nm (MeOH); λabs= 626 nm, λem= 763 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.79 (d, J = 13.0 Hz, 2H, 5,5’), 7.40 (d, J = 7.3 Hz, 
2H, 10,10’), 7.35-7.31 (m, 2H, 12,12’), 7.13-7.08 (m, 4H, 11,11’,13,13’), 5.81 (d, J = 
12.9 Hz, 2H, 6,6’), 3.80 (t, J = 6.7 Hz, 2H, 17), 3.46 (s, 6H, 15,15’), 3.06 (t, J = 6.9 
Hz, 2H, 22), 2.58 (t, J = 6.2 Hz, 4H, 2,2’), 1.88 – 1.81 (m, 4H, 3,18), 1.68 (s, 12H, 
16,16’), 1.56-1,46 (m, 6H, 19,20,21), 1.42 (s, 9H, 25). 
13
C NMR (126 MHz, MeOD) δ: 169.74 (7,7’), 168.47 (23), 157.18 (5,5’), 143.65 (4), 
139.78 (9,9’), 138.84 (14,14’), 128.02 (12,12’), 122.51 (11,11’), 121.63 (10,10’), 
120.31 (1,1’), 108.41 (13,13’), 94.18 (6,6’), 78.43 (24), 50.24 (8,8’), 39.81 (17), 
31.13 (22), 29.65 (18), 29.36 (19), 29.08 (21), 27.70 (16,16’), 27.42 (25), 26.28 
















trimethyl-3H-indolium iodide (29) 
 
 
Chloro dye 14 (75.0 mg, 0.16 mmol), N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-,1,1-
dimethylethyl ester (116.0 mg, 0.47 mmol) and TEA (64.0 µL, 0.47 mmol) were 
dissolved in MeOH (2.0 mL) and stirred for 4 h at 70 C. The solvent was evaporated 
and the crude product was purified by column chromatography [eluting solvent: 
DCM:MeOH (95:5)] to yield a blue solid (34 mg, 31%).  
 
HPLC (method 2) tr = 7.1 min, Purity 100% (ELSD). 
MS (ES): calculated for C43H59N3O4 [M] m/z 695.5. Found 695.2 (100%). 
MS (HRMS, ES) m/z calc 696.46091. Found 696.46036. 
Mp. 125 C. 
IR (): 1724 (C=O), 1562 (C=N), 1166 (OC-O), 1094 (C-O), 1041 (C-N) cm
-1
. 
λabs= 635 nm, λem= 750 nm (MeOH); λabs= 639 nm, λem= 766 nm (DMSO). 
1
H NMR (400 MHz, MeOD) δ: 7.87 (d, J = 13.1 Hz, 2H, 5,5’), 7.41 (d, J = 7.2 Hz, 
2H, 10,10’), 7.34 (td, J = 7.8, 1.0 Hz, 2H, 12,12’), 7.12 (m, 4H, 11,11’,13,13’), 5.84 





– 3.66 (m, 6H, 17,18,19), 3.64-3.63 (m, 2H, 22), 3.49 (s, 6H, 15,15’), 2.58 (t, J = 6.3 
Hz, 4H, 2,2’), 1.91 – 1.82 (m, 2H, 3), 1.70 (s, 12H, 16,16’), 1.46 (s, 9H, 25). 
13
C NMR (100 MHz, MeOD) δ: 168.99 (7,7’), 143.63 (23), 139.92 (5,5’), 139.49 (4), 
128.04 (9,9’), 122.72 (14,14’), 121.66 (12,12’), 120.56 (11,11’), 108.59 (10,10’), 
94.66 (13,13’), 78.70 (1,1’), 70.21 (6,6’), 69.99 (24), 69.94 (22), 69.90 (19), 69.74 
(18), 60.83 (20), 49.74 (8,8’), 39.84 (21), 39.03 (17), 31.68 (2,2’), 29.36 (15,15’), 








Sulfonated chloro dye 18 (0.15 g, 0.23 mmol), N-[2-[2-(2-
aminoethoxy)ethoxy]ethyl]-,1,1-dimethylethyl ester (0.17 g, 0.7 mmol) and TEA 
(97.0 µL, 0.7 mmol) were dissolved in MeOH (3 mL) and stirred for 4 h at 70 C. 
The solvent was evaporated and the crude product was purified by column 







HPLC (method 2) tr =6.0 min, Purity 95% (ELSD). 
MS (ES): calculated for C43H57N4O10S2 [M-H]
-




MS (HRMS, ES) m/z calc 855.36671. Found 855.36642. 
Mp. 103 C. 
IR (): 1704 (C=O) 1530 (C=N), 1475 (S=O), 1206 (S=O), 1170 (OC-O), 1105  
(C-O), 1064 (C-N), 1020 (S-O) cm
-1
. 
λabs= 634 nm, λem= 770 nm (DMSO). 
1
H NMR (500 MHz, MeOH) δ: 7.90 (d, J = 1.6 Hz, 2H, 10,10’), 7.88 – 7.86 (m, 4H, 
5,5’,12,12’), 7.18 (d, J = 8.2 Hz, 2H, 13,13’), 5.94 (d, J = 12.7 Hz, 2H, 6,6’), 4.05 (t, 
J = 4.8 Hz, 2H, 21), 3.91 (t, J = 4.8 Hz, 2H, 20), 3.79 (dt, J = 8.7, 3.6 Hz, 6H, 
17,18,19), 3.59 (t, J = 5.8 Hz, 2H, 22), 3.55 (s, 6H, 15,15’), 2.67 (t, J = 6.3 Hz, 4H, 














Amino dye 30 (50.0 mg, 0.6 mmol) was dissolved in anhydrous MeCN (1.0 mL) and 
cooled to 0 C. While stirring, acetyl chloride (6.2 µL, 0.7 mmol) was added and left 
to stir for 30 min at room temperature. The solvent was evaporated and the residue 
purified by column chromatography [eluting solvent: DCM:MeOH (85:15)] to yield 
a green solid (26 mg, 50%). 
 
HPLC (method 2) tr =7.4 min, Purity 100% (ELSD). 
MS (ES): calculated for C45H59N4O11S2 [M-H]
-
 m/z 895.4. Found 895.9 (100%). 
λabs= 685 nm, λem= 714 nm (DMSO). 
1
H NMR (500 MHz, D2O) δ: 7.86 (s, 2H, 10, 10’), 7.76 (d, J = 8.4 Hz, 2H, 12,12’), 
7.43 (d, J = 13.8 Hz, 2H, 5,5’), 7.09 (d, J = 8.4 Hz, 2H, 13,13’), 6.18 (d, J = 14.0 Hz, 
2H, 6,6’), 3.88 (t, 5.7 Hz, 2H, 18), 3.49 (s, 3H, 27), 3.42 (m, 8H, 2,2’,19,20), 3.22 
(quartet, J = 7.28, 4H, 17,22) 3.13 (t, J = 5.0 Hz, 2H, 21), 2.44 (m, 2H, 3), 1.59 (s, 
6H, 16 or 16’), 1.41 (s, 6H, 16 or 16’), 1.27 (s, 9H, 25). 
13
C NMR (126 MHz, D2O) δ: 173.44 (26), 173.19 (7,7’), 157.90 (23), 144.40 (11, 
11’), 141.29 (14,14’,9,9’), 139.41 (5,5’), 128.79 (4), 126.90 (1,1’), 119.60 
(10,10’,12,12’), 111.11 (13,13’), 102.46 (6,6’), 99.46 (24), 96.92 (8,8’) 69.39 (18), 
67.73 (21), 48.71 (19,20), 46.66 (17), 31.13 (2,2’), 27.64 (22), 27.55 (27), 27.03 












Sulfonated chloro dye 18 (100.0 mg, 0.16 mmol), benzylamine (51.0 µL, 0.47 mmol) 
and TEA (64.0 µL, 0.47 mmol) were dissolved in MeOH (1.5 mL) and stirred at 70 
C for 4 h. The solvent was evaporated and the residue purified by column 
chromatography [eluting solvent: DCM:MeOH (87:13)] to yield a blue solid (61 mg, 
55%). 
 
HPLC (method 1) tr = 6.8 min, Purity 83% (ELSD). 
MS (ES): calculated for C39H43N3O6S2 [M-H]
-




Mp. 260 C decomposed. 
IR (): 1538 (C=N), 1475 (S=O), 1170 (S=O), 1115 (C-N), 1024 (S-O) cm
-1
. 
λabs= 685 nm, λem= 714 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.80 (dd, J = 8.3, 1.5 Hz, 2H, 12,12’), 7.74 (s, 2H, 
10,10’), 7.71 (d, J = 12.9 Hz, 2H, 5,5’), 7.52-7.40 (m, 5H,19,19’,20,20’,21), 7.08 (d, 
J = 8.3 Hz, 2H, 13,13’), 5.86 (d, J = 12.9 Hz, 2H, 6,6’), 4.96 (s, 2H, 17), 3.44 (s, 6H, 
15,15’), 2.63 (t, J = 6.2 Hz, 4H, 2,2’), 1.92-1.88 (m, 2H, 3), 1.49 (s, 12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 168.70 (7,7’), 145.14 (5,5’), 139.52 (4), 139.05 
(9,9’), 137.92 (14,14’), 129.17 (11,11’, 12,12’), 128.00 (18), 127.30 (19,19’,10,10’), 
126.39 (21), 121.52 (20,20’), 119.56 (13,13’), 107.70 (1,1’), 95.29 (6,6’), 53.57 












Sulfonated chloro dye 18 (25.0 mg, 0.4 mmol) and 2 M methylamine in MeOH (10.0 
µL, 35 mmol) were dissolved in MeOH (0.25 mL) and stirred at 70 C for 4 h. The 
solvent was evaporated and the residue purified by column chromatography [eluting 
solvent: DCM:MeOH (85:15)] to yield a blue solid (21 mg, 83%). 
 
HPLC (method 2) tr = 7.6 min, Purity 100% (ELSD). 
MS (ES): calculated for C33H38N3O6S2 [M-H]
-
 m/z 636.2. Found 636.1 (70%). 
MS (HRMS, ES) m/z calc [M-H]
-
 636.22075. Found 636.22490. 
Mp. 177 C. 
IR (): 1523 (C=N), 1482 (S=O), 1271 (S=O), 1098 (C-N), 1018 (S-O) cm
-1
. 
λabs= 608 nm, λem= 772 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.78 (dd, J = 8.2, 1.6 Hz, 2H, 12,12’), 7.75 (d, J = 
1.3 Hz, 2H, 10,10’), 7.64 (d, J = 12.5 Hz, 2H, 5,5’), 7.03 (d, J = 8.3 Hz, 2H, 13,13’), 
5.73 (d, J = 12.6 Hz, 2H, 6,6’), 3.47 (s, 3H, 17), 3.39 (s, 6H, 15,15’), 2.60 (t, J = 6.3 
Hz, 4H, 2,2’), 1.87 – 1.82 (m, 2H, 3), 1.67 (s, 12H, 16,16’). 
13
C NMR (126 MHz, MeOD)δ: 171.59 (7,7’), 167.13 (5,5’), 158.23 (4), 145.33 
(9,9’), 138.99 (14,14’), 136.30 (11,11’), 135.05 (12,12’), 126.37 (10,10’), 
119.56(13,13’), 107.22 (1,1’), 94.12 (6,6’), 35.98 (8,8’), 28.83 (17), 27.50 (16,16’), 
25.65 (15,15’), 23.97 (2,2’), 20.93 (3). 
 
1,3,3-trimethyl-2-((E)-2-((E)-2-(methylamino)-3-((E)-2-(1,3,3-trimethylindolin-
2-ylidene)ethylidene)cyclohex-1-enyl)vinyl)-3H-indolium iodide (33) 
 
 
Chloro dye 14 (80.0 mg, 0.17 mmol) and 2 M methylamine in MeOH (50.0 µL, 175 





was evaporated and the residue washed with water (20.0 mL) to yield a blue solid 
(71 mg, 90%). 
 
HPLC (method 2) tr = 6.8 min, Purity 100% (ELSD). 
MS (ES): calculated for C33H40N3 [M] m/z 478.3. Found 478.3 (100%). 
MS (HRMS, ES) m/z calc [M] 478.32168. Found 478.32100. 
Mp. 208 C. 
IR (): 1525 (C=N), 1097 (C-N) cm
-1
. 
λabs= 612 nm, λem= 767 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.71 (d, J = 12.7 Hz, 2H, 5,5’), 7.36 (d, J = 7.3 Hz, 
2H, 10,10’), 7.31 (t, J = 7.6 Hz, 2H, 12,12’), 7.10 – 7.03 (m, 4H, 11,11’,13,13’), 5.72 
(d, J = 12.7 Hz, 2H, 6,6’), 3.47 (s, 3H, 17), 3.42 (s, 6H, 15,15’), 2.60 (t, J = 5.9 Hz, 
4H, 2,2’), 1.90 – 1.83 (m, 2H, 3), 1.67 (s, 12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 170.62 (7,7’), 167.60 (5,5’), 143.74 (14,14’), 139.71 
(4), 136.91 ( 9,9’), 131.12 (12,12’), 128.69 (1,1’), 127.93 (10,10’), 122.19 (11,11’), 
121.51 (13,13’), 119.64 (6,6’), 93.41 (8,8’), 36.14 (17), 27.59 (15,15’), 25.52 (2,2’), 
21.12 (16,16’), 18.36 (3). 





















Amino dye 33 (20.0 mg, 0.042 mmol) was dissolved in anhydrous DCM (2.0 mL), 
the flask cooled to 0 C and purged with N2. DIPEA (90.0 µL, 0.5 mmol) and acetyl 
chloride (9.2 µL, 0.084 mmol) were added and the reaction allowed to stir at room 
temperature for 30 min. The solvent was evaporated and the green solid was purified 
by column chromatography [eluting solvent: DCM:MeOH (95:5)] to afford the 
desired product as a green solid (12 mg, 55%). 
 
HPLC (method 2) tr = 6.3 min, Purity 100% (ELSD). 
MS (ES): calculated for C35H42N3O [M] m/z 520.3. Found 520.3 (100%). 
MS (HRMS, ES) m/z calc [M] 520.33224. Found 520.33021. 
Mp. 185 C. 
IR (): 1667 (C=O), 1547 (C=N), 1257 (C-O), 1008 (C-N) cm
-1
. 
λabs= 787 nm, λem= 815 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.97 (d, J = 13.8 Hz, 2H, 5,5’), 7.517.49(m, 2H, 
10,10’), 7.43 (td, J=7.5, 0.8 Hz, 2H, 12,12’), 7.31-7.29 (m, 2H, 13,13’), 7.27 (td, J = 
7.5, 0.8 Hz, 2H, 11,11’), 6.25 (d, J = 13.7 Hz, 2H, 6,6’), 3.70 (s, 3H, 19), 3.65 (s, 6H, 
15,15’), 2.80 (s, 3H, 17), 2.68-2.66 (m, 4H, 2,2’), 1.98 – 1.94 (m, 2H, 3), 1.70 (s, 
12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 173.17 (18), 172.26 (7 or 7’), 171.13 (7 or 7’), 
155.07 (4), 151.43 (5 or 5’), 143.03 (5 or 5’), 142.87 (14 or 14’), 142.31 (14 or 14’), 





or 1’), 126.29 (1 or 1’), 125.25 (11 or 11’), 124.65 (11 or 11’), 122.02 (10 or 10’), 
121.88 (10 or 10’), 110.77 (13 or 13’), 110.25 (13 or 13’), 101.37 (6 or 6’), 100.45 
(6 or 6’), 53.40 (8 or 8’), 48.77 (8 or 8 ‘), 36.18 (15 or 15’), 35.46 (15 or 15’), 30.44 
(17), 30.16 (2 or 2’), 27.08 (2 or 2’), 26.89 (16 or 16’), 25.25 (16 or 16’), 25.11 (3), 
24.12 (19). 










Chloro dye 14 (25.0 mg, 0.05 mmol), [2-(2-aminoethoxy)ethoxy]acetic acid (25.3 
mg, 0.15 mmol) and TEA (0.5 mmol, 67 µL) were dissolved in MeOH (1.0 mL) and 
stirred at 70 C for 4 h. The solvent was evaporated and the residue purified by 
column chromatography (94:5:1 DCM:MeOH:AcOH) to yield a blue solid (17 mg, 
54%). 
 
HPLC (method 2) tr = 6.8 min, Purity 100% (ELSD). 
MS (ES): calculated for C38H48N3O4 [M] m/z 610.4. Found 610.3 (100%). 
MS (HRMS, ES) m/z calc [M+H]
+





Mp. 241 C decomposed. 
IR (): 3337 (O-H), 1566 (C=N), 1167 (CO-O), 1097 (C-O), 1044 (C-N) cm
-1
. 
λabs= 652 nm, λem= 777 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.86 (d, J = 13.0 Hz, 2H, 5,5’), 7.40 (d, J = 7.3 Hz, 
2H, 10,10’), 7.34 (td, J = 11.2, 4.2 Hz, 2H, 12,12’), 7.13-7.08 (m, 4H, 11,11’,13,13’), 
5.83 (d, J = 13.1 Hz, 2H, 6,6’), 3.97 (s, 2H, 22), 3.93 (t, J = 4.7 Hz, 2H, 21), 3.83 – 
3.74 (m, 6H, 18,19,20), 3.47 (s, 6H, 15,15’), 2.57 (t, J = 6.3 Hz, 4H, 2,2’), 1.91 – 
1.84 (m, 2H, 3), 1.69 (s, 12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 169.82 (7,7’), 168.92 (23), 143.64 (5,5’), 139.91 (4), 
139.49 (9,9’), 127.99 (14,14’), 122.64 (12,12’), 121.65 (10,10’), 120.54 (11,11’), 
108.49 (13,13’), 94.51 (1,1’), 70.07 (6,6’), 69.95 (22), 69.85 (20,21), 49.73(19), 







Sulfonated chloro dye 18 (50.0 mg, 0.78 mmol), [2-(2-aminoethoxy)ethoxy]acetic 





(1.5 mL) and stirred at 70 C for 4 h. The solvent was evaporated and the residue 
purified by preparative HPLC to yield a blue solid (31 mg, 52%). 
 
HPLC (method 2) tr = 5.7 min, Purity 100% (ELSD). 
MS (ES): calculated for C38H46N3O10S2 [M-H]
-
 m/z 768.3. Found 768.1 (100%). 
MS (HRMS, ES) m/z calc [M+H]
+
 770.27757. Found 770.27678. 
Mp. 201 C decomposed. 
IR (): 1728 (C=O), 1521 (C=N), 1481 (S=O), 1290 (S=O), 1205 (OC-O), 1164 (C-
O), 1095 (C-N), 1016 (S-O) cm
-1
. 
λabs= 637 nm, λem= 771 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 7.82-7.78 (m, 6H, 5,5’,10, 10’,12,12’), 7.09 (d, J = 
8.4 Hz, 2H, 13,13’), 5.85 (d, J = 12.4 Hz, 2H, 6,6’), 3.98 (t, J = 5.0 Hz, 2H, 19), 3.84 
(t, J = 5.0 Hz, 2H, 18), 3.78 (s, 2H, 22), 3.47 (s, 4H, 20,21), 3.37 (s, 6H, 15,15’), 
2.63-2.55 (m, 4H, 2,2’), 1.90-1.85 (dt, J = 12.9, 6.5Hz, 2H, 3), 1.70 (s, 12H, 16,16’). 
13
C NMR (126 MHz, MeOD) δ: 172.39(23), 168.49 (7,7’), 145.24 (5,5’), 139.71(4), 
138.97 (9,9’), 138.91(14,14’), 126.47(11,11’), 121.49 (12,12’), 119.70 (10,10’), 
119.69 (13,13’), 107.67 (1,1’), 70.54(6,6’), 70.42 (20), 69.98(19), 69.89(21), 69.71 
(22), 67.73 (8,8’), 67.63 (18), 49.70 (15,15’), 27.58 (16,16’), 24.51 (2,2’), 21.39 (3). 
 




























Chloro dye 14 (25.0 mg, 0.05 mmol), 6-aminocaproic acid (20.3 mg, 0.16mmol) and 
TEA (0.5 mmol, 67 µL) were dissolved in MeOH (1.0 mL) and stirred at 70 C for 4 
h. The solvent was evaporated and the residue purified by column chromatography 
(95:4:1 DCM:MeOH:AcOH) to yield a blue solid (17 mg, 57%). 
 
HPLC (method 2) tr = 6.7 min, Purity 100% (ELSD). 
MS (ES): calculated for C38H48N3O2 [M] m/z 578.4. Found 578.2 (100%).
 
MS (HRMS, ES) m/z calc [M+H]
+
 579.38193. Found 579.38173. 
Mp. 141 C. 
IR (): 1722 (C=O), 1526 (C=N), 1158 (OC-O), 1101 (C-N) cm
-1
. 
λabs= 631 nm, λem= 767 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ 7.77 (d, J = 12.9 Hz, 2H,5,5’), 7.37 (d, J = 7.2 Hz, 
2H, 10,10’), 7.31 (td, 2H, 7.8, 0.8 Hz, 12,12’), 7.06-7.10 (m, 4H, 11,11’,13,13’), 5.78 
(d, J = 13.0 Hz, 6,6’, 2H), 3.78 (t, J = 6.8 Hz, 2H, 18), 3.44 (s, 6H, 15), 2.55 (t, J = 
6.3 Hz, 4H, 2,2’), 2.30 (t, J = 7.3 Hz, 2H, 22), 1.88 – 1.79 (m, 4H, 19,21), 1.68 (m, 
2H, 3), 1.67 (s,12H, 16,16’), 1.51 – 1.44 (m, 2H, 20). 
13
CNMR (126 MHz, MeOD)δ: 169.82 (7,7’), 168.92 (23), 143.64 (5,5’), 139.91 (4), 





108.49 (13,13’), 94.51 (1,1’), 70.07 (6,6’), 69.95 (18), 69.85 (20,21), 49.73 (22), 







Sulfonated chloro dye 18 (50.0 mg, 0.78 mmol), 6-aminocaproic acid (31.0 mg, 0.24 
mmol) and TEA (109.0 µL, 7.8 mmol) were dissolved in MeOH (1.5 mL) and stirred 
at 70 C for 4 h. The solvent was evaporated and the residue purified by preparative 
HPLC to yield a blue solid (24 mg, 42%). 
 
HPLC (method 2) tr = 6.5 min, Purity 100% (ELSD). 




MS (HRMS, ES) m/z calc [M+H]
+ 
738.28774. Found 738.28807. 
Mp. 220 ºC decomposed. 
IR (): 1714 (C=O), 1528 (C=N), 1437 (S=O), 1291 (S=O), 1167 (OC-O), 1113 (C-
O), 1063 (C-N), 1020 (S-O) cm
-1
. 






H NMR (500 MHz, MeOD) δ: 7.83 – 7.79 (m, 4H, 12, 12’,10,10’), 7.74 (d, J = 12.7 
Hz, 2H, 5,5’), 7.08 (d, J = 8.3 Hz, 2H, 13,13’), 5.83 (d, J = 12.9 Hz, 2H, 6,6’), 3.83 
(t, J = 6.8 Hz, 2H, 18), 3.45 (s, 6H, 15,15’), 2.59 (t, J = 6.3 Hz, 4H, 2,2’), 2.29 (t, J = 
7.4 Hz, 2H, 22), 1.89-1.84(m, 4H, 19,21), 1.73 (m, 2H, 3), 1.70 (s, 12H, 16,16’), 
1.54-1.46 (m, 2H, 20). 
13
C NMR (126 MHz, MeOD)δ: 170.92 (7,7’), 168.01 (23), 145.22 (5,5’), 139.63 (4), 
139.25 (9,9’), 138.28 (14,14’), 126.44 (11,11’), 121.34 (12,12’), 119.61 (10,10’), 
107.54 (13,13’), 94.76 (1,1’), 93.63 (6,6’), 50.14 (8,8’), 35.49 (18), 30.59 (22), 29.35 
(2,2’), 27.58 (15,15’), 27.52 (19), 26.39 (21), 25.09 (16,16’), 24.70 (20), 21.34 (3). 
 
HSQC with DEPT editing (500 MHz, MeOD) 
 
 
Confirmation of 6 aromatic protons, 7 CH2 groups and 2 groups of methyls. 1 CH2 














Sulfonated benz[e]indole 8 (154.0 mg, 0.47 mmol), isophthalaldehyde (25.0 mg, 1.9 
mmol) and NaOAc (152.0 mg, 1.9 mmol) were dissolved in a mixture of AcOH and 
Ac2O (1:1, 5 mL) and left to stir for 5 h at 80 C. The solvent was evaporated and the 
product purified by preparative HPLC to yield a yellow sold (64 mg, 45%) 
 
HPLC (method 2) tr = 5.0 min, Purity 100% (ELSD). 
MS (ES): calculated for C44H47N2O6S2 [M+H]
+ 
m/z 763.3. Found 763.3
 
(80%). 
MS (HRMS, ES) m/z calc. [M] 762.27918. Found 762.27873. 
Mp. 210 C. 




H NMR (500 MHz, MeOD) δ: 8.74 (d, J = 16.4 Hz, 2H, 3,3’), 8.51 (d, J = 8.4 Hz, 
2H, 9,9’), 8.34 (dd, J = 7.8, 1.2 Hz, 2H, 12,12’), 8.30-8.24 (m, 5H, 1,4,4’,15,15’), 
8.20 (d, J = 8.2 Hz, 2H, 14,14’), 8.15 (d, J = 8.9 Hz, 2H, 17,19), 7.85 (td, J = 7.2, 1.0 
Hz, 2H, 10,10’), 7.80 (t, J = 7.7 Hz, 1H, 18), 7.76 (td, J = 7.6, 1.0 Hz, 2H, 11,11’), 
5.20 (t, J = 7.5 Hz, 4H, 20,20’), 3.19 (t, J=5.0 Hz, 4H,22,22’), 2.61 – 2.52 (m, 4H, 
21,21’), 2.22 (s, 12H, 23,23’). 
13
C NMR (126 MHz, MeOD) δ: 183.38 (5,5’), 152.47 (3,3’), 139.66 (7,7’), 138.18 





(17,19), 130.19 (1), 129.95 (18), 128.26 (12,12’), 127.43 (11,11’), 127.30 (10,10’), 
123.00 (9,9’), 113.43 (4,4’), 112.39 (15,15’), 54.48 (6,6), 45.87 (22,22’), 25.14 







Quinolinium salt 12 (0.80 g, 2.8 mmol), NaOAc (0.54 g, 6.6 mmol) and 
isophthalaldehyde (0.15 g, 1.1 mmol) were dissolved in a mixture of acetic acid and 
acetic anhydride (1:1, 15.0 mL) for 4 h at 120 C in a sealed vial. The solvent was 
evaporated and the crude product was purified by column chromatography [eluting 
solvent: Hexane:EtOAc (90:10)] to yield an orange solid (0.13 g, 28 %). 
 
HPLC (method 2) tr= 4.1 min, Purity 95% (31 % isolated as iodide salt) (ELSD). 
Mp. 244 C decomposed. 




H NMR (500 MHz, DMSO-d6) δ: 9.17 (d, J = 8.9 Hz, 2H, 7,19), 8.63 (m, 4H, 
9,12,21,24), 8.42 (dd, J = 8.0, 0.9 Hz, 2H, 3,15), 8.29 – 8.22 (m, 4H,4,6,16,18), 8.17 
– 8.14 (m, 3H, 26,27,28), 8.11 (s, 1H, 1), 8.01 (t, J = 7.6 Hz, 2H, 11,23), 7.75 (t, J = 
7.7 Hz, 2H, 10,22), 4.65 (s, 6H, 29,30). 
13
C NMR (126 MHz, DMSO-d6) δ: 156.48 (5,17), 146.12 (13,25), 145.16 (2,14), 
139.75 (7,19), 136.21 (3,15), 135.64 (26,28), 131.92 9 (11,23), 130.65 (8,20), 
130.43(1), 129.89 (27), 129.75 (9,21), 128.56 (10,22), 121.89 (12,24), 121.27 (4,16), 







6.4.5 Novel Pentamethine Cyanine Dyes 
 
2-((1E,3Z,5E)-3-(5-carboxypyridin-2-yl)-5-(1,1,3-trimethyl-1H-benzo[e]indol-




Benz[e]indolinium salt 6 (0.22 g, 1.0 mmol), 2-(5-carboxypyridin-2-
yl)malondialdehyde (0.098 g, 0.5 mmol) and NaOAc (0.6 g, 7.2 mmol) were 
dissolved in a mixture of acetic acid and acetic anhydride (1:1, 20.0 mL) and stirred 
at 70 C for 3 h under N2. The solvent was evaporated and the product extracted with 
DCM (25.0 mL). The crude product was washed with EtOAc (20.0 mL) and Et2O 
(20.0 mL) and dried under vacuum to yield a blue solid (0.11 g, 37%).  
 
HPLC (method 2) tr = 4.2 min, Purity 100% (ELSD). 
MS (ES): calculated for C41H38N3O2 [M] m/z 604.3. Found 604.3 (100%). 
MS (HRMS, ES) m/z calc [M+H]
+ 
605.30368Found 605.30313. 
Mp. 255 C decomposed 
λabs= 670 nm, λem= 690 nm (MeOH); λabs= 677 nm, λem= 702 nm (DMSO). 




H NMR (500 MHz, MeOD) δ: 9.37 (d, J = 1.8, 1H, 4),8.61 (dd, J = 7.9, 2.0 Hz, 1H, 
2), 8.53 (d, J = 13.1 Hz, 2H, 9,9’), 8.29 (d, J = 8.5 Hz, 2H, 20,20’), 8.02 (t, J = 8.5 
Hz, 4H, 15,15’,18,18’), 7.72 (d, J = 8.0, 1H, 1), 7.70-7.67 (m, 2H, 17,17’), 7.60 (d, J 
= 8.8 Hz, 2H, 21,21’), 7.54 – 7.50 (m, 2H, 16,16’), 5.88 (d, J = 10.5 Hz, 2H, 10,10’), 






C NMR (126 MHz, MeOD) δ: 175.99 (11,11’), 157.48 (7), 150.94 (6), 140.04 
(9,9’), 138.73 (4), 133.86 (22,22’,13,13’), 132.24 (2), 130.30 (20,20’), 129.73 
(17,17’), 128.9 (3), 127.91 (16,16’), 127.42 (18,18’), 124.88 (19,19’,14,14’), 122.03 
(15,15’), 116.07 (8), 111.02 (1), 110.64 (21,21’), 99.97 (10,10’), 51.23 (12,12’), 







Sulfonated indolium salt 10 (4.85 g, 19.4 mmol), 2-(5-carboxypyridin-2-
yl)malondialdehyde (1.50 g, 7.7 mmol) and NaOAc (4.45 g, 543 mmol) were 
dissolved in a mixture of acetic acid and acetic anhydride (1:1, 300.0 mL) and stirred 
at 70 C for 5 h under N2. The solvent was evaporated crude product was crystallised 
with EtOAc and washed with Et2O. The compound was purified by column 
chromatography [eluting solvent: DCM:MeOH (80:20)] to yield a blue solid (1.8 g, 
35%).  
 
HPLC (method 2) tr = 4.4 min, Purity 92% (ELSD). 
MS (ES): calculated for C33H32N3O8S2 m/z 662.2. Found 661.6 (100%).
 
MS (HRMS, ES), m/z calc [M+H]
+ 
664.17819. Found 664.17836. 
Mp. 160 C. 








λabs= 640 nm, λem= 661nm (MeOH); λabs= 650 nm, λem= 676 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 9.29 (d, J = 1.75 Hz, 1H, 4), 8.51 (dd, J = 7.9, 2.0, 
1H, 2), 8.47 (d, J = 14.3 Hz, 2H, 9,9’), 7.94 (d, J = 1.5 Hz, 2H, 14,14’), 7.90 (dd, J = 
8.3, 1.2 Hz, 2H, 16,16’), 7.59 (d, J = 7.9 Hz, 1H, 1), 7.34 (d, J = 8.3 Hz, 2H, 17,17’), 
5.85 (d, J = 14.0 Hz, 2H, 10,10’), 3.44 (s, 6H, 19,19’), 1.84 (s, 12H, 20,20’). 
13
C NMR (126 MHz, MeOD) δ: 176.78 (11,11’), 172.26 (7), 152.21 (6), 145.39 (4), 
143.77 (13,13’), 142.63 (18,18’), 139.84 (9,9’), 139.68 (2), 134.36 (15,15’), 128.00 
(16,16'), 126.78 (3), 122.29 (17,17’), 121.24 (14,14’), 111.74 (8), 102.70 (1), 








Sulfonated benz[e]indole 8 (280.0 mg, 0.85 mmol), 2-(3-hydroxycarbonyl-6-
pyridyl)malondialdehyde (75.0 mg, 0.39 mmol) and NaOAc (190.0 mg, 2.35 mmol) 
were dissolved in a mixture of AcOH and Ac2O (1:1, 8 mL) and left to stir for 5 h at 
80 C. The solvent was evaporated and the product purified by preparative HPLC to 
yield a blue solid (0.18 g, 57 %). 
 
HPLC (method 2) tr = 0.7 min, Purity 100% (ELSD). 
MS (ES): calculated for C45H46N3O8S2 [M+H]
+







MS (HRMS, ES) m/z calc. [M+H]
+ 
820.27209. Found 820.27133. 
Mp. 229 C. 




λabs= 683 nm, λem= 708 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ:9.37 (m, 1H, 4), 8.69 (d, J = 14.2 Hz, 2H, 9,9’), 8.61 
(m, 2H, 20,20), 8.28 (d, J = 8.3 Hz, 2H, 21,21’), 8.05-7.99 (m, 4H, 15,15’,18,18’), 
7.74 (d, J = 8.9 Hz, 1H, 1), 7.71 – 7.65 (m, 2H, 17,17’), 7.54-7.49 (m, 2H, 16,16’), 
5.86 (m, 2H, 10,10’), 4.46 – 4.17 (m, 4H, 23,23’), 2.96-2.87 (m, 4H, 25,25’), 2.23-
2.21 (m, 4H, 24,24’), 2.04 (s, 12H, 26,26’). 
13
C NMR (126 MHz, MeOD)δ: 168.84 (11,11’), 139.61 (7), 134.83 (6), 133.78 
(9,9’), 132.21 (4), 130.40 (13,13’, 22,22’), 129.66 (2), 129.42 (20,20’), 128.09 (3), 
127.33 (16,16’,18,18’), 125.64 (17,17’), 124.86 (19,19’,14,14’), 122.16 (21,21’), 
110.86 (10,10’), 110.72 (15,15’) 101.18 (8), 100.03 (1), 51.49 (12,12’), 46.30 








Sulfonated benz[e]indole 8 (230.0 mg, 0.68 mmol), 2-(4-





mmol) were dissolved in a mixture of AcOH and Ac2O (1:1, 5 mL) and left to stir for 
5 h at 80 C. The solvent was evaporated and the product purified by preparative 
HPLC to yield a blue solid (91 mg, 42 %). 
 
HPLC (method 2) tr = 4.8 min, Purity 87% (ELSD). 
MS (ES): calculated for C45H44ClN2O6S2 [M-H]
-
 m/z 807.2. Found 807.2 (100%). 
MS (HRMS, ES) m/z calc. [M+H]
+ 
809.24804. Found 809.24714. 
Mp. 201 C decomposed. 




λabs= 686 nm, λem= 709 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 8.66 (d, J = 14.0 Hz, 2H, 9,9’), 8.29 (d, J = 8.5 Hz, 
2H, 20,20’), 8.05 – 7.99 (m, 4H, 15,15’, 21,21’), 7.71 (m, 4H, 2,4,18,18’), 7.67 (td, J 
=8.0, 1.5 Hz, 2H, 17,17’), 7.51 (t, J = 7.5 Hz, 2H, 16,16’), 7.42 (d, J = 8.2 Hz, 2H, 
1,5), 5.83 (d, J = 13.0 Hz, 2H, 10,10’), 4.28 (t, J = 8.75 Hz, 4H, 23,23’), 2.91 (t, J = 
6.4 Hz, 4H, 25,25’), 2.25 (m, 4H, 24,24’), 2.03 (s, 12H, 26,26’). 
13
C NMR (126 MHz, MeOD)δ: 178.05 (11,11’), 140.80 (9,9’), 135.08 (13,13’), 
134.88 (22,22’) 133.40 (6), 133.14 (3), 131.69 (20,20’), 130.94 (8), 130.69 
(19,19’,14,14’), 129.35 (17,17’,16,16’), 128.66 (21,21’), 126.13 (1,2,4,5), 123.36 
(18,18’), 111.97 (15,15’), 101.74 (10,10’), 64.34 (12,12’), 52.57 (23,23’), 27.31 



















Sulfonated benz[e]indole 8 (107.0 mg, 0.32 mmol), 2-(4-
nitrophenyl)malondialdehyde (25.0 mg, 0.13 mmol) and NaOAc (107.0 mg, 1.3 
mmol) were dissolved in a mixture of AcOH and Ac2O (1:1, 5.0 mL) and left to stir 
for 5 h at 80 C. The solvent was evaporated and the product purified by column 
chromatography [eluting solvent: CH3CN:iPrOH(60:40)] to yield a blue solid (71 
mg, 67 %). 
 
HPLC (method 2) tr = 5.5 min, Purity 100% (ELSD). 
MS (ES): calculated for C45H44N3O8S2 [M-H]
-
 m/z 819.3. Found 818.2 (90%). 
MS (HRMS, ES) m/z calc. [M+H]
+ 
820.27209. Found 820.27198. 
Mp. 207 C. 




λabs= 684 nm, λem= 710 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 8.62 (d, J = 14.3 Hz, 2H, 9,9’), 8.50 (d, J = 8.6 Hz, 
2H, 20,20’), 8.23 (d, J = 8.5 Hz, 2H, 21,21’), 7.95 (m, 4H, 16,16’,17,17’), 7.65 – 
7.60 (m, 6H, 1,2,4,5,15,15’), 7.45 (td, J = 7.3, 0.5 Hz, 2H, 18,18’), 5.74 (d, J = 13.3 
Hz, 2H, 10,10’), 4.22 (t, J = 8.1 Hz, 4H, 23,23’), 2.83 (t, J = 6.8 Hz, 4H, 25,25’), 






C NMR (126 MHz, MeOD) δ: 175.05 (11,11’), 152.07 (9,9’), 147.70 (13,13’), 
139.54 (22,22’), 133.76 (6), 132.19 (20,20’), 131.59 (3), 130.40 (8), 129.66 (14,14’), 
128.53 (19,19’), 128.08 (16,16’,17,17’), 127.82 (14,14’), 127.35 (21,21’), 124.88 
(2,4), 124.42 (1,5), 122.14 (18,18’), 110.78 (15,15’), 100.10 (10,10’), 51.45 (12,12’), 







Sulfonated indolium salt 10 (124.0 mg, 0.33 mmol), 2-(4-nitrophenyl) 
malondialdehyde (25.0 mg, 0.13 mmol) and NaOAc (107.0 mg, 1.3 mmol) were 
dissolved in a mixture of acetic acid and acetic anhydride (1:1, 5 mL) and stirred at 
80 C for 5 h. The solvent was evaporated and the crude product purified by column 
chromatography [eluting solvent: CH3CN:iPrOH (75:25)] to yield a blue solid (68 
mg, 81%). 
HPLC (method 1) tr = 4.9 min Purity 99% (ELSD). 
MS (ES): calculated for C33H32N3O8S2 [M-H]
-
 m/z 662.2. Found 662.3
 
(100%). 
MS (HRMS, ES) m/z calc. [M+H]
+ 
664.17819. Found 664.17851. 
Mp. 235 C decomposed. 
IR (): 1574 (N=H), 1496 (N=O), 1458 (S=O), 1350 (N-O), 1191 (S=O), 1096 (C-
N), 1016 (S-O) cm
-1
. 
λabs= 650 nm, λem= 676 nm (DMSO). 
1
H NMR (500 MHz, MeOD) δ: 8.48-8.43 (m, 4H, 8,8’, 1, 5), 7.92 (s, 2H, 13,13’), 





2H, 16,16’), 5.73 (d, J = 14.1 Hz, 2H, 9,9’), 3.40 (s, 6H, 18,18’), 1.81 (s, 12H, 
19,19’). 
13
C NMR (126 MHz, MeOD) δ: 178.52 (10,10’), 176.57 (3), 164.44 (14,14’), 154.46 
(8,8’), 149.02 (6), 145.22 (17,17’), 143.73 (12,12’), 142.48 (2,4), 132.69 (13,13’), 
127.89 (1,5), 125.51 (15,15’), 121.16 (7), 111.62 (16,16’), 102.53 (9,9’), 50.53 







Sulfonated indole 10 (130.0 mg, 0.34 mmol), 2-(4-chlorophenyl) malondialdehyde 
(25.0 mg, 0.14 mmol) and NaOAc (112.0 mg, 1.4 mmol) were dissolved in a mixture 
of acetic acid and acetic anhydride (1:1, 5 mL) and stirred at 80 C for 5 h. The 
solvent was evaporated and the crude product purified by column chromatography 
[eluting solvent: CH3CN:iPrOH (77:23)] to yield a blue solid (73 mg, 82%). 
HPLC (method 6) tr = 5.3 min, Purity 94% (ELSD). 
MS (ES): calculated for C33H32ClN2O6S2 [M-H]
-
 m/z 651.2. Found 651.2 (30%). 
MS (HRMS, ES) m/z calc. [M+H]
+
 653.15414. Found 653.15322. 
Mp. 230 C decomposed. 
IR (): 1573 (C=N), 1497 (S=O), 1188 (S=O), 1097 (C-N), 1016 (S-O) cm
-1
. 
λabs= 654 nm, λem= 678 nm (DMSO). 
1
H NMR (400 MHz, MeOD) δ: 8.41 (d, J = 14.1 Hz, 2H, 8,8’), 7.91 (m, 2H, 15,15’), 





8.5 Hz, 2H, 16,16’), 7.31-7.37 (m, 4H, 1,2,4,5), 5.76 (d, J = 14.1 Hz, 2H, 9,9’), 3.40 
(s, 6H, 18,18’), 1.79 (s, 12H, 19,19’). 
13
C NMR (100 MHz, MeOD) δ: 178.91 (10,10’), 174.91(8,8’), 153.69 (3), 144.03 9 
(14,14’), 142.24 (17,17’), 141.13 (12,12’), 133.87 (6), 131.59 (2,4), 130.51 (13,13’), 
129.35 (1,5), 126.62 (15,15’), 119.87 (7), 110.22 (16,16’), 101.56 (9,9’), 49.27 
(11,11’), 26.16 (18,18’), 22.75 (19,19’). 
 
6.5 Experimental for Chapter 3 
6.5.1 NIR Inherent Heptamethine Nanoparticles  
General procedure for the synthesis of nanoparticles (58) 
Styrene (122.0 µL, 1 mmol, freshly washed with 4 x 25% NaOH and 4 x brine), 
divinylbenzene (3.1 µL, 22.0 µmol freshly washed with 4 x 25% NaOH and 4 x 
brine), 4-vinylbenzylamine hydrochloride (5.9 mg, 35.0 µM), compound 25 (22.5 
mg, 35.0 µM), 2,2-azobis (2-methylpropionamidine) dihydrochloride (V-50) (1.6 
mg, 6 µmol) and MgSO4 (0.4 mg, 3.0 µmol) were added to N2 purged water (2.0 
mL). The reaction mixture was stirred at 80 C for 15 h. After cooling to room 
temperature, the particles were collected by centrifugation (15 min at 30000 g, 
eppendorf 5430R) and washed with DMF (6 x 2 mL), MeOH (8 x 2 mL) and water 




6.5.2 Solid-Phase Cyanine 3 Synthesis 
 






A mixture of (4-hydroxyphenyl)carbamic acid tert-butyl ester 61 (6.3 g, 30 mmol), 
Cs2CO3 (9.8 g, 30 mmol), KI (0.17 g, 1 mmol) and 1% DVB cross-linked 
chloromethyl polystyrene (2 mmol g
-1





heated at 70 °C for 16 h. The resin was isolated by filtration, washed with water (4 × 
100.0 mL), DMF (4 × 50.0 mL), DCM (3 × 50.0 mL), Et2O (3 × 50.0 mL) and dried 
overnight in vacuo at 40 °C to give the product as a beige resin. 
 
IR (neat) 1717 (C=O), 1510 (N-H), 1156 (C-O) cm
-1
.  










Resin 62 (5.0 g, 7.5 mmol) was shaken at room temperature with a 20% solution of 
TFA in DCM (75.0 mL) for 2 h, filtered and washed with DCM (50.0 mL). The resin 
was then shaken with a 10% solution of TEA in DCM (75.0 mL) for 15 min, filtered, 
washed with DCM (50.0 mL) and dried overnight in vacuo at 40 C to give a product 
as a beige resin.  
 
IR () 3023 (N-H) 1601 (N-H), 1217 (C-O) cm
-1
. 










To resin 63 (6.0 g, 9.9 mmol) was added a solution of triethylorthoformate (25.0 mL, 
150.0 mmol) and a solution of BF3·OEt2 (1.9 mL, 15 mmol) in dry DCM (50.0 mL) 
and the solution stirred at room temperature for 6 h. Dry DIPEA (3.5 mL, 20.0 





filtration, washed with DCM (3 x 20 mL), and dried in vacuo to give the product as a 
brown resin.  
 
IR () 1630 (N=N), 1219 (C-O) cm
-1
.  











To resin 64 (1.0 g, 1.53 mmol) and indolium salt 9 (2.3 g, 7.65 mmol) was added 
DMF (8.0 mL) and the mixture stirred at 120 °C for 15 min under microwave 
irradiation. After cooling, the resin was isolated by filtration, washed with DMF (3 × 
10.0 mL) and DCM (3 × 10.0 mL), and dried in vacuo to give the product as an 
orange resin. 
 
IR () 3023 (N-H), 1684 (C=N), 1227 (C-N), 1004 (C-O) cm
-1
. 




















To resin 65 (1.1 g, 0.80 mmol) were added dry pyridine (5.0 mL), DIPEA (1.3 mL, 
7.4 mmol), Ac2O (0.7 mL, 7.4 mmol) and indolium salt 7 (35.0 mg, 0.10 mmol). The 
mixture was stirred at room temperature for 2 h. The solvent was removed by 
filtration and the resin washed with DCM (3 x 10.0 mL). The filtrates were combined 
and evaporated and the resulting solid was dissolved in DCM (15.0 mL) and washed 
with water (3 x 10.0 mL). After removal of the solvent in vacuo, a red solid was 
recovered and was purified by column chromatography [eluting solvent: 
DCM:MeOH (90:10)] to give a dark glassy red solid (37 mg, 81%). 
 
HPLC (method 2) tr = 5.6 min, purity 81% (ELSD). 
MS (ES): calculated for C30H37N2O2 [M+H]
+
 m/z 457.3. Found 457.2 (100%). 
λabs= 547 nm, λem= 570 nm (MeOH). 
1
H NMR (500 MHz, CD3OD) δ: 8.51 (t, J = 13.5 Hz, 1H, 1), 7.50 (d, J = 7.4 Hz, 2H, 
8,15), 7.39-7.42 (m, 2H, 10,17), 7.30 (m, 4H, 9,11, 16,18), 6.43 (d, J = 13.5 Hz, 1H, 
2 or 3), 6.40 (d, 1H, J = 13.5 Hz, 2 or 3), (m, 2H, 20), 3.65 (s, 3H,26), 2.15 (t, 2H, J 
= 7.4 Hz, 24), 1.82 (quintet, 2H, J = 7.8 Hz, 21), 1.73 (s, 12H, 27,28), 1.66 (quintet, 
2H, J = 7.5 Hz, 23), 1.44-1.50 (m, 2H, 22). 
13
C NMR (125MHz, CD3OD) δ: 182.51 (25), 176.62 (5),176.11 (4) 152.09 (1), 
144.24 (12), 143.43 (7), 142.31 (19), 142.09 (14), 130.12 (10), 130.00 (17), 126.82 





51.52 (6), 50.63 (13) 45.21 (20), 38.64 (24), 31.82 (26), 28.34 (21), 28.30 (27), 
28.21(28), 27.73 (23), 27.24 (22). 












To resin 63 (2.0 g, 3.34 mmol) was added a solution of 1,1,3,3- 
tetramethoxypropane (7.4 mL, 45.1 mmol) and a solution of BF3·OEt2 (0.46 mL, 
3.71 mmol) in dry DCM (9.0 mL) and the mixture stirred at room temperature for  
6 h. Dry DIPEA (0.94 mL, 5.51 mmol) was added and the mixture stirred for a 
further 5 min. The resin was isolated by filtration, washed with DCM (3 x 20.0 mL), 
and dried in vacuo to give the product as a dark blue-black resin. 
 
IR () 1630 (C=N), 1219 (C-O) cm
-1
. 











To resin 66 (1.0 g, 1.56 mmol) and indolium salt 9 (2.3 g, 7.6 mmol) was added 





irradiation. After cooling, the resin was isolated by filtration, washed with DMF (3 × 
10.0 mL) and DCM (3 × 10.0 mL), and dried in vacuo to give the product as a 
blue/black resin.  
 
IR () 1566 (C=N), 1505 (C=N), 1190 (C-N), 1171 (C-O) cm
-1
. 









To resin 67 (1.1 g, 1.1 mmol) were added dry pyridine (7.0 mL), DIPEA (1.9 mL, 11 
mmol), Ac2O (1.0 mL, 11 mmol) and indolium salt 7 (50.0 mg, 0.14 mmol). The 
mixture was stirred at room temperature for 2 h. Afterwards the resin was removed 
by filtration and washed several times with DCM (4 x 10.0 mL). The filtrates were 
combined and evaporated and the resulting solid was dissolved in DCM (15.0 mL) 
and washed with water (3 x 10.0 mL). After removal of the solvent in vacuo, a blue 
solid formed and was purified by column chromatography [eluting solvent: 
DCM:MeOH (90:10)] to give 60 as a dark blue solid (57 mg, 84%).  
 
HPLC (method 2) tr = 6.0 min, Purity 91% (ELSD). 
MS (ES): calculated for C32H40N2O2 [M+H]
+
 m/z (%) 484.3. Found 484.3 (35%) 






H NMR (500 MHz, MeOD) δ: 8.29 (t, J = 13.1 Hz, 2H, 2,5), 7.50 (d, J = 7.5 Hz, 
2H, 10,17), 7.43-7.40 (m, 2H, 12,19), 7.32-7.25 (m, 4H, 11,13,18,20), 6.71 (dd, J = 
9.6Hz, J = 18.2 Hz, 1H, 1), 6.33 (t, J = 14.4 Hz, 2H, 3,6), 4.14 (t, J = 7.5 Hz, 2H, 
22), 3.66 (s, 3H, 28), 2. 33 (t, J = 7.3 Hz, 2H, 26), 1.88-1.82 (m, 2H, 23), 1.72 (s + 
m, 14H, 25,29,30), 1.56-1.50 (m, 2H, 24). 
13
C NMR (125 MHz, MeOD) δ: 177.6 (27), 175.1 (4), 174.4 (7), 155.3 (2), 144.1 
(14), 143.4 (9), 142.5 (21), 142.4 (16), 129.6 (5), 129.5 (1), 126.7 (12), 126.0 (19), 
124.5 (11), 123.3 (18), 123.1 (10), 122.7 (17), 111.9 (13), 111.7 (20), 104.4 (3), 
104.3 (6), 50.4 (8), 50.3 (15), 44.7 (22), 34.8 (26), 31.6 (28), 28.0 (24), 27.9 (29), 
27.8 (30), 27.2 (23), 25.7 (25). 








Styrene (122.0 µL, 1 mmol, freshly washed with 4 x 25% NaOH and 4 x brine), 
divinylbenzene (3.1 µL, 22 µmol freshly washed with 4 x 25% NaOH and 4 x brine), 
4-vinylbenzylamine hydrochloride (5.9 mg, 35.0 µM), 4-vinylbenzylboronic acid ( 
5.2 mg, 35.0 µM), 2,2-azobis (2-methylpropionamidine) dihydrochloride (V-50) (1.6 
mg, 6.0 µmol) and MgSO4 (0.4 mg, 3.0 µmol) were added to N2 purged water (2.0 
mL). The reaction mixture was stirred at 80 C for 15 h. After cooling to room 
temperature, the particles were collected by centrifugation (15 min at 30000 g, 
eppendorf 5430R) and washed with DMF (3 x 2.0 mL), MeOH (3 x 2.0 mL) and 
water (3 x 2.0 mL). The particles were stored in water at a solid content of  
20 mg/ml. 
 
General Procedure for Pd-mediated Particle Conjugation (69) 
 
Conjugation of iodated cargo was carried out by Suzuki-Miyaura cross-coupling. A 





added to a suspension of (HO)2B/H2N nanoparticles 68 (0.8 µmol, 1 equiv.) in PBS 
(1.0 mL, pH 7.4) and sonicated for 1 min. Afterwards, a catalyst stock solution 
(Table 5) were added and the reaction mixture shaken at 1400 rpm at 37 C for 12 h. 
The particle mixture was washed in water (3 x 1.0 mL) and stored in PBS at a 
concentration of 10 mg/mL. 
 
6.6 Experimental for Chapter 4 




3-Aminophenol (50.0 g, 0.46 mol) was dissolved in hot EtOAc (175.0 mL). Ethyl 
chloroformate (21.7 mL, 0.23 mol) was added dropwise over 30 min while heating to 
reflux. The mixture was allowed to stir at reflux for a further 15 min after addition 
and then cooled. The solution was filtered and the solid washed with EtOAc before 
removal of the solvent to yield a white solid (4.0 g, 96%). 
 
HPLC (method 2) tr = 1.9 min, Purity 100% (ELSD). 
MS (ES): calculated for C9H11NNaO3 [M+Na]
+
 m/z 204.1. Found 204.1 (100%). 
Mp. 96 C. 





H NMR (500 MHz, DMSO-d6) δ: 9.46 (s, 1H, NH), 9.31 (s, 1H, OH), 7.03 – 
6.98(m, 2H, 3, 6), 6.84 (dd, J = 8.7, 1.5 Hz,1H, 4) 6.37 (dd, J = 8.0, 1.7 Hz, 1H, 2), 
4.09 (quartet, J = 7.1 Hz, 2H, 8), 1.23 (t, J = 7.1 Hz, 3H, 9). 
13
C NMR (126 MHz, DMSO-d6) δ: 158.13 (1), 153.88 (7), 140.74 (5), 129.79 (3), 
109.88 (4), 109.45 (2), 105.76 (6), 60.46 (8), 15.01 (9). 











Carbonate 72 (2.0 g, 11 mmol) and diethylacetylsuccinate (2.2 mL, 0.11 mmol) were 
dissolved in 75% H2SO4 (5.0 mL). The mixture was stirred at room temperature for 3 
h. Ice water was added (50.0 mL) and the filter cake was washed with cold water 
until the washings became ~ pH 7. The compound was confirmed by IR 
spectroscopy before taking compound to the next step. 
 












Carbonate 73 (0.3 g, 0.98 mmol) and LiOH.H2O (0.12 g, 4.9 mmol) were dissolved 
in a mixture of EtOH and H2O (1:1, 25.0 mL) and stirred at reflux for 4 h. The 
solution was cooled and acidified with 2 M HCl to produce a pink precipitate which 
was washed with water. The 7-[(ethoxycarbonyl)amino]-4-methyl-2-oxo-2H-1-
benzopyran-3-acetic acid (1.8 g, 6.2 mmol) and NaOH (2.5 g, 62.0 mmol) were the 





cooled to room temperature and acidified with 2 M H2SO4 to give a white solid (1.15 
g, 80%). 
 
HPLC (method 2) tr = 3.0 min, Purity 99% (ELSD). 
MS (ES): calculated for C12H11NNaO4 [M+Na]
+
 m/z 256.1. Found 256.1. 
Mp. 226 C decomposed. 
Absorption and Emission (H2O) λabs= 325 nm, λem= 450 nm. 




H NMR (500 MHz, DMSO-d6) δ: 12.34 (s, 1H, 13), 7.47 (d, J = 8.7 Hz, 1H,6), 6.59 
(dd, J = 8.7, 2.2 Hz, 1H, 1), 6.42 (d, J = 2.2 Hz, 1H,3), 6.06 (s, 2H, 15), 3.50 (s, 2H, 
11), 2.28 (s, 3H, 10). 
13
C NMR (126 MHz, DMSO-d6) δ: 172.52 (12), 161.93 (7), 154.53 (2), 152.95 (4), 
150.13 (9), 126.87 (6), 113.27 (8), 111.86 (5), 109.57 (1), 98.83 (3), 32.92 (11), 
15.26 (10). 








Coumarin 74 (0.5 g, 2.1 mmol) was dissolved in anhydrous DCM (3.0 mL). Freshly 
distilled TMS-Cl (0.5 mL, 4.3 mmol) was added and the solution cooled to 0 C. 
Fmoc-OSu (0.8 g, 2.4 mmol) and DIPEA (0.56 mL, 4.3 mmol) were added and the 
solution refluxed for 3 h. After cooling, the solvent was evaporated and the product 
precipitated in Et2O to give a yellow solid (0.98 g, 99%).  
 





Mp. 240 C decomposed. 




H NMR (500 MHz, DMSO) δ: 12.45 (s, 1H, OH), 10.19 (s, 1H, NH), 7.93 (d, J = 
7.5 Hz, 2H, 20,20’), 7.79 – 7.72 (m, 4H 1,6,17,17’), 7.55 (s, 1H, NH), 7.46-7.41 (m, 
J = 7.4 Hz, 3H, 3,19,19’), 7.37 (td, J = 7.4, 0.9 Hz, 2H, 18,18’), 4.57 (d, J = 6.5 Hz, 
2H, 14), 4.39 – 4.30 (m, 1H, 15), 3.59 (s, 2H, 11), 2.37 (s, 3H, 10). 
13
C NMR (126 MHz, DMSO) (Fmoc Ar together) δ: 171.98 (12), 161.31 (7), 153.72 
(13), 152.91 (4), 149.31 (9), 144.14 (2), 142.55 (16,16’), 141.30 (21,21’), 128.20 
(18,18’), 127.63 (19,19’), 126.67 (17,17’), 125.56 (6), 120.70 (20,20’), 117.95 (1), 







Coumarin 75 was attached onto the solid-phase by coupling to a polystyrene resin 
with rink-amide linker using standard coupling conditions. Fmoc deprotection was 
carried out with 20% piperidine in DMF followed by twice coupling to Fmoc-
alanine-OH with 3 eq HATU and 3 eq DIPEA. Cleavage from the linker was carried 
out with TFA:DCM:TIS (95:2.5:2.5) and purification was carried out by preparative 
HPLC. 
 
HPLC (method 2) tr = 0.8 min, Purity 100% (ELSD). 
MS (ES): calculated for C15H18N3O4 [M+H]
+






H NMR (500 MHz, MeOD) δ: 7.86 (d, J = 2.1 Hz, 1H, 3), 7.80 (d, J = 8.8 Hz, 1H, 
6), 7.49 (dd, J = 8.8, 2.1 Hz, 1H,1), 4.11-4.06 (m, 1H, 16), 3.67 (s, 2H, 11), 2.47 s, 
3H,10), 1.62 (d, J = 7.1 Hz, 3H,18). 
13
C NMR (126 MHz, MeOD) δ: 173.68 (12), 168.24 (15), 162.26 (7), 152.84 (4), 
149.98 (2), 140.75 (9), 125.74 (6), 118.60 (1), 116.77 (5), 115.53 (8), 106.55 (3), 







Procedure and purification for compound 78 repeated with use of Fmoc-D-Ala-OH. 
 
HPLC (method 6) tr = 1.1 min, Purity 88% (ELSD). 
MS (ES): calculated for C15H18N3O4 [M+H]
+
 m/z 304.1. Found 304.2 (100%). 
1
H NMR (500 MHz, D2O) δ: 7.79 (d, J = 8.3 Hz, 1H, 6), 7.64 (s, 1H, 3), 7.41 (d, J = 
8.9 Hz, 1H, 1), 3.65 (s, 2H, 11), 3.15 – 3.10 (m, 1H, 16), 2.42 (s, 3H, 10), 1.35 (d, J 
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